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Introduction
This thesis focuses on determinants and consequences of insulin-associated weight 
gain in patients with type 2 diabetes mellitus (T2DM). It presents the results of studies 
performed in patients with T2DM who initiated insulin treatment, in patients on 
long-term insulin therapy and in healthy (lean and obese) subjects. This chapter 
summarizes the benefits and disadvantages of insulin treatment in patients with 
T2DM and discusses insulin-associated weight gain in more detail. At the end of the 
chapter, the outline of the thesis is presented. 
Type 2 diabetes mellitus and insulin therapy
Diabetes is a disease characterized by a chronically elevated blood glucose 
concentration (hyperglycemia). Chronic hyperglycemia can lead to a number of 
complications if untreated (1, 2). Patients with T2DM thus require regular monitoring 
and ongoing treatment to maintain normal or near-normal blood glucose levels and 
minimize the risk of diabetes and cardiovascular-related complications. Treatment 
starts with lifestyle adjustments, but in the majority of patients with T2DM, lifestyle 
changes fail or are insufficient to control glucose levels and additional oral glucose- 
lowering medication is needed. Despite the development of alternative therapies in 
recent years, insulin remains an essential treatment for type 2 diabetes once oral 
therapy alone becomes inadequate. As T2DM is a progressive disorder, most patients 
with T2DM will eventually need insulin therapy to achieve adequate glycolic control (3, 4). 
Insulin treatment has a number of benefits. First, insulin therapy will lead to better 
glycemic control. Improving glycolic control by insulin decreases the risk to develop 
macro and micro vascular complications (2, 5). Second, insulin might preserve 
beta-cell function of the pancreas (6).
 There are two main disadvantages with respect to insulin therapy. Insulin can 
induce hypoglycemia which might incur co-morbidity and is related to increased 
mortality (7). Moreover, insulin treatment is associated with weight gain (8-11). 
Insulin-associated weight gain in type 2 diabetes patients 
In the United Kingdom Prospective Diabetes Study (UKPDS) a significant mean 
weight gain of 5 kg after the start of the study was seen in those who received insulin 
treatment (5). Reported weight gain associated with insulin treatment in patients with 
T2DM is highly variable (range 1.7-8.7kg) (2;5-7). The change in weight gain varies 
with duration of insulin therapy, the use of metformin, and is dependent on the 
treatment protocol (conventional or intensive insulin regimens) (5). In Figure 1 trends 
in weight gain are shown in patients with T2DM starting different glucose lowering 
treatment protocols (5). 
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Weight gain was seen in all groups, with the exception of the metformin treatment 
arm, but was largest in insulin-treated patients. Large inter-individual differences in 
weight gain can be seen in patients on insulin therapy. Some patients gain much 
weight (“gainers”), while other patients treated similarly do not gain weight or even 
lose body weight (“non-gainers”). 
 This weight gain is obviously undesirable in a population showing pre-existent 
overweight and may negatively affect blood pressure, lipid levels, inflammatory and 
fibrinolytic parameters, and may also deter further optimization of insulin therapy. 
Several determinants and consequences on cardiometabolic risk profile of insulin- 
associated weight gain are proposed although formal prospective studies are lacking. 
Proposed determinants of insulin-associated weight gain
In literature, the exact determinants of insulin-associated weight gain are unknown. 
A number of potential determinants is often listed: 
1) Change in glycemic control 
Insulin therapy improves glycemic control, which results in a decrease in glucosuria. 
When glucosuria decreases, less glucose, hence energy is lost and more energy 
will be stored as fat. Patients may experience weight gain if caloric intake is not 
Figure 1  Weight change by treatment in overweight patients with T2DM in UKPDS 
assigned to intensive intervention with insulin. Chlorpropamide or metformin, or 
conventional treatment.
(Reprinted from the Lancet, 352(9131), no authors listed, “Effect of intensive blood-glucose control with 
metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)”, 854-65, Copyright 
(1998), with permission from Elsevier).
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reduced (12). Carlson and Campbell have demonstrated this effect in patients with 
type 1 diabetes (11). A significant rise in weight (+2.6 kg) was found with insulin 
therapy, of which 2.4 kg was attributed to an increase in fat mass. Mäkimattila et al. 
also found a relation between decrease of glucosuria and weight gain in patients with 
T2DM. (10). During 12 months of insulin therapy, glucosuria decreased considerably 
(change in energy loss 0.83 ± 0. 27 MJ/day), with no differences between patients 
who used metformin and those who did not. The initial improvement of glycemic 
control within 6 months was associated with weight gain in this time-frame. If HbA1c 
remains stable, patients may still gain weight, suggesting that changes in glycemic 
control do not determine further weight gain (13). The greatest weight gain will occur 
over the first months after starting with insulin therapy. This suggests that most initial 
weight gain is a ‘catch-up’ re-gain (14), which refers to the amount of weight loss 
patients experienced before insulin initiation. Patients who gain most weight after 
insulin initiation are those with the worst metabolic control before the treatment and 
those who experienced most weight loss prior to insulin therapy. So, the change in 
glycemic control (as reflected by the drop in HbA1c) is probably an important 
contributor to insulin-associated weight gain over the first months after initiation 
insulin treatment. Some authors view the changes in glycemic control to be the major 
determinant of insulin-induced weight gain (10, 15, 16). However, the number of 
prospective and long-term follow-up studies of patients treated with insulin supporting 
this concept is limited.
2) Anabolic effects of insulin
Insulin, being an anabolic hormone, may in itself cause weight gain as insulin 
increases muscle protein synthesis and lipogenesis in fat tissue (17, 18). Insulin could 
also increase water and salt retention (19) resulting in weight gain. 
 The total (exogenous) insulin dose appears to be directly correlated with weight 
gain (20, 21). Henry et al. (21) found that the insulin dose (average 86-100 U/day of 
intermediate and regular insulin combined) was directly correlated with the amount of 
weight gain. Insulin detemir is a long-acting insulin that has consistently shown in 
randomized, controlled trials to have a weight sparing effect in both type 1 and type 
2 diabetes (22, 23). 
3) Energy intake
An increase in energy intake will lead to weight gain. Insulin may lead to defensive 
eating habits because of (fear of) hypoglycemia. Consequently, individuals may 
increase energy intake to proactively avoid such an event, resulting in weight gain 
(24). It has been shown in the Diabetes Control and Complications Trial (DCCT) that 
patients who had experienced one or more hypoglycemic episodes gained 6.8 kg in 
weight compared to 4.6 kg in patients with no hypoglycemia. DCCT, however, found 
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no relation between reported caloric intake and weight changes. A number of studies 
reported even a decrease of caloric intake after start of insulin therapy, suggesting 
that overeating did not contribute to weight gain (16, 25, 26). 
4) Physical activity
Obesity is caused by an imbalance of energy intake and energy expenditure. Total 
daily energy expenditure (TDEE) is the result of basal metabolic rate (BMR), dietary- 
induced thermogenesis (DIT) and the energy expenditure of physical exercise (EEPE) 
or in formula: TDEE = BMR + DIT + EEPE (27-29). BMR in humans is the most 
important factor which contributes to TDEE. Normally BMR is about 1 kcal/kg/hour. 
As such, weight gain in diabetes may be due to a decrease in energy expenditure or 
basal metabolic rate. Makimatilla et al. (10) showed that improvement of glycemic 
control in type 2 diabetes led to a reduced BMR (expressed as per kg body weight) 
and thus reduced TDEE. This was counterbalanced by an increase in BMR caused 
by weight gain itself. The exact mechanisms underlying the correlation between 
glycemia and BMR has not been established so far but it may be related to increased 
gluconeogenesis (30, 31) and glucose cycling (32). In these studies it was concluded 
that even if energy intake (diet) would have been reduced by an amount corresponding 
with the energy loss due to glucosuria, weight gain will still occur because improvement 
of glycemic control in itself will decrease energy expenditure. When physical activity 
is reduced, a person will gain weight when keeping caloric intake similar. Jacob et al. 
(16) found no difference in physical activity between 3 groups of patients starting 
insulin therapy for T2DM (monotherapy insulin, insulin/pioglitazone and insulin/
metformin). Only few studies have addressed physical activity changes after starting 
insulin therapy, and further research will be needed to answer this question.
5) Insulin effects on the central nervous system
The brain plays an important role in glucose and energy homeostasis (33, 34). The 
hypothalamus (more specifically the arcuate nucleus) contains neurons that exert 
action on food intake and energy expenditure both regulated by hormonal and 
 nutrient-related signals. Neuropeptide Y (NPY) and Agouti-related peptide (AgRP) 
are ‘anabolic’ neurons which are inhibited by insulin and leptin (35). NPY and AgRP 
promote food intake, reduce energy expenditure and thus induce weight gain. 
A decrease in the secretion of insulin and leptin might lead to weight gain, because 
of increased signaling by NPY and AgRP. Furthermore, insulin resistance and T2DM 
may also reduce neuronal insulin/leptin action and thereby induce weight gain. Figure 2 
depicts a model in which the brain, glucose control and energy balance signaling are 
closely interrelated. It has been suggested that administration of exogenous insulin 
can disrupt pathways in the central nervous system that might lead to increase of 
food intake and weight gain (36-38). The precise role of (exogenous) insulin and 
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other hormones (i.e. ghrelin, adiponectin, cholecystokinin, triiodothyronine, glucagon 
peptide-1) on the central regulation of food intake and hence weight gain still needs 
to be elucidated. 
Potential consequences of insulin-associated weight gain
Weight gain may have several clinical and metabolic consequences such as:
 
1) Increase in insulin-resistance
Insulin-associated weight gain will further increase insulin resistance in patients with 
type 2 diabetes mellitus. As a consequence, patients need to increase their insulin 
dose to adjust for or to overcome the insulin-resistant state. Using more insulin will 
induce more weight gain with concomitant increase of insulin resistance; hence a 
vicious circle emerges. This scenario occurs in some patients and is feared by both 
Figure 2  Defects in the secretion of insulin or leptin (1), in the hypothalamic sensing 
of adiposity- or nutrient related signals (2), or in the neuronal responsiveness to these 
inputs (3) predispose to both positive energy balance and increased glucose production. 
If sustained, these will result in pathological weight gain and insulin resistance.
NPY: neuropeptide Y, AgRP: Agouti-related peptide, POMC: proopiomelanocortin.
(Reprinted from reference 37, “Diabetes, obesity and the brain”, 375-379, Copyright (2005), with permission 
from Science/AAAS).
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patients and clinicians: a patient started on insulin becomes more and more obese 
while glycemic control remains worse despite increasing doses of insulin. 
2) “Psychological insulin resistance”
Another indirect effect of insulin-associated weight gain may be reluctance to inject 
insulin, because patients relate the weight gain to insulin treatment. It can be 
envisioned that this phenomenon, also called “psychological insulin resistance” (39, 40) will 
be a barrier against initiation of insulin therapy but will also hamper improvement of 
glycemic control because of reluctance to properly increase insulin dose. In general, 
adherence to insulin therapy is poor. Davies et al. investigated factors related to 
adherence of insulin therapy (41). Four categories of factors associated with 
non-adherence were identified: predictive factors for non-adherence, patient-per-
ceived barriers to adherence, type of delivery device and cost of medication. So, not 
only psychological factors at the start of insulin therapy, but also patient-perceived 
barriers to adherence of insulin therapy may lead to reduced treatment satisfaction.
 
3) Reduced quality of life
Patients with T2DM and high body mass index suffer from a reduced quality of life 
(42). When starting insulin therapy patients may experience an increase of quality of 
life (43). Whether insulin-associated weight gain diminishes quality of life is unknown. 
Weight management interventions in obese patients with T2DM show a positive 
effect on quality of life (44). 
4) Cardiovascular consequences 
In the DCCT (45), patients with type 1 diabetes mellitus on intensive insulin treatment 
(multiple daily injections or continuous subcutaneous insulin injection) experienced 
more weight gain compared to those who received standard therapy (2 or 3 times 
daily injections). In addition, in the intensive study arm of DCCT patients had higher 
blood pressure and higher levels of cholesterol. 
 These results suggest that intensive insulin treatment and weight gain in patients 
with type 1 diabetes is associated with an unfavourable cardiovascular risk profile. 
Of course, cardiovascular risk can and probably will subsequently be managed by 
pharmacological interventions. The DCCT/EDIC study has reported that long-term 
cardiovascular outcomes in the intensively treated group were better, which supports 
the concept that lowering glucose on the long run decreases the risk to develop 
cardiovascular disease (46). Whether the benefit of improved glycemic control in the 
group with pronounced weight gain was similar has not been reported.
 Several studies in patients with type 2 diabetes have examined the effect of 
glycemic treatment on cardiovascular endpoints (47-49). While intensive treatment 
reduced the incidence of non-fatal myocardial infarction, cardiovascular and 
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all-cause mortality was not affected or even increased. The ACCORD-trial, was 
prematurely ended after a mean follow-up of 3.5 years because of increased mortality 
in the intensive treated arm (48). The increased mortality in the intensively treated arm 
is not well explained. One possible explanation was the increased rate of 
hypoglycaemia in this group (50). It can be hypothesized that weight gain also 
influences cardiovascular outcome, because weight gain might offset the beneficial 
effects of improvement of glycemic control. Again, in the ACCORD-trial, more than 
25 % of the patients in the intensively treated group (HbA1c < 6,0 %) showed a mean 
weight gain of more than 10 kg (48)!
5) Metabolic consequences 
Over the last two decades, the endocrine function of adipose tissue has received 
much attention. The adipose tissue is now viewed as an active endocrine organ, that 
produces many hormones, including adipocytokines. Expansion of adipose tissue 
mass is generally paralleled by profound morphological and inflammatory changes 
that include enlargements in adipocyte size and influx of various immune cells 
including macrophages. It can be hypothesized that the anti-inflammatory effects on 
insulin at the systemic level may be counteracted by pro-inflammatory changes 
associated with an increased fat mass. This may be particularly true in those who 
gain most weight. The effects of insulin-associated weight gain in patients with T2DM 
on the mechanisms listed above have not yet been studied.
 Obesity and weight-gain may affect the autophagy process. Autophagy, an 
evolutionary conserved process aimed at recycling damaged organelles and protein 
aggregates in the cell, also modulates proinflammatory cytokine production in peripheral 
blood mononuclear cells. Because adipose tissue inflammation accompanied by 
elevated levels of proinflammatory cytokines is characteristic for the development of 
obesity, it can be hypothesized that modulation of autophagy alters adipose tissue 
inflammatory gene expression and secretion. This in turn may have an impact on 
cardiometabolic risk. 
Conclusion
Insulin therapy is frequently needed to achieve adequate glycemic control in type 2 
diabetes mellitus, but often at the expense of weight gain. This weight gain is highly 
variable across individuals but if it occurs it may negatively affect glycemic control, 
cardiometabolic risk profile and quality of life. 
 Mechanisms for insulin-associated weight gain are complex and incompletely 
understood. While the change in glycemic control (decrease of glucosuria) is an 
important determinant of weight gain in T2DM patients using insulin therapy, many 
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other factors probably play a role. Meanwhile, the consequences of insulin-associat-
ed weight gain, especially when outspoken, have so far received limited attention. 
Hence, we set out a series of studies aimed at elucidating in more detail the 
determinants and consequences of insulin-associated weight gain.
Methods used in this thesis
In this thesis, we have used several methodologies to assess physical activity, body 
fat content and distribution and adipose tissue morphology and function. 
 In a number of our studies we have used accelerometry to quantitatively measure 
physical activity (see Figure 3). Furthermore, we have performed subcutaneous 
adipose tissue biopsies to investigate adipose tissue morphology and inflammatory 
characteristics.
1) Accelerometry
Accelerometry is noninvasive and commonly used to asses free-living physical 
activity. The device used in our studies, the SenseWear™ device, has also been 
validated for study of sleep patterns, as the internal body media algorithm can identify 
sleep and wakefulness with moderate-to-high sensitivity, specificity, and accuracy 
(51, 52).The device is placed on the right upper arm over the triceps muscle for 4 
consecutive 24-h periods. It contains a 2-axis accelerometer, heat flux sensor, 
galvanic skin response sensor, and a skin temperature sensor and is worn in 
Figure 3  Physical activity in the presented studies is quantitatively measured using an 
2-axis accelerometer (SenseWear Pro Armband™, Body Media, Pittsburgh, PA, USA). 
Image courtesy Body Media, Inc. (a wholly owned subsidiary of AliphCom dba Jawbone®).
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free-living conditions. Outcome variables from the activity monitor include: average 
metabolic equivalent (METS; 1 MET = consuming 1 kcal/kg of body weight per hour), 
time (minutes/day) spent at different activity intensity categories averaged per day 
over the measurement period and number of steps per day, sleep duration and 
fragmentation index (i.e. the number of interruptions measured per sleep). 
2) Subcutaneous adipose tissue biopsy
When obesity develops, the adipose tissue undergoes distinct morphological changes 
including adipocyte enlargement, and macrophage influx. Furthermore, the subcutaneous 
adipose tissue produces several proteins related to inflammation (e.g. leptin, 
interleukin-6 and tumor necrosis factor α). We have performed subcutaneous adipose 
tissue biopsies (Figure 4) to investigate four potential changes in adipose tissue: 
morphological characteristics, macrophage influx, mRNA expression and protein 
levels of key inflammatory markers within the adipose tissue. Morphometry of 
individual fat cells was assessed using digital image analyses. For detection of 
macrophages, adipose tissue sections were incubated with a CD68-monoclonal 
antibody. Thereafter, the number of macrophages was counted per microscopic 
field. Total messenger RNA was extracted from adipose tissue and expression of 
genes was determined by real-time PCR analysis using an Applied Biosystem. Lastly, 
protein levels of adipocytokines in the adipose tissue were measured by Luminex 
fluorescent bead human cytokine immunoassays. The adipose tissue biopsies were 
performed in patients with type 2 diabetes mellitus before and 6 months after the 
start of insulin therapy. We also compared these tissue samples to those obtained in 
a set of lean, and weight-matched obese non-diabetic subjects.
Outline of the thesis
Most of the aforementioned factors related to insulin-associated weight gain have 
not been studied in a prospective way. Therefore, we have designed a number of 
studies aimed at identifying factors that determine weight gain after starting insulin 
treatment. Furthermore, we assessed the influence of insulin-associated weight gain 
on cardiovascular risk, particularly on the subcutaneous adipose tissue. Figure 5 
shows an overview of studies presented in this thesis. 
This thesis consists of two parts: determinants of insulin-associated weight gain in 
patients with T2DM are investigated in studies presented in part I. Thereafter, studies 
concerning the consequences of insulin-associated weight gain, particularly on the 
(subcutaneous) adipose tissue, and liver fat content related to the cardiometabolic 
profile will be addressed in part II. 
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Part I – Determinants of insulin-associated weight gain
As mentioned, many authors view the changes in glycemic control to be the major 
determinant of insulin-induced weight gain. This conclusion is based on studies that 
usually relate the difference in body weight between two time-points to the difference 
in HbA1c in patients who initiated insulin therapy. These studies do not show to what 
extent change in body weight depends on change in HbA1c over time. In chapter 2 
Figure 4  Technique of abdominal subcutaneous adipose tissue biopsy by aspiration- 
needle. Superficial subcutaneous adipose tissue samples of ≈1–2 cm3 (corresponding 
to ≈1–2 g) are obtained from the periumbilical area, under local anesthesia, from a 
comparable site of the abdomen. A region 5 cm lateral from the umbilicus (either to 
the left or right side of the abdomen) is sterilized. A half circular small dermal injection 
(intracutaneous) is made, and 2 mL of a local anesthetic agent injected. After 5 min, 
the skin is sterilized again. A needle (16 G) is then adapted to a 20-mL syringe and 
the piston is compressed. Approximately one-third of the length of the needle is 
inserted into the subcutaneous fat, and the needle piston is released maximally until 
it is locked by a stopper, thereby creating a vacuum. Tissue resistance is created by 
the surgeon gripping the abdominal wall with one hand while the other hand rotates 
the needle throughout the tissue in an up-down motion. Once the tissue is aspirated 
by the syringe, the needle is withdrawn and the piston is removed; adipose tissue 
samples are washed in physiologic serum, placed immediately in liquid nitrogen, and 
stored at −80°C until analysis.
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we first investigated whether there was a relationship between change in glycated 
hemoglobin and weight gain. Here, we used a linear mixed model, which allowed us 
to study the relationship between insulin-associated weight gain and change in 
glycated hemoglobin in a large group of patients who had used insulin for three or 
more years. 
 A decrease in physical activity is inevitably related to weight gain if caloric intake 
remains stable. We questioned whether physical activity is reduced in insulin-treated 
patients with T2DM compared to lean, but especially to weight-matched obese 
subjects. In addition, we also compared quantitative and qualitative sleep character-
istics between lean, obese subjects and patients with T2DM, as sleep duration and 
quality may influence physical activity. The results of these investigations are 
described in chapter 3.
 Besides (change in) physical activity, a number of other potential determinants 
were tested in a prospective design. From literature it is known that insulin dose is 
correlated with weight gain (53). Also patients with diabetes mellitus who suffer from 
depressive complaints are at risk to gain weight. However, these two potential 
determinants of insulin-associated weight gain have not been investigated in a 
prospective design. In chapter 4 we describe to what extend (change in) diabetes- 
related distress, insulin dose, age and physical activity determines insulin-associated 
weight gain in patients with type 2 diabetes. These potential relationships were tested 
Figure 5  Overview of the studies and related subjects presented in this thesis.
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in a prospective study in which patients started insulin therapy and were followed 
for 12 consecutive months. Insulin dose was noted every 3 months. Diabetes-related 
distress was measured with the Problem Areas In Diabetes (PAID) questionnaire at 
baseline, after 6 and 12 months of insulin therapy. Physical activity was objectively 
measured with accelerometry (SenseWear Pro Armband™ (Body Media, Pittsburgh, 
PA, USA) (Figure 3). Furthermore, caloric intake was investigated as a potential 
determinant of insulin-associated weight gain.
Part II – Consequences of insulin-associated weight gain
To assess the influence of insulin-associated weight gain on the cardiometabolic 
profile, we investigated several “classical” and “non-classical” cardiometabolic risk 
factors of weight gain in long-term insulin-treated patients with T2DM. We first 
investigated several cardiometabolic risk factors in two specific groups: “gainers” 
(i.e. those who had large weight gain after start of insulin therapy) and “non-gainers” 
(i.e. those who did not experienced weight gain). We hypothesized that gainers would 
have a worse cardiometabolic profile compared to non-gainers. This was investigated 
in a cross-sectional study, in which fat content and distribution (physical examination, 
bioelectrical impedance analysis, dual energy X-ray absorption, and magnetic resonance 
imaging), liver fat content and physical activity levels (accelerometry (Sensewear®) 
armband) were assessed quantitatively. High hepatic fat content is associated with 
increased cardiometabolic risk (54, 55). In this study we specifically assessed hepatic 
fat content by means of magnetic resonance spectroscopy, which is the gold 
standard for non-invasive measurement of liver fat content. The results of this study 
are described in chapter 5.
 Obesity / expansion of adipose tissue mass is accompanied by inflammatory 
changes in the adipose tissue. We wondered whether an insulin-induced increase in 
adipose tissue mass would have similar effects. To determine the effects of insulin 
therapy on adipose tissue morphology and inflammatory status, we prospectively 
studied subcutaneous adipose tissue characteristics before and after six months of 
insulin therapy. Adipose tissue morphology was assessed and influx of adipocytokines 
into the adipose tissue were measured. The results of this study are described in 
chapter 6. 
 Most patients with type 2 diabetes mellitus are obese and have an accumulation 
of abdominal fat. Additionally, liver fat content is strongly associated with intra- abdominal 
fat mass and clearly increased in subjects with T2DM. The exact mechanisms involved in 
liver fat accumulation are currently unclear. It has been suggested that adipose tissue 
dysfunction is associated with the development of hepatic steatosis yet data that link 
liver fat content to adipose tissue inflammation are scarce. To investigate the 
relationship between hepatic fat content and subcutaneous adipose tissue we 
conducted a cross-sectional study in which characteristics of subcutaneous adipose 
1General introduction and outline of the thesis
23
tissue and liver fat (LFAT) content were analyzed. LFAT content was measured by 
proton magnetic resonance spectroscopy. Subcutaneous fat biopsies were obtained 
to determine morphology and protein levels within adipose tissue. In addition to fat 
cell size, the percentage of macrophages and the presence of crown like structures 
within subcutaneous fat was assessed by CD68-immunohistochemical staining. 
The results of this study are described in chapter 7. 
 Autophagy, an evolutionary conserved process aimed at recycling damaged 
organelles and protein aggregates in the cell, also modulates pro-inflammatory 
cytokine production in peripheral blood mononuclear cells. Since adipose tissue 
inflammation accompanied by elevated levels of pro-inflammatory cytokines is 
characteristic for the development of obesity, we hypothesized that modulation of 
autophagy alters adipose tissue inflammatory gene expression and secretion. We 
performed in vitro and in vivo animal and human experiments and measured 
autophagy marker LC3. Again, adipose tissue biopsies were taken from healthy lean 
and obese subjects. Chapter 8 describes the results of analyses of adipose cell size, 
number of macrophage influx and adipocytokines (mRNA and protein levels). 
 Although inflammatory characteristics of the adipose tissue are frequently described 
in literature, a general classification of the adipose tissue inflammatory status is 
currently lacking. To identify patients with increased adipose tissue inflammation, 
we used the morphological characterization of the adipose tissue to define an 
inflammatory score. This score was applied in a discriminant analysis aimed at 
predicting the adipose tissue inflammatory status using a combination of circulating 
parameters (chapter 9).
 In chapter 10 the main findings of the experiments presented in this thesis are 
summarized, discussed and put into perspective.
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Abstract
To investigate the contribution of glycated haemoglobin change (HbA1c) on body 
weight in patients with type 2 diabetes (T2DM) after start of insulin therapy, we 
analyzed 122 individual weight-profiles in relation to the change in HbA1c per se in 
these patients up to 36 months after the start of insulin therapy. Data were analyzed 
separately for the first 9 months after commencement of insulin therapy and for the 
period thereafter. Within the first 9 months of insulin therapy mean body weight 
increased by 0.52 kg per month. HbA1c decreased from 9.9 ± 1.8 to 7.9 ± 1.3%. Only 
12% of the initial weight gain could be attributed to the change in HbA1c. Furthermore, 
the mean monthly increase in body weight gain was reduced by 0.006 kg for every 
1 kg higher body weight at baseline. From 9 to 36 months after start of insulin therapy, 
body weight increased by 0.1 kg/month, which was independent of change in HbA1c. 
Improvement of glycemic control per se contributes little to initial weight gain after 
start of insulin therapy in patients with T2DM. After 9 months of insulin treatment, 
weight gain is unrelated to change in glycated haemoglobin. Other factors have to be 
responsible for weight gain after start of insulin therapy.
Change in HbA1c and insulin-associated weight gain
33
2
Introduction
Insulin therapy is frequently needed to achieve adequate glycemic control in patients 
with type 2 diabetes mellitus (T2DM), but often at the expense of significant weight 
gain (1-3) .
 This weight gain is obviously undesirable in an already overweight population 
and may negatively affect blood pressure, lipid levels, inflammatory and fibrinolytic 
parameters, and may also deter further optimization of insulin therapy (4-7). Four 
putative mechanisms have been proposed for this weight gain: 1) improvement of 
glycemic control (HbA1c), 2) anabolic effect of insulin increasing fat storage, 3) a 
decrease in metabolic rate and a fall in energy expenditure and 4) defensive eating 
habits because of (fear of) hypoglycemia (8, 9). 
 Most authors view the improvement in glycemic control per se (expressed as 
change in HbA1c) as the major determinant of weight gain. This conclusion is based 
on studies that usually relate the difference in body weight between two time-points 
to the difference in HbA1c in patients who initiated insulin therapy (8-10). Mäkimattila 
et al. (2) showed that after 12 months of insulin therapy a decrease in HbA1c by 2.5 % 
is associated with a 5 kg weight gain (i.e. 2 kg/1% decrease in HbA1c). However, these 
studies do not show to what extent change in body weight may depend on change in 
HbA1c. The relationship between change in glycaemic control (i.e. change in HbA1c) 
and weight gain may vary over time. First, the change in HbA1c may primarily 
contribute to weight gain in the first months after the start of insulin therapy rather 
than later-on, when factors unrelated to glycemic control become more important 
such as change in energy intake or physical activity, anabolic effects of insulin, and 
defensive eating behavior probably (2, 9). Second, patient’s and physician’s 
responses to changes in glycemic control and body weight may affect the subsequent 
course of these variables.
 Analyzing data of HbA1c and body weight just at two time-points may negate 
these variations and lead to incomplete or even wrong conclusions. A more accurate 
evaluation of a relationship between change in HbA1c and weight after initiation of 
insulin therapy, requires a longitudinal assessment with repeated measures of body 
weight and HbA1c in the same individuals. Therefore, we used a linear mixed model 
for repeated measures data to investigate the relationship between the changes in 
HbA1c and body weight at different time-points after commencing insulin therapy in 
patients with T2DM.
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Patients and Methods
Subjects
Patients with T2DM, who all started biphasic insulin therapy in our academic center 
between March 2000 and November 2004 were included in this study. Patients who 
started biphasic insulin therapy were selected because most patients starting insulin 
therapy in this timeframe were assigned to this insulin regimen by their physician. 
Furthermore, to prevent confounding with respect to influences of different types of 
insulin on body weight we only included patients with biphasic insulin. All patients 
were seen at the diabetes clinic of the Radboud University Nijmegen Medical Center. 
The diagnosis of T2DM was made according to the diagnostic criteria of the WHO. 
The decision to start insulin treatment was at the discretion of the responsible 
physician and was always based on failure of glycemic control on oral glucose-low-
ering agents and/or diet. Patients were excluded if they did not use biphasic insulin or 
had steroid-induced diabetes, latent auto-immune diabetes in adults (LADA) or 
maturity onset diabetes of the young (MODY). Patients were followed for a maximal 
of 36 months after start of insulin therapy. We conducted an observational study in 
which data of all patients starting biphasic insulin within the timeframe 2000-2004 
was included.   
 Clinical data were retrieved from medical records at baseline and at 3-month 
intervals, which included body weight, HbA1c, age, gender, diabetes duration, blood 
pressure, lipids, doses of oral glucose-lowering medication, and insulin dose. We 
assumed that most of the weight gain that could be directly attributed to improvement 
in glycemic control would appear within the first 9 months after start of insulin therapy. 
This was based on studies viewing that most of the weight gain and change in HbA1c 
appears within the first 9-12 months after start of insulin therapy (9, 11). After this 
period, weight gain tends to level-off. Therefore, we studied the short-term weight- 
profiles (i.e. the first 9 months after start of insulin therapy) and the long-term weight- 
profiles (i.e. from 9-36 months after start of insulin therapy) separately. To analyze the 
short-term weight-profiles, data of baseline body weight and at least 3 subsequent 
weight measurements had to be available within the first 9 months. To study the long- 
 term weight-profiles, data of at least 4 body weight measurements between 9 and 
36 month after commencing insulin therapy had to be available. 
Statistical methods
We studied the individual weight profiles of patients with T2DM up to 36 months after 
the start of insulin therapy and the dependence on HbA1c with the use of linear mixed 
models for repeated measures (12). At first, we found that the models were not 
statistical significant improved when a quadratic term in time was included in the 
linear part of the models (Likelihood-Ratio test) in neither time period. We studied 
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weight profiles unadjusted and adjusted for change in HbA1c. Hence, the following 
initial mixed model was used:
Yi (t) = β0 + β1 x BBWi + β2 x t + β3 x BBWi x t + β4 x ∆HbA1cit + β5 x ∆HbA1cit x t + 
b1i + b2i x t + εit
where Y refers to body weight, i to subject, t to the time (month) after start of insulin 
therapy, β0 to the general mean, β to a fixed effect, b to a random effect, BBW to the 
baseline body weight, ∆HbA1c to the change in HbA1c since baseline and εit to the 
normal distributed residual with mean zero. We studied weight-profiles unadjusted 
and adjusted for change in HbA1c in each time period, separately. Note that in case 
of the unadjusted weight-profiles the terms related to ∆HbA1c were omitted from the 
model presented above.
In total four models were designed:
- Short-term linear mixed model (0-9 months; model I)
The dependent variable in this model was body weight. The independent continuous 
variables were: body weight at the start of insulin therapy and the time (t) since the 
start of insulin therapy (month). Furthermore, the interaction term between both 
variables (body weight*t) was included in the model, representing different increase 
in body weight with higher initial body weight. The independent random variables 
were: intercept (representing baseline body weight) and the regression in time 
(representing weight gain or loss per month).
This allows the calculation of different regression lines for different patients, both in 
intercept and regression. 
- Short-term linear mixed model (0-9 months; model II)
The same dependent and independent (continuous and random) variables were 
entered into the model as in model I. Model II was designed to study the short-term 
weight profile adjusted for change in HbA1c. Therefore, the independent continuous 
variables (time-dependent) change in HbA1c since the start of insulin therapy 
(∆HbA1c) and the interaction term between time and change in HbA1c (∆HbA1c*t) 
were included in the model.
- Long-term linear mixed model (9-36 months; model III)
The same dependent and independent variables as in model I were entered in this 
model, except for the interaction term between body weight and time (body weight*t). 
The reason for this was that aforementioned interaction term did not significantly alter 
the outcome of the model. 
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- Long-term linear mixed model (9-36 months; model IV)
The same dependent and independent variables as in model III were entered into 
this model.  
 The independent continuous variables were: weight at the start of insulin therapy, 
and time since the start of insulin therapy (month). Model IV was designed to study 
the long-term weight profile adjusted for change in HbA1c. Therefore, absolute 
change in glycosylated haemoglobin since start of insulin therapy (∆HbA1c) was 
included as an independent variable. The interaction term between time and change 
in HbA1c was not included because of a non-significant contribution to the model.  
 Estimated regression parameters and mean profiles are presented, with the 
appropriate standard error (SE) and 95% confidence interval (CI). Statistical analyses 
were performed by using SAS® statistics 9.2 for Windows (SAS Institute Inc. Cary, 
NC, USA). A P-value <0.05 was considered statistically significant.
Results
A total of 146 patients who were assigned to biphasic insulin therapy were screened. 
Finally, 122 patients were included in our analysis. We excluded 24 patients (18 patients 
of whom no baseline HbA1c or body weight was available, in 6 patients the responsible 
physician changed the initiating insulin regimen (i.e. 4 patients started prandial insulin 
and 2 patients started basal insulin therapy instead of biphasic insulin)). All patients 
included started twice-daily biphasic human insulin/isophan insulin 30 (Mixtard® 30) 
or aspart 30 (Novomix® 30). 
Crude data
Baseline characteristics of the study population are shown in Table 1. 
Median follow-up was 33 months and 90 % of all study subjects had a minimum 
follow-up of 18 months. Patients had a median age of 64 years and a median diabetes 
duration of 9 years. At baseline, mean body weight was 85 kg (range 47-157 kg) and 
HbA1c averaged 10 %. After 9 and 36 months of insulin therapy, mean body weight 
was 90.6 ± 18.6 (SD) kg and 91.1 ± 17.2 kg, respectively (both P<0.001 for mean 
change in body weight compared to baseline body weight). Furthermore, mean 
HbA1c after 9 months of insulin therapy was 7.9 ± 1.3 %, and after 36 months 8.1 ± 
1.3 % (both P<0.001 for mean change in HbA1c compared to baseline HbA1c). At the 
time of data collection, the median insulin dose was 56 units insulin per day (0.7 U/
kg). Figure 1 shows the interpolation of crude data of body weight and change in 
HbA1c after start of insulin therapy. The mean increase in body weight was more 
pronounced in the first 9 months after start of insulin than from 9 months further 
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Table 1 Baseline characteristics of the study population (N=122). 
Number  Median (range) / n (%)
Age (years)
Sex
  Male
  Female
Diabetes duration (years) 
Body weight (kg)
Body mass index (kg/m2)
HbA1c (%)
Oral glucose-lowering Medication
  SU only
  MET only
  SU and MET
  TZD only
  SU and TZD
  SU and MET and TZD
  SU and MET and Acarbose
  None *
Blood pressure (mmHg)
  Systolic
  Diastolic
Anti-hypertensive therapy
  Yes
  No
  Unknown
Statin use
  Yes
  No
  Unknown
Smoking
  Yes
  No
  Unknown
Alcohol
  Yes
  No
  Unknown
Lipid profile (mmol/l)
  Total cholesterol
  Triglycerides
  HDL-cholesterol
  LDL-cholesterol
122
122
122
122
122
122
122
 99
122
122
122
122
 90
 64 (35-94)
 63 (52%)
 59 (48%)
  9 (2-36)
 85.3 (47-157)
 30 (21-48)
 10 (6-15)
 
 16 (13%)
 18 (15%)
 69 (57%)
  2 (2%)
  4 (3%)
  1 (1%)
  4 (3%)
  8 (6%)
142 (100-190)
 80 (62-105)
 81 (66%)
 33 (27%)
  8 (7%)
 48 (39%)
 61 (50%)
 13 (11%)
 
 17 (14%)
 72 (59%)
 33 (27%)
  9 (7%)
 79 (65%)
 34 (28%)
 
  5.2 (2.5-8.2)
  2.5 (0.6-21.1)
  1.0 (0.5-2.4)
  2.9 (08.-5.1)
* no use of oral glucose-lowering medication prior to the start of insulin therapy. 
HbA1c, glycated haemoglobin. SU, sulfonylurea derivatives. MET, metformin. TZD, thiazolidinedione derivatives. 
HDL-cholesterol, high-density lipoprotein cholesterol. LDL-cholesterol, low-density lipoprotein cholesterol.
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onwards (0.52 kg/month versus 0.10 kg/month, P<0.05). HbA1c decreased steeply in 
the first 3 months after the start of insulin, followed by a more gradual decline.
Figure 1  Interpolation of crude data of body weight (panel A) and HbA1c (panel B) 
after start of insulin therapy.
A
B
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Fit of linear mixed models to crude data
Figure 2 visualizes the fit of the short-term weight model to the crude data. In this 
figure the crude data (stars) and estimated profiles (line) of four different patients with 
complete data up to 9 months after start of the insulin therapy are displayed. This 
figure shows that this model is sufficiently flexible to obtain a good fit in all cases: high 
(top panels) or low (bottom panels) values of the weight profile as well as increasing 
(left panels) or non-increasing (right panels) weight profiles. A similar good fit was 
obtained using the long-term weight model. 
Figure 2  The crude data (stars) and estimated profiles (line) of four different patients 
with complete data up to 9 months after start of the insulin therapy.
A
B
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Outcome of linear mixed models (short-term and long-term profiles)
Figure 3 shows the mean weight profile in the 36 months after insulin therapy (mean 
baseline body weight 85.3 kg, baseline HbA1c of 9.9 %, decrease of HbA1c 2.0 %). 
Table 2 shows the regression parameters for the weight profiles.
Figure 2  Continued.
C
D
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- Short-term weight-profiles 
Estimated mean body weight increased from 85.6 kg (95 % confidence interval (CI): 
85.4-85.9 kg) to 90.3 kg (89.3-91.2 kg) after 9 months of insulin therapy. When 
expressed as percentage of baseline body weight, the average increase in weight 
was 5.5 % after 9 months of insulin therapy. Estimated mean HbA1c decreased from 
9.5 (9.4-9.6) to 7.6 % (7.3-7.9). 
 We found that the monthly increase in body weight decreased by 0.006 kg per kg 
of higher body weight above mean body weight at baseline (85.6 kg). Thus, with the 
use of model I it was calculated that a patient with a baseline body weight of 50 kg 
increased 0.70 kg per month, whereas for a patient with a baseline body weight of 
100 kg this was 0.40 kg per month. Table 2 also shows that 0.46 kg/month (0.350-0.574 
kg/month) of weight gain within the first 9 months after start of insulin therapy was 
independent of the change in HbA1c (model II). Thus, only 12 % of the total monthly 
increase of 0.52 kg per month could be attributed to the change in HbA1c. 
 Furthermore, we found that the effect of a decrease in HbA1c on weight gain 
diminished later in time after start of insulin therapy. The effect of HbA1c change on 
body weight after 3 month was 0.37 kg/month (=0.510 - 3*0.050) per absolute 
Figure 3  The estimated mean weight profile (solid line) with the appropriate 95% 
confidence bands (dashed lines) in the 36 months after start of insulin therapy (mean 
baseline body weight of 85.3 kg and baseline HbA1c of 9.9%). The decrease in HbA1c 
since baseline at 3, 6 and 9 month is 1.6%, 1.8% and 2.0%, respectively. The vertical 
bars indicate the crude data (mean with one standard error).
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percentage decrease in HbA1c and after 9 month this was only 0.1 kg/month (=0.510 
- 9*0.050) per absolute percentage decrease in HbA1c. Figure 4 shows the short-term 
mean weight profiles with varies decreases in HbA1c and the effects on weight gain. 
- Long-term weight-profiles
Table 2 shows that the estimated increase in body weight from 9 to 36 month after 
start of insulin therapy was 0.1 kg/month (0.055-0.143 kg/month) and that this weight 
gain was independent of the baseline body weight. As a result, body weight of the 
patient with mean baseline body weight increased from 90.5 kg ( 89.4-91.5 kg) at 9 
month to 93.1 kg (91.6-94.7 kg) at 36 months after start of insulin therapy. In addition, 
the results of the mixed model for the HbA1c profiles showed no statistical significant 
change during this time period (-0.004 ± 0.005 % per month). As a result, for every 
Table 2  The estimated regression parameters with the 95% confidence  
intervals (CI) of the crude data on body weight and the HbA1c adjusted weight 
profiles by period using a linear mixed model. 
0-9 months
Model I Model II
Effect Estimate (95% CI) Estimate (95% CI)
Intercept
baseline body weight #
t (month) #
baseline body weight*t $
∆ HbA1c #
∆ HbA1c*t $
85.643
1.000
0.516
-0.006
-
-
(85.399:85.887)
(0.987:1.013)
(0.420:0.613)
(-0.011:-0.001)
-
-
85.400
1.000
0.462
-
0.510
-0.050
(85.167:85.634)
(0.988:1.012)
(0.350:0.574)
-
(0.336:0.684)
(-0.09:-0.001)
9-36 months
Model III  Model IV
Effect Estimate (95% CI) Estimate (95% CI)
Intercept
baseline body weight #
t (month) #
∆ HbA1c $
90.452
0.931
0.099
-
(89.450:91.455)
(0.878:0.985)
(0.055:0.143)
-
89.918
0.954
0.099
0.548
(89.066:90.771)
(0.909:0.999)
(0.056:0143)
(0.060:1.036)
Model I and III represent the estimated regression parameters of the crude data on body weight for the 
short (0-9 months after start of insulin therapy) and long-term (9-36 months after start of insulin therapy) 
period, respectively. Model II and IV represent the HbA1c adjusted weight profiles for the short and 
long-term period, respectively. 
All variables entered into the models contributed significantly to the change in weight profiles (# P<0.001 
and $ P<0.05). 
∆ HbA1c, absolute change in HbA1c after start of insulin therapy.
- denotes not applicable.
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patient in the model, the increase in weight per month (i.e. slope) on the long-term 
was similar. However, body weight at 9 months was dependent on baseline body 
weight and HbA1c. For example, a patient with a 1 kg higher baseline body weight will 
have a 0.95 kg (0.909-0.999 kg) higher body weight at 9 months. In addition, a patient 
with a 1% higher baseline HbA1c will have a 0.55 kg (0.060-1.036 kg) higher body 
weight at 9 months.
Discussion
In the present study, we studied individual weight-profiles of patients with T2DM up to 
36 months after initiation of insulin therapy. Mean body weight increased by more 
than 0.5 kg per month during the first 9 months after initiation of insulin therapy. 
Thereafter, the increase in body weight was more gradual, but still patients had a 
weight gain on average of 1.2 kg per year. This is well in line with other studies which 
investigate weight gain and insulin therapy (9, 13).
Figure 4  The estimated mean weight profile in the first nine months after insulin 
therapy (baseline body weight of 85.3 kg) with varies decrease in HbA1c. Solid line: 
decrease in HbA1c since baseline at 3, 6 and 9 month is 0.6%, 1.1% and 1.6%, 
respectively. Short dashed line: decrease in HbA1c since baseline at 3, 6 and 9 month 
is 1.6%, 1.6% and 1.6%, respectively, i.e. already the maximal decrease in HbA1c is 
reached at 3 months. Long dashed line: decrease in HbA1c since baseline at 3, 6 and 
9 month is 0.0%, 0.0% and 0.0%, respectively, i.e. no decrease in HbA1c.
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 However, although glycemic control improved considerably, only 12% of the 
monthly weight gain within the first 9 months could be attributed to the change in 
HbA1c. We also found that the effect of a decrease in HbA1c was most prominent 
during the first months after start of insulin therapy. After 9 months of insulin therapy, 
the change in HbA1c did no longer affect the change in body weight. 
 To our knowledge, this is the first study to show results of a longitudinal analysis 
of change in body weight after commencing insulin therapy and its relation to the 
change in HbA1c. Other studies showed that after short-term insulin therapy the level 
of improvement of glycemic control correlated with the increase in body weight, with 
reported correlations between -0.21 and -0.47 (9, 10). We believe our study adds 
valuable information by assessing to what extent the change in glycemic control 
contributes to weight gain over time. To study the relationship between body weight 
and HbA1c over time, we performed an observational longitudinal analysis using a 
linear mixed model for repeated measures data. The strength of the model allowed 
different regression lines for different patients, both in intercept and regression. In this 
way, the contribution of (change in) HbA1c to (change in) body weight in time could 
be estimated more accurately. 
 Although the model analyzed the crude data properly, these data were collected 
retrospectively. As a consequence, we were not (fully) informed about other factors 
that determined weight gain. We can only speculate about other potentially contributing 
factors, unrelated to glucose control (9). For example, anabolic effects of insulin may 
directly induce weight gain. Anabolic effects of insulin on adipose and muscle tissue 
may lead to sodium and water retention (14, 15). The anabolic effects of insulin might 
play a dominant role inducing weight gain after short-term insulin therapy. Furthermore, 
it could be argued that the insulin dose itself and change of insulin dose determines 
weight gain (10). Unfortunately, we were not informed about the insulin dose of each 
patient at every time point. Weight gain might also be determined by changes in 
caloric intake (whether or not due to initiation of insulin therapy), physical activity and 
basal metabolic rate (16, 17). The use of insulin may also lead to defensive eating 
habits because of (fear of) hypoglycemia (18). Consequently, individuals may increase 
caloric intake to proactively avoid such an event, resulting in weight gain. All these 
factors might contribute to weight gain after start of insulin therapy. To investigate 
these other factors/predictors a prospective analysis and follow-up will be required. 
 In clinical practice, many physicians are reluctant to initiate insulin treatment in 
poorly controlled obese patients because of fear of insulin-associated weight gain. 
Biesenbach et al. already reported that the risk of weight gain and increase in insulin 
requirement was similar in insulin-treated type 2 diabetic patients with normal and 
elevated BMI (19). We now show that obese patients are even less likely to gain weight 
after initiation of insulin therapy than leaner patients. However, we believe our data 
are more accurate since in the study of Biesenbach et al. patients were pooled and 
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assigned to one of three BMI subgroups (<26, 26-30 and >30) and calculations were 
based on only two time-points, thus ignoring variations in weight between these 
time-points. We think that obesity per se should not preclude physicians to initiate 
insulin therapy in poorly controlled patients with type 2 diabetes.
 After long-term insulin therapy, change in HbA1c was not a predictor of weight 
gain at all. Still, patients gained an average of 1.2 kg/year. We cannot determine 
whether (part of) this weight gain was due to the “natural” course of body weight 
associated with aging, since we lacked a control group of either matched non-diabetic 
subjects, or subjects with T2DM on oral medication. In the UKPDS (20), it was shown 
that patients assigned to the intensive glucose control with glibenclamide gained an 
average of approximately of 4 kg over 12 years of treatment, whereas those on insulin 
gained an additional 3 kg. Most of this weight gain developed within the first year of 
treatment. After one year of treatment patients with glibenclamide gained an average 
of approximately of 0.5 kg/year and those on insulin gained similar up to three years 
of treatment. Thereafter, little change in weight occurred in the group of patients on 
glibenclamide, in contrast to patients using insulin who continued to gain weight. It 
was shown that glycemic control continued to deteriorate in both groups. 
 In conclusion, the present study shows that initiation of insulin in patients with 
T2DM was associated with substantial increase in body weight. However, the 
contribution of change in HbA1c to insulin-associated weight gain was rather small in 
the short-term and even had no effect in the longer term. Further studies are needed 
to identify alternative factors that contribute to (insulin-associated) weight gain, such 
as differential effects on body composition, caloric intake and physical activity/energy 
expenditure. 
Disclosure
The authors have no relevant conflicts of interest to disclose.
Copyright Notice
Springer and the original publisher Endocrine, 39, 2011, 190-197, “Contribution of 
change in glycated haemoglobin to insulin-associated weight gain: results of a 
longitudinal study in type 2 diabetic patients”, H.J. Jansen, J.C. Hendriks, B.E. de 
Galan, G. Penders, C.J. Tack, G. Vervoort:, figure number 1-3, original copyright 
notice is given to the publication in which the material was originally published; with 
kind permission from Springer Science and Business Media.
Chapter 2
46
References
1. Hickey, M.E., and Hall, T.R. 1993. Insulin therapy and weight change in Native-American NIDDM patients. 
Diabetes Care 16:364-368.
2. Makimattila, S., Nikkila, K., and Yki-Jarvinen, H. 1999. Causes of weight gain during insulin therapy with 
and without metformin in patients with Type II diabetes mellitus. Diabetologia 42:406-412.
3. Turner, R.C., Cull, C.A., Frighi, V., and Holman, R.R. 1999. Glycemic control with diet, sulfonylurea, 
metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple 
therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012.
4. Kahn, S.E., Zinman, B., Haffner, S.M., O’Neill, M.C., Kravitz, B.G., Yu, D., Freed, M.I., Herman, W.H., 
Holman, R.R., Jones, N.P., et al. 2006. Obesity is a major determinant of the association of C-reactive 
protein levels and the metabolic syndrome in type 2 diabetes. Diabetes 55:2357-2364.
5. McCarron, D.A., and Reusser, M.E. 1996. Body weight and blood pressure regulation. Am J Clin Nutr 
63:423S-425S.
6. Purnell, J.Q., Hokanson, J.E., Marcovina, S.M., Steffes, M.W., Cleary, P.A., and Brunzell, J.D. 1998. Effect 
of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: 
results from the DCCT. Diabetes Control and Complications Trial. JAMA 280:140-146.
7. Yki-Jarvinen, H., Ryysy, L., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., Niskanen, L., Rajala, S., 
Salo, S., Seppala, P., et al. 1997. Effect of obesity on the response to insulin therapy in noninsulin-depen-
dent diabetes mellitus. J Clin Endocrinol Metab 82:4037-4043.
8. Heller, S. 2004. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Res 
Clin Pract 65 Suppl 1:S23-27.
9. Salle, A., Ryan, M., Guilloteau, G., Bouhanick, B., Berrut, G., and Ritz, P. 2005. ‘Glucose control-related’ 
and ‘non-glucose control-related’ effects of insulin on weight gain in newly insulin-treated type 2 diabetic 
patients. Br J Nutr 94:931-937.
10. Jacob, A.N., Salinas, K., Adams-Huet, B., and Raskin, P. 2007. Weight gain in type 2 diabetes mellitus. 
Diabetes Obes Metab 9:386-393.
11. Holman, R.R., Thorne, K.I., Farmer, A.J., Davies, M.J., Keenan, J.F., Paul, S., Levy, J.C., and Group, T.S. 
2007. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 
357:1716-1730.
12. G.Verbeke, G.M. 1997. Linear mixed models in practice: a SAS-oriented approach Springer-Verlag, New 
York, 1997.
13. Holman, R.R., Farmer, A.J., Davies, M.J., Levy, J.C., Darbyshire, J.L., Keenan, J.F., Paul, S.K., and Group, 
T.S. 2009. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361:1736-1747.
14. DeFronzo, R.A. 1981. The effect of insulin on renal sodium metabolism. A review with clinical implications. 
Diabetologia 21:165-171.
15. Lasserson, D.S., Glasziou, P., Perera, R., Holman, R.R., and Farmer, A.J. 2009. Optimal insulin regimens 
in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 52:1990-2000.
16. Rodin, J., Wack, J., Ferrannini, E., and DeFronzo, R.A. 1985. Effect of insulin and glucose on feeding 
behavior. Metabolism 34:826-831.
17. Wolfe, R.R. 2000. Effects of insulin on muscle tissue. Curr Opin Clin Nutr Metab Care 3:67-71.
18. Gougeon, R., Lamarche, M., Yale, J.F., and Venuta, T. 2002. The prediction of resting energy expenditure 
in type 2 diabetes mellitus is improved by factoring for glycemia. Int J Obes Relat Metab Disord 
26:1547-1552.
19. Biesenbach, G., Raml, A., and Alsaraji, N. 2006. Weight gain and insulin requirement in type 2 diabetic 
patients during the first year after initiating insulin therapy dependent on baseline BMI. Diabetes Obes 
Metab 8:669-673.
20. No authors listed. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with 
conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK 
Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853.
Change in HbA1c and insulin-associated weight gain
47
2

Physical activity is reduced 
in insulin-treated patients with 
type 2 diabetes mellitus 
H.J. Jansen, C.J. Tack, S. Arons, G. Vervoort
Submitted
Chapter 3
Chapter 3
50
Abstract
Insulin treatment in patients with type 2 diabetes mellitus (T2DM) is often associated 
with weight gain. This weight gain may be explained by a reduced daytime physical 
activity (PA) possibly related to sleep disturbances. In a cross-sectional approach, 
we assessed free-living 24-hour PA including habitual sleep characteristics in patients 
with T2DM and compared results to those obtained in age-matched non-diabetic 
lean and age- and weight-matched obese individuals.
 A total of 48 insulin-treated patients with T2DM, 38 lean and 42 obese subjects 
were studied. Free-living PA and characteristics of sleep (average lying down duration 
(ALDD), and average sleep duration (ASD) were objectively assessed by accelerometry 
(SenseWear Pro ArmbandTM, Body Media, Pittsburgh, PA, USA), which was worn for 
four consecutive 24-hour periods.
 Mean PA expressed as metabolic equivalent (METS) was significantly lower in 
patients with T2DM using insulin therapy compared to weight-matched obese 
subjects, while PA was highest in lean subjects. Patients with T2DM spent significantly 
more time in the lower PA levels compared to lean and obese individuals. The average 
number of steps per day was also significantly reduced in patient with T2DM. 
Quantitative sleep characteristics (ALDD and ASD) were similar across the groups, 
although in insulin-treated patients with T2DM sleep was more disturbed. 
 Insulin-treated type 2 diabetic patients display a significant reduction in daytime 
PA which cannot be solely attributed to obesity-related effects. The decrease in PA 
does not seem to be related to disturbed sleep characteristics.
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Introduction
After initiation of insulin treatment, patients with type 2 diabetes (T2DM) generally 
gain weight, which is, at least partly, attributed to an improvement of glycemic control 
and a decrease in glucosuria. Still, even at stable metabolic control, most insu-
lin-treated patients with diabetes have the propensity to suffer from ongoing weight 
gain (1). Weight gain is obviously undesirable in an already obese population. The 
determinants of this insulin-associated weight gain are not entirely elucidated.
 From large obesity studies using questionnaires to assess physical activity (PA), 
it is known that PA is inversely associated with body weight and fat mass (2). Hence, 
insulin-associated weight gain may be explained by a reduced daytime PA, but 
detailed analyses of PA in patients with T2DM as compared to matched controls have 
not been performed. PA may decrease as a result of changes in daily behaviour, for 
example to avoid hypoglycemia. Because sleep duration and quality has been 
associated with weight gain and obesity, sleep disturbances may also be involved in 
insulin-induced weight gain (3-5). Sleep quality, in turn, may affect daytime PA and 
vice versa. Again, sleep characteristics have so far not been studied in patients with 
insulin-treated T2DM. 
 We hypothesized that insulin treatment in patients with T2DM impacts on PA and/
or sleep, which may reduce energy expenditure and lead to weight gain. To test this 
hypothesis, we performed a cross-sectional study in which we quantitatively measured 
daytime PA and habitual sleep characteristics in insulin-treated T2DM patients and 
compared the results to those obtained in age-matched non-diabetic lean and age- 
and weight-matched obese individuals. 
Research Design and Methods
Study population
In this cross-sectional study long-term (> 4 years) insulin-treated patients with T2DM 
were included. Patients were excluded if diagnosed with steroid-induced diabetes, 
latent auto-immune diabetes in adults or maturity onset diabetes of the young. 
Other exclusion criteria were clinical evidence of manifest cardiovascular, pulmonary, 
rheumatic diseases with impaired joint mobility, (chronic) arthritis, lower limb 
amputation, pregnancy or intention to become pregnant during the study, painful 
(diabetic) neuropathy and depression which may influence daytime PA. 
 Lean and obese controls were recruited through advertisements in local news - 
papers. Obese subjects were matched to the diabetes group for body weight and 
age. Lean subjects (BMI 20-27 kg/m2) were age matched. A fasting plasma glucose 
> 7.0 mmol/l, and similar conditions as described above for diabetes patients were 
also reasons for exclusion criteria for controls. 
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Demographic and clinical characteristics
Subject characteristics (age, diabetes duration, gender, race, socio-occupational 
status, smoking habits, type of oral glucose-lowering medication, and insulin dose) 
were noted. A questionnaire was used to assess engagement in sports and average 
duration of sport per day. Body weight, height, waist- and hip circumference, and 
blood pressure were measured by standard procedures. 
Biochemical analyses
Fasting blood samples were drawn to determine glucose, glycated hemoglobin 
(HbA1c), and lipids. 
Physical activity and sleep characteristics measured by accelerometry
Free-living daytime PA and sleep was objectively measured using a SenseWear Pro 
Armband™ (Body Media, Pittsburgh, PA, USA) (6). Accelerometry is non-invasive 
and assess free-living PA. The SenseWear™ device has been validated for study of 
sleep patterns, as the internal body media algorithm can identify sleep and 
wakefulness with moderate-to-high sensitivity, specificity, and accuracy (5, 7). Unlike 
polysomnography, accelerometry does not appear to alter sleep behavior because 
there is no first-night effect (3). The device was placed on the right upper arm over the 
triceps muscle for 4 consecutive 24-h periods in free-living conditions and includes a 
2-axis accelerometer, heat flux sensor, galvanic skin response sensor, and a skin 
temperature sensor. Measurements between 7.00 am and 11.00 pm were used for 
calculations of daytime PA if > 90% of these recordings were available. Outcome 
variables from the daytime activity included: average metabolic equivalent (METS; 1 
MET = consuming 1 kcal/kg of body weight per hour), time (minutes/day) spent at 
different activity intensity categories averaged per day over the measurement period 
and number of steps per day. The average lying down duration (ALDD, i.e. the 
average interval between going to bed and getting up), average sleep duration (ASD, 
i.e. average minutes from sleep onset to awakening) and average fragmentation 
index (AFI, i.e. average number of nocturnal interruptions) were retrieved from the 
activity monitor using a sleep scoring algorithm. SenseWear Innerview™ professional 
software 6.1 was used to analyse the data.
Informed consent
The ethical committee of the RadboudUMC, Nijmegen, the Netherlands approved 
the study protocol. All subjects provided written informed consent. 
Statistical analyses
Variables are expressed as means ± SD. Differences between groups were analyzed 
using the analysis of variance (ANOVA) with the Least Significant Difference post hoc 
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test. Dichotome variables were analyzed with the Pearson’s chi-squared test. All 
calculations were performed using SPSS software (version 20.0; SPSS Inc., Chicago, 
IL, USA). Two-tailed P < 0.05 was considered significant.
Results
Characteristics of the study population
A total of 48 insulin-treated patients with T2DM, 38 lean and 42 obese subjects 
without diabetes were included in this study. Table 1 shows the demographic and 
clinical characteristics of the groups. 
As per definition, lean subjects had significant lower body weight compared to obese 
and patients with T2DM. The obese group was weight-matched with the group of 
patients with T2DM. Patients with T2DM were slightly, although significantly, older as 
compared to obese and lean subjects. As expected, there were significant clinical 
differences between lean subjects and patients with T2DM with respect to lifestyle 
parameters (use of alcohol), and blood pressure. There were also significant 
differences between groups with respect to lipid levels. Within the diabetes group the 
mean dose of insulin was 76 ± 47 U/day), 31 patients (65 %) used metformin and 4 
patients (8 %) were on sulfonylurea derivatives. 
Free-living objectively measured daytime PA 
Mean daytime PA expressed as metabolic equivalent (METS) was significant lower in 
insulin-treated patients with T2DM compared to obese and lean subjects (1.35 ± 
0.22 vs. 1.53 ± 0.33 vs. 1.85 ± 0.35, respectively; P < 0.01 between groups). 
Furthermore, patients with T2DM display reduced PA levels in the different activity 
intensity categories. The average number of steps per day also was significantly 
reduced in patient with T2DM (5188 ± 2825 compared to 8474 ± 3129 and 9575 ± 
3233 and in obese and lean subjects, respectively; P < 0.001 between T2DM vs. lean 
and T2DM vs. obese). Figure 1A-E shows the differences in PA and intensity between 
the groups. 
The vertical box-plots displayed represent summary statistics for the analyzed 
variables stated (A-E). The plot elements and the statistics represented are as follows: 
the length of the box represents the interquartile range (the distance between the 
25th and the 75th percentiles), the horizontal line in the box interior represents the 
median, and the vertical lines issuing from the box extend to the minimum and 
maximum values of the analyzes variables.
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From Figure 2 it can be appreciated that lean controls exhibit a higher baseline PA 
level compared to the obese and T2DM group. In addition, lean subjects displayed 
more and higher peaks of (vigorous; METS ≥ 6) PA compared to the two other groups. 
Table 1  Demographic and clinical characteristics of obese patients with T2DM 
compared to lean and obese individuals. 
T2DM
(n = 48)
Obese
(n = 42)
Lean
(n = 38)
Demographics
 Age (yr) 61 ± 10$ 55 ± 9 54 ± 8 
 Gender, males (%)
 Duration diabetes (yr)
56$
11± 7 
43
-
53
-
Anthropometry and hemodynamics
 BMI (kg/m2) 31.7 ± 5.5$ 31.4 ± 3.5* 23.6 ± 1.8
 Waist circumference (cm) 110 ± 13$ 107 ± 10* 86 ± 6
 Hip circumference (cm) 104 ± 11$ 107 ± 8* 97 ± 5
 SBP (mmHg) 151 ± 23$# 143 ± 18* 132 ± 15
 DBP (mmHg) 82 ± 10# 87 ± 9* 82 ± 9
Metabolic characteristics
 HbA1c (%) 7.5 ± 0.9 - -
 TC (mmol/l) 4.5 ± 1.0 4.9 ± 1.3 4.4 ± 1.3 
 TG (mmol/l) 2.6 ± 3.0$# 1.6 ± 1.0 0.8 ± 0.4
 HDL (mmol/l) 1.1 ± 0.3$ 1.2 ± 0.5 1.3 ± 0.5
 LDL (mmol/l) 2.5 ± 0.7$# 3.1 ± 0.9 2.9 ± 1.0
 Alcohol use (%) 22$ 36* 80
 Smoking (%) 18 17* 3
Data presented as mean ± SD. BMI denotes body mass index, SBP = systolic blood pressure, DBP = 
diastolic blood pressure, HbA1c = glycosylated hemoglobin, TC = total cholesterol, TG = triglycerides, 
HDL = high-density lipoprotein cholesterol, LDL = low-density lipoprotein cholesterol, MET = metformin, 
SU = sulphonylurea derivatives, - = not applicable.
$ T2DM vs. lean; P < 0.05
# T2DM vs. obese; P < 0.05
* Obese vs. lean; P < 0.05
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Figure 1  Physical activity and intensity objectively measured by SenseWear Pro 
Armband™ comparing insulin-treated patients with T2DM, obese and lean subjects. 
Average PA expressed as metabolic equivalent (METS) which is consuming 1 kcal/kg 
of body weight per hour (A). Average number of steps taken per day (B). Time spent 
in sedentary PA category (METS 0-3) (C), time spent in moderate PA category (METS 
3-6) (D), time spent in vigorous PA category (METS 6-9) (E). * P < 0.05, # P = 0.07, 
$ P = 0.08.
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To correct for age differences between groups, separate analyses were performed to 
assess the influence of age on PA. There was no correlation between age and PA 
within the diabetes group (Pearson correlation r = 0.03; P = 0.80). When data were 
reanalyzed after exclusion of diabetes patients who were older than 70 years (in total 
10 patients), differences in PA between groups were not affected (METS 1.34 ± 0.24 
vs. 1.53 ± 0.33 vs. 1.85 ± 0.35 in type 2 diabetic patients, obese and lean individuals, 
respectively; P < 0.001 between groups). 
 There were no differences with respect to occupation and educational level between 
patients with T2DM and obese subjects (Table 2) which suggests that differences in 
 socio-occupational status between the groups cannot explain the observed differences in 
PA levels. Surprisingly, patients with T2DM reported to be significantly more engaged 
in sports than obese individuals. 
Sleep characteristics
The quantitative sleep parameters ALDD and ASD were similar between the groups 
(ALDD: 451 ± 88 vs. 431 ± 94 and 441 ± 66 min. in patients with T2DM, obese and 
lean subjects, respectively; ASD: 356 ± 88 vs. 344 ± 78 and 356 ± 88 min. in patients 
with T2DM, obese and lean subject). The qualitative sleep parameter AFI was 
significantly higher in patients with T2DM compared to lean and obese controls (16 ± 
Figure 2  Free-living objectively measured daytime PA profile (16 hrs) of a typical 
insulin-treated patient with T2DM, obese and lean subject.
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6 vs. 13 ± 5 vs. 13 ± 5, respectively, P < 0.05 for T2DM vs. obese and P = 0.07 for 
T2DM vs. lean). In addition, the AFI differences remained significant even after 
adjustment for age and BMI. Figure 3 displays the sleep characteristics of the groups. 
Conclusions 
So far, few studies have reported data concerning PA and sleep characteristics in 
patients with T2DM. The main novel finding of the present study is that patients with 
insulin-treated T2DM show a reduction in free-living daytime PA in comparison to 
weight-matched obese individuals. We found no evidence for a difference between 
the groups with respect to sleep duration although diabetes patients showed a more 
disturbed sleep.
Table 2  Differences in socio-occupational status and engagement in sports 
between groups. 
T2DM
(n = 48)
Obese
(n = 42)
Lean
(n = 38)
Occupation
 Employed 70$ 57** 76
 Self-employed 0 0 0
 Partially employed 0 2 0
 Retired 7$# 17 13
 Unemployed 21$# 24* 8
 Missing data 2 0 3
Educational level
 Middle school 94$# 81 78
 High school 3$# 17 21 
 University 3 2 0
 Missing data 0 0 1
Sports
 Engaged in sports 35$ 22* 68
 Average min/day 42 ± 18 40 ± 17 49 ± 29
Data as percentages or mean ± SD. 
*  Obese vs. lean; P < 0.05. ** Obese vs. lean; P = 0.09, # T2DM vs. lean; P < 0.05, $ T2DM vs. obese; 
P < 0.05.
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 We also found that objectively measured free-living daytime PA was reduced in 
obese individuals compared to age-matched lean subjects. This finding is in line with 
several studies (2, 8) and confirms the fact that obesity per se is inversely associated 
with PA.
 The method to measure PA in our study (accelerometry by SenseWear Pro 
ArmbandTM, Body Media, Pittsburgh, PA, USA), has been validated versus double 
labelled water for the assessment of total energy expenditure in patients with T2DM 
(9) and shown to be reliable to objectively assess physical exertion in free-living 
conditions (6, 10). A few studies have assessed PA in patients with T2DM, also with 
the use of accelerometry to assess energy expenditure (9). However, none of the 
known literature primarily investigated PA in insulin-treated patients with T2DM. One 
study reported on average >7000 steps per day in patients with T2DM (11), which is 
much higher than ~5200 steps taken per day in patients in our study. In this study 
Figure 3  Quantitative and qualitative sleep characteristics (lying down duration (A), 
sleep duration (B), and average fragmentation index (C)) comparing insulin-treated 
patients with T2DM, obese and lean subjects. * P < 0.05 and # P = 0.07.
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patients had a similar BMI compared to our diabetes subjects. In this study, it was not 
reported whether participants were treated with insulin therapy or oral glucose 
lowering medication. Another report showed that patients recruited from primary care 
clinics with T2DM recorded more sedentary time compared to healthy lean subjects 
(12). When adjusting for BMI, the differences in sedentary time were attenuated. In 
this study, most patients used metformin, and only 10 % of the participants were on 
insulin (personal communication). Jakicic et al. (13) studied activity patterns of obese 
adults with T2DM in the Look AHEAD study and compared data across various 
categories. The results provide a hint towards patients using insulin displaying lower 
levels of PA, which is in line with our study results. The study had no non-diabetic 
control group. 
 Thus, while our results suggest that insulin-treated patients with T2DM have 
lower levels of PA, our study cannot determine whether this is explained by the insulin 
treatment or by the diabetic state per se. Combined with findings from the literature a 
relationship with insulin therapy seems likely. 
 Insulin treatment may decrease PA, because patients may pro-actively avoid 
hypoglycemia. We did not measure the number and severity of hypoglycemic 
episodes and hence cannot determine whether there is a correlation with 
hypoglycemia incidence and PA. However, even when no hypoglycemic events 
occur, patients may decrease PA just because of fear for hypoglycemia. Insulin-treat-
ed patients with T2DM may also perform less PA, because of more advanced disease 
state reflected in a higher rate of micro-vascular complications. For example, diabetic 
peripheral neuropathy is negatively associated with walking in persons with T2DM 
(14). Clearly, the prevalence of peripheral polyneuropathy in our diabetes group was 
higher than in the control groups, but we found no association between presence of 
neuropathy and PA level. As we found no differences in socio-occupational class or 
engagements in sports, both known to be major contributing factors to PA (15), these 
cannot explain the dissimilarity in PA levels found in our study. Other factors relevant 
to physical inactivity such as disease burden, injecting insulin, stress, and emotional 
or depressive complaints may also contribute to the decreased PA in insulin-treated 
T2DM patients (16, 17). 
 Short sleep duration is associated with reduced reported PA (18, 19). Earlier 
studies have also found that sleep duration is inversely related to hyperglycemia, 
weight gain, and insulin resistance (20, 21). The present study, however, found no 
significant differences between the groups with respect to sleep duration implying 
that quantitative sleep characteristics in T2DM are not associated with reduced PA. In 
our study, sleep duration in patients with T2DM was less than reported in a previous 
study (21). This may be due to slight differences in analysis software. The average 
fragmentation index (AFI), a qualitative sleep parameter, was significantly higher in 
patients with T2DM compared to lean and weight-matched obese subjects, but 
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numerically the difference was rather small (AFI obese ~ 13 interruption/night vs. ~ 
16 interruptions per night in patients with T2DM). Trento et al. also investigated sleep 
characteristics using actigraph accelerometry in patients with T2DM (21). They found 
that patients had on average 22 interruptions per night, which is slightly higher 
compared to our results. Given the small absolute differences in sleep interruptions, 
we do think it is unlikely that these differences explain the lower daytime PA observed 
in patients with insulin-treated T2DM. 
 Accelerometry has been used before to study sleep disturbances in a variety of 
populations, most frequently for the evaluation of insomnia, sleep state misperception 
and circadian rhythm disorders (22). 
 The American Academy of Sleep Medicine recognizes it as a useful adjunct to 
the clinical assessment of sleep disorders (23). Accelerometry has been validated 
against polysomnography, demonstrating a correlation between 0.82 and 0.97 in 
healthy subjects (24). A SenseWear device, allows estimation of sleep and wakefulness 
based on motor activity and provides a low-cost, non-invasive, objective, and 
longitudinal method for diagnostic and post-treatment evaluation of patients 
evaluating sleep in the ambulatory setting. Accelerometry does not differentiate rapid 
eye movement (REM) sleep from non-REM sleep, so in this study disturbances in 
sleep stages could not be detected.
 Our study has limitations. Due to the cross-sectional comparison, we cannot 
determine whether decreased daytime PA in patients with T2DM is rather a cause or 
consequence of obesity or weight gain. Patients with diabetes were slightly older than 
the obese subjects, which might affect PA levels. Two additional analyses, however, 
suggest that it is unlikely that the difference in age explains the observed difference 
in PA. As stated above, our study only included patients on insulin therapy, and 
hence, we cannot judge whether patients on oral therapy show similar results of PA. 
 In summary, we show that free-living objectively measured daytime PA is reduced 
in insulin-treated patients with T2DM which cannot be solely attributed to obesity-re-
lated effects. This suggests that a reduction in daytime PA may be linked to treat-
ment-related (i.e. insulin therapy) effects of diabetes per se. Sleep duration was 
similar amongst the groups and hence does not seem to be involved in the decreased 
PA level. Prospective studies are needed to confirm these findings. 
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Abstract
The determinants of insulin-associated weight gain in type 2 diabetes mellitus (T2DM) 
are partly unknown. Therfore, we conducted a prospective study to identify predictors 
of insulin-associated weight gain. 
 In patients with T2DM, we assessed physical activity by accelerometry, caloric 
intake by diet diaries, and diabetes-related distress measured by questionnaires, 
before, and 6, and 12 months after starting insulin therapy. Glycemic control (HbA1c), 
and insulin dose were monitored.
 After 12 months of insulin therapy mean body weight had increased by 3.0 ± 2.5 kg 
(P < 0.001). The drop in HbA1c was correlated with insulin-associated weight gain. 
With the use of a multiple linear regression model a cluster of variables was identified 
that significantly related to weight gain. Diabetes- related distress, initial insulin dose, 
and the increase of insulin dose during the course of the study as well as age 
appeared to be important predictors of weight gain after initiation of insulin therapy. 
Physical activity (measured as metabolic equivalent (METS)) decreased from 1.40 ± 
0.04 at baseline to 1.32 ± 0.04 METS (P < 0.05), but was not significantly related to 
weight changes. Reported caloric intake decreased significantly. 
 Diabetes-related distress, initial and titration of insulin dose and age, all significantly 
predict insulin-associated weight gain. After the initiation of insulin therapy, physical 
activity decreased significantly, but this did not determine weight gain over the first 12 
months. Our study findings may have clinical implications.
Trial registration: clinicaltrials.gov Identifier: NCT00781495
Diabetes-related distress and insulin dose predict weight gain in T2DM
67
4
Introduction
Insulin therapy is frequently needed to achieve adequate glycemic control in patients 
with type 2 diabetes mellitus (T2DM), but often at the expense of weight gain. This is 
obviously a disadvantage of insulin therapy in an already obese population. The 
reported weight gain during the first year of insulin therapy ranges from approximately 
2 to 6 kg (1). This weight gain shows large inter-individual differences, with some 
patients experiencing substantial insulin-associated weight gain, while others do not 
show any weight gain at all or even lose weight. 
 Identification of clinical variables related to insulin-associated weight gain in 
T2DM would be valuable to predict or potentially prevent this side effect. While a 
number of putative mechanisms are postulated to explain this weight gain (2,3), 
formal prospective studies including these different clinical variables are lacking. 
 Improvement in glycemic control (change in HbA1c) by itself seems to be related 
to insulin-induced weight gain, but the contribution appears to be rather small and 
even non-significant in the long term (4). Even so, a decrease in HbA1c is inevitably 
related to insulin therapy. Insulin dose should therefore be regarded as a potential 
contributor to weight gain rather than changes in HbA1c. 
 Insulin-associated weight gain may be related to a decrease in physical activity, 
but this possibility has received limited attention. In a cross-sectional study, we 
showed that patients with pronounced weight gain (“gainers”) during insulin therapy 
performed less daily physical activity overall compared to those who did not gain 
weight (“non-gainers”) (5).
 Diabetes mellitus is associated with a significantly increased risk for depressive 
symptoms (6). Depressive complaints and anxiety are related with larger weight gain 
and an increase in cumulative incidence of obesity in men and women (7). As a 
result, it can be reasoned that depressive complaints and anxiety in patients with 
T2DM incur weight gain.
 In the current study, we first prospectively investigated whether baseline (i.e. at 
the start of insulin therapy) glycemic control, physical activity, insulin dose, and dia-
betes-related distress and also changes of these variables during the course of the 
study (changes over time) correlated with insulin-associated weight gain in patients 
with type 2 diabetes mellitus. Second, we modeled the relationship between baseline 
variables and changes over time in order to predict the amount of weight gain one 
year after the start of insulin treatment.
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Patients and Methods
Patients 
In this prospective, multicenter, observational study, patients with T2DM who were 
starting insulin therapy were included. Patients were recruited from one university 
hospital (Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands), 
3 non-university teaching hospitals (Jeroen Bosch Hospital, ‘s-Hertogenbosch, 
Slingeland Hospital, Doetinchem, and Bernhoven Hospital, Oss, The Netherlands), 
and 4 large primary care practices (“de Teselaar”, Bemmel; “De Vier Kwartieren”, 
Boxtel; “Hoevense Veld”, Uden and “Berghem”, Berghem, the Netherlands). The 
diagnosis of T2DM was made according to the diagnostic criteria of the WHO. The 
decision to start insulin treatment was at the discretion of the responsible physician 
and was always based on a failure of glycemic control while on oral glucose-lowering 
agents and diet. All patients were treated according to national guidelines (8). The 
choice of insulin preparation, insulin regime, dose and titration was left to the 
responsibility of the treating physician. Patients were excluded if they already used 
insulin or had steroid-induced diabetes, latent auto-immune diabetes in adults 
(LADA) which was excluded by testing anti-glutamic acid decarboxylase (anti-GAD) 
antibodies or maturity onset diabetes of the young (MODY). Furthermore, clinical 
evidence of psychiatric, renal, cardiovascular or liver or other diseases and medication 
(prednisone) which may influence study results regarding glucose and weight, 
hormonal disorders which may influence weight (i.e. thyroid diseases), unless properly 
treated with stable hormonal levels, bariatric treatment, excessive alcohol consumption 
(>20 g/day), drug abuse, use of thiazolidine derivatives and pregnancy or intention to 
become pregnant during the study were all considered exclusion criteria. 
 Patients were followed for 12 months after the initiation of insulin therapy. Patient 
characteristics (age, gender, race, smoking habits) were noted and clinical data were 
retrieved at baseline (i.e. prior to start insulin) and at 3-month intervals, which included 
body weight, blood pressure, HbA1c, diabetes duration, co-morbidities, number of 
hypoglycemic events, lipids, type of oral glucose-lowering medication, and insulin 
type and dose. 
 Before and at 6 and 12 months after the initiation of insulin therapy physical 
activity levels, diabetes-related distress, depressive complaints both measured by 
questionnaires and caloric intake were assessed. 
 The inclusion and exclusion criteria were reviewed at a screening visit, where 
patients underwent a history taking and a complete physical examination. The study 
protocol was approved by the local ethical committee (CMO region Arnhem- Nijmegen, 
the Netherlands). All patients provided written informed consent. 
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Measures
Patients were studied in fasted overnight conditions. Weight was measured with 
subjects wearing light underwear only. Scales were calibrated annually. Waist 
circumference was measured midway between the lower rib margin and the iliac 
crest at expiration, and hip circumference over the greater trochanter; waist-to-hip 
ratio (WHR) was calculated. Skin fold measurements at 5 specific sites (abdomen: 
next to the belly site, suprailiac: just above the iliac crest of the hip bone, quadriceps: 
middle of the upper thigh, triceps: the back of the upper arm and subscapula: 
beneath the edge of the shoulder blade) on the right site of the body were taken by 
using the Slim Guide ® Skinfold Calliper (Creative Health Products, Plymouth, USA). 
The scale of 0 to 85 mm is especially useful in assessing skin folds at the upper ranges, 
which are not accommodated by most other callipers. Accuracy may be interpolated 
to 0.5 mm. Measurements were taken twice and averaged. Body composition was 
assessed by using formulas described by Jackson and Pollock (9,10). 
 Blood pressure was measured twice by a manual sphygmomanometer in supine 
position after a minimum of 5 minutes rest at the right arm. The average blood 
pressure (mean systolic and diastolic blood pressure) was calculated. Furthermore, 
fasting blood samples were drawn to assess: glucose, HbA1c, thyroid hormone and 
lipids. 
 Physical activity was objectively measured using a SenseWear Pro Armband™ 
(Body Media, Pittsburgh, PA, USA) (11). The device was placed on the right upper 
arm over the triceps muscle for 4 consecutive days at baseline and at 6 and 12 months 
follow-up. Measurements between 7.00 am and 11.00 pm were used for calculations 
if > 90% of these data were available. Outcome variables from the activity monitor 
included: average metabolic equivalent (METS; 1 MET = consuming 1 kcal/kg of body 
weight per hour), time (minutes/day) spent at different activity intensity categories 
averaged per day over the measurement period and the number of steps per day. 
SenseWear Innerview professional software 6.1 was used to analyze the data.
 Dietary intake was measured by food records. Participants returned a handwritten 
food record in which self-reported detailed description of the types and amounts of 
food, beverage and/or supplements was documented over a 3-day period. This food 
record was modified from Thompson et al. (12). Most of the patients provided weighed 
diet records (i.e. participants weighed used food and beverages). Patients were 
asked to complete the food record for three consecutive days prior to the start of 
insulin therapy, and at 6 and 12 months follow-up. Food records were checked 
by a dietician and the intake of nutrients was calculated with a computer program 
(© Vodisys Medical Software b.v., the Netherlands, 2008). 
 Diabetes-related distress and depression was measured with the Problem Areas 
In Diabetes Scale (PAID) questionnaire (13,14). PAID-scores were calculated using a 
five-point Likert-scale with options ranging from “0 - not a problem” to “4 - serious 
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problem”. Summing all item scores and multiplying by 1.25 resulted in an overall 
PAID-score. A minimum score of 0 indicated no diabetes-related distress. A maximum 
score of 100 indicated significant diabetes-related distress. The questionnaire was 
taken at baseline and at 6 and 12 months follow-up.
Data analysis 
The sample size was based on data from a pilot study where physical activity was 
measured in 9 patients with T2DM. This group showed a physical activity level of 1.31 
METS and a standard deviation of 0.30 METS. This study was powered to detect a 
difference in physical activity of 15 % after 12 months of insulin therapy, with a power 
of 90 % at a significance level of 0.05 %. This translated to the inclusion of 65 subjects. 
It was estimated that 10-15 % of the included patients would drop-out, resulting in the 
need for 72-75 patients to be included. 
 The results of the study are displayed as means ± SD, unless otherwise indicated. 
 To study changes in clinical variables (insulin dose, body weight, HbA1c, physical 
activity, caloric intake and PAID-score) during the course of the study, a general linear 
model for repeated measures was used. 
 To determine whether selected baseline variables were related to the change 
in body weight after the start of insulin treatment, a univariate approach by simple 
correlations was performed using Pearson’s correlation coefficient for normally distributed 
variables and Spearman’s correlation coefficient for non-Gaussian distributed data. 
 Relationships between changes in clinical variables during the course of the 
study (changes over time) were investigated by a linear mixed model for repeated 
measures (15).
 Finally, a multiple linear regression model was designed in order to estimate the 
relationship between the dependent variable (insulin-associated weight gain) and 
different independent variables or predictors. Both baseline parameters (from the 
correlation analyzes) and the change in parameters over time (from the linear mixed 
model for repeated measures) were included into the model. 
 For both the multiple linear regression model and for the linear mixed model 
estimated regression parameters are presented, with the appropriate standard error 
(SE) and 95% confidence interval (CI). Details of both models are presented in the 
supplemental data.
 All calculations were made using SPSS 20.0 for Windows (SPSS Inc., Chicago, 
Illinois, USA). A P-value < 0.05 was considered significant in all statistical comparisons.
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Results
A total of 79 patients were eligible to enter the study. Seventy-seven patients 
consented and underwent screening. Of these, 74 patients with type 2 diabetes 
mellitus enrolled in the study. We excluded 9 patients (8 patients with missing 
follow-up data or withdrawal, and 1 patient was diagnosed with maturity-onset 
diabetes of the young (MODY)). Finally, 65 subjects were included in the analysis. 
Table 1 displays the descriptive characteristics of the patients at baseline.
Patients started with a mean of 18 ± 2 units (0.21 ± 0.02 U/kg) of insulin per day. 
At 6 and 12 months patients used a mean of 39 ± 3 units (0.42 ± 0.03 U/kg) and 
46 ± 4 units (0.49 ± 0.04) of insulin per day, respectively (P < 0.05 compared to 
baseline). In addition, at 6 months a shift in the use of different types of insulin was 
observed: 9 % of the patients who used long-acting insulin were switched to biphasic 
or prandial insulin. At 12 months, 46 % of the patients used long-acting insulin, 14 % 
used biphasic insulin and 40 % used basal/bolus insulin. Within the study period no 
severe hypoglycemic episodes requiring a third party occurred. 
 Mean body weight increased from 89.4 ± 2.4 to 92.4 ± 2.5 kg at 12 months of 
insulin therapy (P < 0.001, see Figure 1a), and waist circumference from 106 ± 2 to 
109 ± 2 cm at 12 months (P < 0.01). Seventy-one percent of the patients showed 
body weight gain, whereas twenty-nine percent had stable body weight or even lost 
weight after 12 months of insulin treatment (Figure 1b).
Calculated lean body mass decreased from 70 ± 2 to 69 ± 2 kg at 12 months 
(P = NS), while calculated body fat increased from 21 ± 1 to 24 ± 1 % at 12 months 
(P < 0.001). 
 Mean HbA1c decreased from 8.8 ± 0.2% (73 mmol/mol) to 7.3 ± 0.1% (56 mmol/
mol) after 12 months (P < 0.001). 
 After 12 months of insulin therapy, quantitatively measured physical activity was 
significantly reduced (Fig. 2a-e). Average metabolic equivalent (METS) decreased 
from 1.39 ± 0.04 to 1.32 ± 0.04 at 12 months of follow-up (P < 0.05), and time spent 
in sedentary physical activity level numerically increased but this difference was not 
statistically significant. The amount of moderate physical activity (METS 3-6) at 12 
months was significantly lower compared to 6 months of insulin therapy (P < 0.05). 
The average number of steps per day diminished significantly after the start of insulin 
therapy (from 6441 ± 426 to 5746 ± 343 steps/day at baseline, after 12 months of 
treatment; P < 0.05).
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Table 1  Descriptive characteristics of the study patients at baseline. 
Baseline
N 65
Age (yr) 60 ± 10
Gender (female %) 46
Race (Caucasian %) 95
Duration diabetes (yr) 9 ± 8
Weight loss prior start insulin therapy (kg) † 2.0 ± 3.8
BMI (kg/m2) 30.8 ± 5.7
SBP (mmHg) 144 ± 20
DBP (mmHg) 79 ± 10
Fasting glucose (mmol/l) 11.7 ± 3.8
HbA1c (%)/(mmol/mol) 8.9 ± 1.4/74
TC (mmol/l) 4.5 ± 1.9
TG (mmol/l) 3.4 ± 6.3
HDL (mmol/l) 1.0 ± 0.3
LDL (mmol/l) 2.3 ± 1.1
Alcohol use (%) 28
Smoking (%) 20
Type of insulin (%) #
- Long-acting only 58
- Biphasic 17
- Short-acting only 0
- Long-acting/short-acting (basal/bolus) 25
Concomitant use of oral glucose lowering agents (%)
- MET* 22
- SU** 9
- MET + SU 69
Diabetic related complications (%)
- Nephropathy 15
- Polyneuropathy 10
- Retinopathy 10
Data are means ± SD. Baseline: prior to the start of insulin therapy. † = experienced weight loss within 
12 months prior to start of insulin therapy. # = type of initiated insulin after baseline measurement and 
type of insulin used at 6 and 12 months. BMI denotes body mass index, SBP = systolic blood pressure, 
DBP = diastolic blood pressure, HbA1c = glycosylated haemoglobin, TC = total cholesterol, TG = 
triglycerides, HDL = high-density lipoprotein cholesterol, LDL = low-density lipoprotein. *MET denotes 
metformin, **SU denotes sulphonylurea derivatives.
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After insulin initiation, reported caloric intake decreased (from baseline 1599 ± 72 to 
1392 ± 41 kcal/day at 12 months; P < 0.05). Obviously, a decrease in dietary intake 
cannot explain the insulin-induced weight gain.
 Patients suffered from minor depressive complaints at baseline and this did not 
change significantly over time (PAID scores: 10.0 ± 1.4 vs. 9.7 ± 1.3 vs. 9.4 ± 1.4 at 
baseline, after 6 and 12 months, respectively, P = NS).
Correlations of baseline variables and insulin-associated weight gain
Simple correlation coefficients were calculated between baseline variables and insulin- 
associated weight gain after 12 months of insulin therapy. These results are shown in 
Table 2. The baseline variables HbA1c, insulin dose and PAID score were positively 
correlated with weight gain. The baseline variables age and body fat were negatively 
correlated with weight gain. 
Figure 1  A) Change in body weight after the start of insulin therapy. * P < 0.001. 
B) Inter-individual differences in absolute body weight gain (kg) after 12 months of 
insulin treatment.
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Figure 2  The vertical box-plots displayed represent summary statistics for the 
analysed variables stated (A-E). The plot elements and the statistics represented are 
as follows: the length of the box represents the interquartile range (the distance 
between the 25th and the 75th percentiles), the horizontal line in the box interior 
represents the median, and the vertical lines issuing from the box extend to the 
minimum and maximum values of the analyses variables.
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Changes in clinical variables over time related to insulin-associated 
weight gain 
Using a linear mixed model for repeated measures, we assessed the relationship 
between changes in clinical variables over a 12 months period of insulin treatment 
and weight gain. Details from the outcome of the linear mixed model are described in 
Supplementary Tables 1, 2 and 3. Both the change in HbA1c and insulin dose over 
time were significantly related with insulin-associated weight gain. A decrease in 
HbA1c and an increase in insulin dose contributed to weight gain. Changes in physical 
activity and diabetes-related distress over time were not related with weight gain. 
Multiple linear regression modeling
With a multiple linear regression model we retrieved a cluster of clinical parameters 
consisting of baseline variables as well as variables that change over time that are 
related to weight gain. The change in Hba1c was omitted from the prediction model 
A) Change in physical activity levels after the start of insulin therapy. METS = 
metabolic equivalent. 1 MET = consuming 1 kcal/kg of body weight per hour). 
* P < 0.05. B) Change in sedentary physical activity (METS 0-3) after the start of 
insulin therapy. C) Change in moderate physical activity (METS 3-6) after the start 
of insulin treatment. * P < 0.05. D) Change in vigorous physical activity (METS 6-9) 
after the start of insulin therapy. E) Change in average number of steps per day after 
commencing insulin therapy. * P < 0.05.
Table 2  Pearson correlation coefficients between baseline predictors and  
insulin-associated weight gain after 12 months of insulin therapy.
Variable r P-value
Age (yr) - 0.27 0.03
Body fat (%) - 0.28 0.04
HbA1c (%/mmol/mol) 0.42 0.001
Insulin dose (U/day)* 0.43 < 0.001
PAID-score** 0.31 0.03
* Analysis performed with Spearman’s rank correlation. HbA1c = glycosylated haemoglobin. ** Diabetes- 
related distress was measured by Problem Areas In Diabetes (PAID) scale. The other (non-significant) 
variables tested in simple correlation coefficients were: gender (male/female), diabetes duration (yr), 
presence of diabetes related complications (neuropathy, nephropathy (microalbuminuria), retinopathy), 
body weight (kg), waist-to-hip ratio, skin fold measurement umbilicus (mm), body fat (%), use of 
metformin (yes/no), insulin dose (U/day), number of hypoglycemic episodes, and physical activity 
(METS), thyroid hormone level (mU/l), PAID-score and centre (patients treated in hospital vs. treated 
by general practitioner).
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(see discussion). Table 3 shows that baseline diabetes-related distress as measured 
by PAID questionnaire/score, initial insulin dose, age, and change in insulin dose over 
time were the main contributors to the prediction model with respect to weight gain 
after the initiation of insulin therapy. In this model a significant interaction between 
age and PAID-score was observed. Hence, this indicates that the aforementioned 
variables are significantly related to insulin-associated weight gain but should be 
corrected for the interaction between age and diabetes-related distress.
Discussion
From our prospective study that was performed in a fairly large number of patients, 
we were able to predict insulin-associated body weight gain with the use of a cluster 
of clinical variables. Diabetes-related distress (PAID-score), insulin dose at the 
beginning of insulin therapy and age, together with the change in insulin dose during 
Table 3  Multiple linear regression analysis to assess independent baseline 
factors of insulin-associated weight gain after 12 months of insulin therapy by 
including interactions terms and change in insulin dose over time.
Variable B SE 95%-CI P-value
Constant -8.635 5.023 -18.745 to 1.475 0.092
PAID-score * 0.964 0.384 0.192 to 1.736 0.016
Initial (baseline) insulin dose 
(U/day) 
0.165 0.060 0.044 to 0.285 0.008
∆ insulin dose ** 0.048 0.019 0.009 to 0.087 0.017
Age (yr) 0.106 0.082 -0.059 to 0.271 0.202
(Age x PAID-score) -0.015 0.006 -0.028 to -0.002 0.025
Linear regression analysis with weight gain after 12 months as dependent variable. Variables were 
selected using a manual backward selection method. The following baseline variables were considered 
for the model: age (yr), body fat (%), HbA1c (%) or (mmol/l), insulin dose (U/day), PAID-score, ∆ insulin 
dose (change in insulin dose at 12 months compared to baseline), the interaction terms: (HbA1c x PAID), 
(HbA1c x body fat), (HbA1c x initial insulin dose), (HbA1c x age), (HbA1c x ∆ insulin dose), (PAID x body 
fat), (PAID x initial insulin dose), (PAID x age), (PAID x ∆ insulin dose), (initial insulin dose x body fat), (age 
x body fat), (∆ insulin dose x body fat), (age x initial insulin dose), (initial insulin dose x ∆ insulin dose), 
(∆ insulin dose x age). Only the variables that had a P-value < 0.05 remained in the final model (R2 = 0.43, 
adjusted R2 = 0.36). B = unstandardized coefficients, SE = standard error, 95%-CI = 95 % confidence 
interval for B.
In formula: body weight gain = -8.635 + 0.106 x (age) + 0.964 x (PAID-score) + -0.015 x (age x PAID-score) 
+ 0.165 x (initial insulin dose) + 0.048 x (∆ insulin dose).
* Diabetes-related distress was measured by Problem Areas In Diabetes (PAID) scale.
** ∆ insulin dose = change in insulin dose at 12 months compared to baseline.
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the study period (i.e. 12 months) are the main independent variables that contribute 
to this prediction model. Physical exercise decreased after the initiation of insulin 
treatment, but was not related to insulin-induced weight gain. 
 In this real practice-based study, most patients (58%) started with a basal insulin 
regimen. The up-titration of insulin and the corresponding decrease in HbA1c was 
well in line with the LANMET trial and other previous reports (1,16). The mean insulin- 
associated weight gain in our study patients was approximately 3 kg after 12 months 
of insulin therapy and is comparable with other data from the literature (4,17). 
 Our study is the first to explore the relationship between the change in insulin- 
associated body weight and diabetes-related distress (PAID score). We showed that 
diabetes-related distress significantly contributed to the model that predicts the 
amount of weight gain after the initiation of insulin therapy. An increase in diabetes- 
related distress reflected by a higher PAID score before the start of insulin therapy is 
related to a more pronounced weight gain. The PAID scale is a reliable and validated 
questionnaire, which is able to assess emotional distress and significant motivational 
problems in patients related to their diabetes management (13,18). Although a 
relationship between emotional factors and body mass index has been described 
(19), no link has been identified between emotional distress per se and subsequent 
changes in weight after the initiation of insulin therapy. This study was not powered to 
investigate the influence of specific components of the PAID survey having an impact 
on body weight gain. It should be pointed out that patients with evident depressive 
disorders or on psychiatric medication, both known to have a significant impact on 
body weight, were excluded from the study. However, it can be hypothesized that 
diabetes-related distress contributes to an unhealthy diet or to physical inactivity (20). 
From the multiple linear regression analyses it was shown that diabetes-related 
distress (PAID scale) and age interact with each other. This means that age negatively 
affected the strength of the relationship between PAID score and weight gain. In other 
words, the predictive value of diabetes distress with respect to insulin-associated 
weight gain will be less with increasing age. 
 Intriguingly, we found that a higher initial insulin dose at the start of the study 
significantly contributed to a more pronounced weight gain after 12 months of insulin 
therapy. Also, an increase in the insulin dose during the course of the study 
significantly contributed to the increase of body weight. Both an increase in total body 
lipid stores due to an increase in lipid synthesis and an inhibition of fatty acid release 
(lipolysis) (21) as well as fluid retention (22) may play a role in insulin-associated 
weight gain. 
 The reason why the initial insulin dose independently contributes to body weight 
gain after 12 months has to be determined. The starting amount of insulin was established 
by the treating physician and may be partly based on the level of hyperglycemia and/
or on the estimated insulin resistance. A separate analysis showed that HbA1c and 
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body weight at baseline were similar between patients starting with a low insulin dose 
compared to a high insulin dose, indicating that initial insulin dose was not determined 
by initial body weight or HbA1c. Furthermore, it was shown that HbA1c at the end of 
the study in patients who started with a relatively low insulin dose or high dose was 
well-matched. This may suggest that a gradual decrease of HbA1c in comparison 
with a steeper decrease has a favorable effect on ultimate weight gain. A possible 
explanation for this observation may be that patients suffering from a steep decrease 
of HbA1c will experience more hypoglycemic episodes (which indeed was observed) 
leading to an increase in caloric intake. The change in caloric intake between these 
two groups, however, did not differ.
 Age was shown to have a significant effect on insulin-associated weight-gain. 
Older patients starting insulin therapy were prone to gaining more body weight. This 
could be related to a decrease in daily physical activity and fitness (23,24). Indeed, a 
sub-analysis of changes in physical activity revealed that reduction in physical activity 
(METS and number of steps) was more pronounced in older patients. 
 As stated, physical activity did not seem to be related to insulin-associated 
weight gain in our study i.e. it could not be identified as an independent predictor of 
insulin-associated weight gain. Age and physical activity are covariates. From the 
analysis it appeared that only age was an independent variable. Nevertheless it can 
still be viewed as an unfavorable finding from the perspective of general health. The 
decrease in energy expenditure after insulin initiation may be explained by a number 
of mechanisms. Patients who start insulin may experience (or at least fear) 
hypoglycemic episodes and as a consequence perform less physical activity in 
order to prevent hypoglycemia. In our patient cohort, the number of hypoglycemic 
episodes was low and no severe hypoglycemia occurred. However, fear of 
hypoglycemia remains a potential explanation. Alternatively, a low physical exercise 
level may rather be a consequence than of a cause of body weight gain. 
 An increase in caloric intake is frequently mentioned as a determinant of weight 
gain. Especially after initiating insulin therapy it can be reasoned that caloric intake 
may increase in relation to (the avoidance of) hypoglycemic events resulting in weight 
gain (25). In our present study however, reported food intake did not increase, and 
even diminished significantly over time, arguing against increased food consumption 
being an important determinant of body weight gain. Several factors such as the 
intervals between the time points of taking the questionnaire, recall bias, true changes 
and intrinsic feelings could have had an impact on reported caloric intake outcomes 
as these may have potentially affected test-retest reliability. We did not perform a 
test-retest correlation analysis in order to test the reliability of the questionnaire prior 
to the study.
 We and several others, have reported that changes in HbA11c are related to 
 insulin-associated weight gain, although we found that this contribution was rather 
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small (4). In the present study, we prospectively confirmed that an improvement in 
glycemic control is significantly related to insulin-associated weight gain. Nevertheless, 
the primary intention of insulin therapy is to improve glycemic control and decrease 
HbA1c. As such, the change in HbA1c is the consequence of insulin therapy. Therefore, 
although the change in HbA1c was related to weight gain in the linear regression 
model, we did not include this variable in the multiple linear regression model because 
it does not represent a true independent variable. 
 Importantly, about 30 % of the patients did not gain or even lost weight after the 
initiation of insulin therapy. From the results of the multiple linear regression model it 
can be concluded that a young patient with a low PAID score, starting on a low insulin 
dose and in need of a more lenient up-titration of insulin to achieve adequate glycemic 
control, will probably suffer from less body weight gain after 12 months of insulin 
treatment.
 Our study has limitations. First, this study cannot assess whether the decrease 
in physical activity is rather a consequence or a cause of body weight gain. Second, 
between-centre differences and treatment effects could have influenced outcomes 
but could not be tested due to the small numbers of participating centres. Furthermore, 
while our study provides predictors of insulin-associated weight gain, it cannot 
determine whether intervening on these factors, for example a lower starting dose 
and a more lenient insulin up-titration, or interventions aimed at mood improvement 
will affect weight gain. 
 Our study results may have implications for clinical practice. The decrease in 
physical activity, although not related to insulin-associated weight gain in this study, 
is an unfavorable consequence of insulin therapy. Health education should be aimed 
at improving physical fitness in patients starting with insulin therapy, as this may be 
beneficial to reduce cardiovascular risk. The clinical importance of identifying 
emotional factors that might impact body weight gain in patients with type 2 diabetes 
adds value to understanding this novel relationship. Furthermore, it can be suggested 
that (low) initial insulin dose and a more gradual titration of insulin over time may limit 
or even prevent body weight gain.
 In conclusion, the initiation of insulin therapy in patients with T2DM is associated 
with weight gain and a decrease in physical activity. Although the reduction in physical 
activity was not associated with weight gain, it is an important issue for patients 
starting insulin therapy. A cluster of clinical variables predicts insulin-associated 
weight gain. This includes diabetes-related distress (PAID-score), initial insulin dose, 
change in insulin dose and age.
 Further prospective studies are needed to investigate the exact role of emotional 
factors, types of insulin regimens and strategies of insulin titration on weight gain. 
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Supplemental data.  
Linear mixed models presented in this study 
We studied the individual weight-profiles of patients with T2DM up to 12 months after 
the start of insulin therapy and the dependence on physical activity (METS), insulin 
dose, and diabetes-related distress (PAID), with the use of linear mixed models for 
repeated measures (14). At first, we found that the models were not statistically 
significant improved when a quadratic term in time was included in the linear part of 
the models (Likelihood-Ratio test). The following initial model was used:
Yi (t) = β0 + β1 x BBWi + β2 x t + β3 x BBWi x t + β4 x ∆VARit + β5 x ∆VARit x t + b1i + 
b2i x t + εit 
 
where Y refers to body weight, i to subject, t to the time (month) after start of insulin 
therapy, β to a fixed effect, b1i to the random intercept, b2i to the random slope, BBW 
to the baseline body weight, ∆VAR to the change in variable entered into the model 
since baseline and εit to the normal distributed residual with mean zero. 
 We fitted 4 separate models: 1) ∆VAR is the change in physical activity (∆METS), 
2) ∆VAR is the change in insulin dose (∆insulin dose), 3) ∆VAR is the change in 
 diabetes-related distress (PAID) and 4) ∆VAR is the change in HbA1c .  
 The model explained in words: the dependent variable in all models was body 
weight. The independent continuous variables were: body weight at the start of 
insulin therapy and the time (t) since the start of insulin therapy (month). Furthermore, 
the interaction term between both variables (BBW x t) was included in the unadjusted 
model (supplemental Table 1), representing different increase in body weight with 
higher initial body weight. The independent random effects were: intercept and the 
slope of the regression in time (representing weight gain or loss per month). This 
allows different regression lines for different patients, both in intercept and slope.
 We studied weight-profiles unadjusted and adjusted for change in physical activity 
(METS), insulin dose, PAID and HbA1c , separately. 
 The first model was designed to study weight profile adjusted for change in 
physical activity (METS). As mentioned, physical activity was measured at 3 time- 
points (at baseline, 6 and 12 months after start of insulin therapy). The independent 
continuous variable (time-dependent) change in METS since the start of insulin 
therapy (∆METS) was included in the model. It was found that the variable ∆METS 
did not changed the model significantly. The second model was designed to 
study weight profile adjusted for change in insulin dose. The change in insulin dose 
(∆ insulin dose) contributed significantly to the change of the model (supplemental 
Table 2). The third model was designed to study weight profile adjusted for change in 
PAID. This variable did not contribute significantly to the change of the model. Lastly, 
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the change in HbA1c was entered into the model. This variable did contribute 
significantly to the change of the model (supplemental Table 3). 
 Finally, we analyzed two time frames separately (0-6 months, and 6-12 months) 
with the use of our linear mixed model, as we expected different relationships between 
variables (change in METS, insulin dose, and PAID) and change in body weight gain 
in each time period. In Table 4 it is shown that only the change in insulin dose between 
0-6 months contributes significantly to the model.
Multiple linear regression model presented in this study
A multiple stepwise linear regression model was used to predict body weight gain. 
All two-way the interaction terms were included in order to investigate possible effect 
modification of combinations of these variables in predicting body weight gain. 
The stepwise procedure started with the removal of non-significant interactions 
followed by the removal of non-significant variables while keeping a hierarchical structure 
(i.e. if the interaction term stayed in the model, the main effect of both variables also 
stayed in the model). In other words, we used a manual backward selection regression 
method to remove non-significant interactions (P > 0.05). Thereafter, we removed 
non-significant (P > 0.05) main effects keeping the hierarchical structure.
For both the linear mixed model as well as for the multiple linear regression model 
estimated regression parameters are shown, with the appropriate standard error (SE) 
and 95% confidence interval (CI). 
Diabetes-related distress and insulin dose predict weight gain in T2DM
83
4
Supplemental tables
Table 1  The estimated regression parameters with the 95% CI of the crude data 
on body weight. 
Effect
Estimate (95% CI)
Intercept 89.555 (88.684 to 90.427)
(BBW – 89.4) 0.976 (0.929 to 1.023)
t (month) 0.253 (0.154 to 0.353)
BBW x t 0.006 (0.001 to 0.011)
Data represent the estimated regression parameters of the crude data on body weight for the period 
0-12 months after start of insulin therapy. 
Table 2  The estimated regression parameters with the 95 % CI of the change in 
insulin dose adjusted weight profile. 
Effect
Estimate (95% CI)
Intercept 89.091 (88.186 to 89.996)
(BBW – 89.4) 0.969 (0.917 to 1.013)
t (month) 0.206 (0.099 to 0.313)
∆ Insulin dose 0.038 (0.015 to 0.061)
Data represent the estimated regression parameters of the crude data on body weight adjusted for the 
change in insulin dose (∆ Insulin dose) for the period 0-12 months after start of insulin therapy.
Table 3  The estimated regression parameters with the 95 % CI of the change in 
HbA1c adjusted weight profile. 
Effect
Estimate (95% CI)
Intercept 88.790 (88.002 to 89.581)
(BBW – 89.4) 0.988 (0.958 to 1.017)
t (month) 0.267 (0.135 to 0.400)
∆ HbA1c -0.451 (-0.777 to -1.125)
Data represent the estimated regression parameters of the crude data on body weight adjusted for the 
change in HbA1c (∆ HbA1c) for the period 0-12 months after start of insulin therapy.
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Table 4  The estimated regression parameters with the 95 % CI of the change in 
insulin dose adjusted weight profile for the time period 0-6 months.
Effect
Estimate (95% CI)
Intercept 88.072 (86.919 to 89.225)
(BBW – 89.4) 0.976 (0.942 to 1.011)
t (month) 0.219 (-0.057 to 0.496)
∆ Insulin dose 0.070 (0.035 to 0.106)
Data represent the estimated regression parameters of the crude data on body weight adjusted for the 
change in insulin dose (∆ Insulin dose) for the period 0-6 months after start of insulin therapy. 
All variables entered into the models contributed significantly to the change in weight profiles. 
BBW baseline body weight (minus mean baseline body weight = 89.4), t time (month), ∆ Insulin dose 
absolute change in insulin dose.
Diabetes-related distress and insulin dose predict weight gain in T2DM
85
4
References
1. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC. Addition of biphasic, prandial, 
or basal insulin to oral therapy in type 2 diabetes. New Eng J Med 357(17):1716-30. 2007
2. Heller S. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Res Clin 
Pract 65 Suppl 1:S23-7. 2004
3. Salle A, Ryan M, Guilloteau G, Bouhanick B, Berrut G, Ritz P. ‘Glucose control-related’ and ‘non-glucose 
control-related’ effects of insulin on weight gain in newly insulin-treated type 2 diabetic patients. British J 
Nutr 94(6):931-7. 2005
4. Jansen HJ, Hendriks JC, de Galan BE, Penders G, Tack CJ, Vervoort G. Contribution of change in 
glycosylated haemoglobin to insulin-associated weight gain: results of a longitudinal study in type 2 
diabetic patients. Endocrine 39(2):190-7. 2011
5. Jansen HJ, Vervoort G, van der Graaf M, Tack CJ. Pronounced weight gain in insulin-treated patients with 
type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile. Netherlands J 
Med 68(11):359-66. 2010
6. Rotella F, Mannucci E. Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal 
studies. Diabetes Res Clin Pract: 99(2):98-104. 2012
7. Brumpton B, Langhammer A, Romundstad P, Chen Y, Mai XM. The associations of anxiety and 
depression symptoms with weight change and incident obesity: The HUNT Study. Int J Obesity 
37(9):1268-74. 2012
8. Bouma M, Rutten GE, Wiersma T. [The practice guideline ‘Diabetes mellitus type 2’ (second revision) 
from the Dutch College of General Practitioners; a response from the perspective of general practice]. 
Nederlands Tijdschrift voor Geneeskunde 150(42):2339-40. De standaard ‘Diabetes mellitus type 2’ 
(tweede herziening) van het Nederlands Huisartsen Genootschap., 2006
9. Jackson AS, Pollock ML. Generalized equations for predicting body density of men. Brit J Nutr 
40(3):497-504. 1978
10. Jackson AS, Pollock ML, Ward A. Generalized equations for predicting body density of women. Med Sci 
Sports Exercise 12(3):175-81. 1980
11. Fruin ML, Rankin JW. Validity of a multi-sensor armband in estimating rest and exercise energy 
expenditure. Med Sci Sports Exercise 36(6):1063-9. 2004
12. Thompson FE , Subar AF. Dietary assessment methodology. In Nutrition in the Prevention and Treatment 
of Disease. 2nd ed. Coulston AM, Boushey CJ, Eds. San Diego, CA, Academic Press: p. 3–392. 2008 
13. Welch G, Weinger K, Anderson B, Polonsky WH. Responsiveness of the Problem Areas In Diabetes 
(PAID) questionnaire. Diabetic Med J Brit Diabetic Assoc 20(1):69-72. 2003
14. Hosoya T, Matsushima M, Nukariya K, Utsunomiya K. The relationship between the severity of depressive 
symptoms and diabetes-related emotional distress in patients with type 2 diabetes. Internal Med 
51(3):263-9. 2012
15. Verbeke G. Linear mixed models in practice: a SAS-oriented approach. New-York: Springer-Verlag; 1997.
16. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, et al. Insulin 
glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 
49(3):442-51. 2006
17. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulphonylurea, metformin, or insulin 
in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK 
Prospective Diabetes Study (UKPDS) Group. JAMA 281(21):2005-12. 1999
18. Snoek FJ, Pouwer F, Welch GW, Polonsky WH. Diabetes-related emotional distress in Dutch and U.S. 
diabetic patients: cross-cultural validity of the problem areas in diabetes scale. Diabetes Care 
23(9):1305-9. 2000
19. Miller ST, Elasy TA. Psychometric evaluation of the Problem Areas in Diabetes (PAID) survey in Southern, 
rural African American women with Type 2 diabetes. BMC Public Health 8:70. 2008
20. Forman-Hofmann VL, Yankey JW, Hillis SL et al. Weight and depressive symptoms in older patients: 
directions of influence? J Gerontol B Psychol Sci Soc Sci 62(1):S43-51. 2007 
21. Wolfe RR. Effects of insulin on muscle tissue. Curr Opin Clin Nutr Metab Care 3:67-71. 2000 
Chapter 4
86
22. deFronzo RA. Insulin and renal sodium handling: clinical implications. Int J Obes 5(Suppl 1), 93–104. 1981
23. Ekelund U, Brage S, Franks PW, Hennings S, Emms S, Wong MY, Wareham NJ. Am J Clin Nutr 964-9. 
2005
24. St-Arnaud-McKenzie D, Payette H, Gray-Donald K. Low physical function predicts either 2-year weight 
loss or weight gain in healthy community-dwelling older adults. the NuAge Longitudinal Study. J Geront 
A Biol Sci Med Sci. 65(12):1362-1368. 2010
25. Ryan M, Livingstone MB, Ducluzeau PH, Salle A, Genaitay M, Ritz P. Is a failure to recognize an increase 
in food intake a key to understanding insulin-induced weight gain? Diabetes Care 31(3):448-50. 2008
Diabetes-related distress and insulin dose predict weight gain in T2DM
87
4

Consequences of  
insulin-associated weight gain
Part II

Pronounced weight gain  
in insulin-treated patients with  
type 2 diabetes mellitus is associated  
with an unfavorable cardiometabolic  
risk profile 
H.J. Jansen, G. Vervoort, M. van der Graaf, C.J. Tack
Netherlands Journal of Medicine 2010; 68: 359-366.
Chapter 5
Chapter 5
92
Abstract
Pronounced weight gain after start of insulin therapy in patients with type 2 diabetes 
mellitus (T2DM) may offset beneficial effects conferred by the improvement of 
glycaemic control. This hypothesis was tested by comparing the cardiometabolic risk 
profile of a group of type 2 diabetes patients with a marked increase in body weight 
(‘gainers’) after the start of insulin treatment and a similar group without any or only 
minimal weight gain (‘non-gainers’).
 In a cross-sectional study, we compared two predefined groups of patients with 
T2DM who had been on insulin therapy for a mean of 4.0 years: ‘gainers’ vs 
‘non-gainers’. Cardiometabolic risk was assessed by measuring fat content and 
distribution (physical examination, bioelectrical impedance analysis, dual energy 
X-ray absorption, and magnetic resonance imaging), liver fat content (magnetic 
resonance spectroscopy), physical activity levels (Sensewear® armband) and 
plasma markers. Each subgroup consisted of 14 patients. Gainers had significantly 
more total body and trunk fat (especially subcutaneous fat) compared with 
non-gainers. Gainers had similar liver fat content, and slightly higher levels of fat 
hormones. Furthermore, gainers performed significantly less physical activity. Lastly, 
gainers had higher total cholesterol, low-density lipoprotein cholesterol, and alanine 
aminotransferase levels with similar cholesterol-lowering treatment.
 Patients with T2DM who show pronounced weight gain during insulin therapy 
have a less favourable cardiometabolic risk profile compared with patients who show 
no or minimal weight gain.
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Introduction
Insulin therapy is frequently needed to achieve adequate glycemic control in patients 
with type 2 diabetes mellitus (T2DM), but often at the expense of weight gain. 
Although values differ between studies, and studies are generally of limited duration, 
the estimated weight gain during the first year of insulin therapy ranges from 
approximately 2 to 6 kg (1). This weight gain shows large inter-individual differences, 
with some patients experiencing substantial insulin-associated weight gain, while 
others do not show any weight gain at all or even lose weight. 
 The determinants of insulin-associated weight gain are not entirely elucidated; 
most authors view the improvement in glycaemic control as the major determinant of 
weight gain. However, the level of improvement in glycemic control is only weakly 
correlated with the increase in body weight (2, 3). A frequently mentioned clinical 
experience is that a subset of patients exists that shows a persistent and continuous 
increase in body weight over time even when stable glycemic control has been 
obtained. 
 It is obvious that weight gain in an already overweight population is undesirable. 
Weight gain will deter further optimization of insulin therapy (4) and in itself will 
adversely influence the cardiometabolic risk profile (5). Little is known about the 
effects of insulin-associated weight gain on cardiometabolic risk in patients with 
T2DM. One may hypothesize that the benefits of insulin treatment conferred by the 
improvement of glycemic control may be offset by the disadvantages associated with 
pronounced weight gain. An increased fat mass may cause aggravation of insulin 
resistance, dyslipidaemia and hypertension and may increase the levels of 
inflammatory markers and the propensity for thrombotic events (6). Indeed, in type 1 
diabetes, patients who experienced pronounced weight gain during intensive insulin 
therapy showed a less favourable cardiovascular risk profile (7). In the ACCORD trial 
(8), the intensively treated group with T2DM showed increased mortality. In this group, 
more than 75% of the patients used insulin therapy in combination with several oral 
drugs. More than 25% of the patients treated in the intensive-therapy group showed 
a mean weight gain of > 10 kg during follow-up. Although the study did not reveal any 
direct effect of the exaggerated weight gain on cardiovascular events, extensive 
weight gain might have had a negative influence on cardiometabolic risk. 
 In the present study, we hypothesized that pronounced weight gain during insulin 
therapy would be associated with an unfavorable cardiometabolic risk profile. This 
hypothesis was tested by comparing cardiometabolic risk profile of insulin-treated 
patients with T2DM who showed weight gain at the extreme ends of the spectrum 
(“gainers” versus “non-gainers”). 
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Research Design and Methods
Patient groups 
Patients were selected out of cohort of patients with T2DM who started insulin therapy 
in our university diabetes clinic between 2001-2006. To prevent confounding with 
respect to influences of different types of insulin on body weight we only included 
patients who started and continued on biphasic insulin (NovoMix® or Mixtard® 
insulin), twice-daily. Patients were selected based on the weight gain after starting 
insulin. We defined a “gainer” as a patient who showed an increase in body weight of 
≥ 0.5 kg/month within the first 18 months after starting insulin therapy and ≥ 5% weight 
gain at total follow-up (i.e. at the time of cross-sectional measurement, which was 
different for each patient). We defined a “non-gainer” as a patient with a maximum 
weight gain ≤ 2.5 kg at follow-up. These criteria were derived from a historical insulin 
treated group (N=140), and represent the upper and lower subgroups of weight gain. 
Assessment at follow-up of the cardiometabolic risk profile between the two groups 
(gainers vs. non-gainers) was performed. All selected patients had a minimal 
follow-up of 18 months. Exclusion criteria were: heart failure (NYHA class III-IV), liver 
or renal disease (defined by chronic renal disease stage ≥ III), hypoalbuminaemia, 
use of alcohol of more than 2 units/day, drug abuse, use of thiazolidinedione 
derivatives or prednisone, and pregnancy or the intention to become pregnant during 
the study. Eligible patients did not use anti-obesity medications and acarbose 
treatment. Also weight loss surgery patients or patients who followed any other weight 
management program were excluded. 
 The inclusion and exclusion criteria were reviewed at a screening visit, where 
patients underwent a history taking and a complete physical examination. The study 
protocol was approved by the local ethical committee. All patients provided written 
informed consent. 
Cardiometabolic risk assessment 
Cardiometabolic risk profile at follow-up was assessed by the following: 1) body fat 
distribution (weight, height, waist and hip circumference, bioelectrical impedance 
analysis (BIA), dual energy X-ray absorption (DEXA), and MRI) (9, 10), 2) liver fat 
content (LFAT) by magnetic resonance spectroscopy (MRS) (11), 3) physical activity 
levels (12), 4) classical risk factors, other biochemical cardiometabolic markers (13). 
 Patients were measured in fasted overnight conditions with an empty bladder. 
To determine body mass index (BMI), weight (kg) was divided by height in meters, 
squared. Weight was measured with subjects wearing light underwear only. Scales 
were calibrated annually. Waist circumference was measured midway between the 
lower rib margin and the iliac crest at expiration, and hip circumference over the 
greater trochanter; waist-to-hip ratio (WHR) was calculated. 
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 To assess fat distribution three different methods were used: BIA, DEXA and 
MRI. BIA was carried out using an Akern soft tissue analyser (BIA Quatum/S Body 
Composition Analyzer model no. BIA-101, Akern Srl, Pontassieve (Florence), Italy). 
BIA was performed to assess total body water (TBWa) and fat-free mass (FFM). 
Patients rested in supine position for approximately 5 minutes to equalise fluid 
compartments. Four surface electrodes were applied (two each to an arm and a leg). 
Phase sensitive sensors separated the components of the modulus into Reactance 
and Resistance. 
 Total-body DEXA scanning was performed using a Hologic QDR 4500 
densitometer (Hologic Inc., Bedford, USA) to determine fat mass (total fat mass and 
trunk fat) and lean mass. To assess non-trunk fat the trunk-to-leg ratio (trunk mass 
devided by leg mass) was calculated for each patient.
 MRI measurements were performed on a Tim-Trio MR system (Siemens, 
Erlangen, Germany). A series of T1-weighted (flash 2D) axial MR images was acquired 
from a region extending from 4 cm above to 4 cm below the fourth to fifth lumbar 
interspace. Visceral and subcutaneous fat areas were determined based on signal 
intensity. Proton MR spectra (STEAM; TE/TR:20/3000ms) were obtained without 
water suppression from a 8-ml voxel positioned in the liver during breath holding. 
The water signal intensity (Swater) and the methylene lipid signal intensitiy (Sfat) were 
used to calculate the percentage of liver fat by the following formula: ((Sfat)/(Sfat + 
Swater)) x 100% (14)). Total MR examination time was 30 minutes. Patients with pace - 
makers, implantable cardioverter defibrillators, metal implants, and claustrophobia 
were included, but did not undergo magnetic resonance imaging (MRI). In 11 gainers 
and 12 non-gainers MRI/MRS was performed. The remaining patients experienced 
claustrophobia during the MRI/MRS scan although they were not known with 
claustrophobia at inclusion.
 Physical activity was measured using a SenseWear Pro Armband™ (Body Media, 
Pittsburgh, PA, USA) (15, 16). The device was placed on the right upper arm over the 
triceps muscle for 5 consecutive days. Measurements were only used for calculations 
if > 90% of data were available. SenseWear Innerview professional software 6.1 was 
used to analyse the data.
 Classical risk factors as blood pressure, smoking habits, lipids, renal function 
and albumin excretion ratio (AER) were determined. Blood pressure was measured in 
supine position after a minimum of 5 minutes rest at the right arm. All patients already 
had taken their antihypertensives. Blood pressure was determined twice by a manual 
sphygmomanometer. The average blood pressure (mean systolic and diastolic blood 
pressure) was calculated. Furthermore, fasting blood samples were drawn to assess: 
HbA1c, lipids, alanine aminotransferase (ALT), and creatinin (all determined by 
standard laboratory methods). Renal function expressed as glomerular filtration rate 
(GFR) was calculated by the (MDRD formula (17). The adipocytokines, adiponectin 
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and leptin were determined by using DuoSet ELISA development system kits (R&D 
systems, Minneapolis, USA), free fatty acids (FFA) using Cobas Mira Plus® (Roche 
Diagnostics Ltd., Basal, Switzerland), and the inflammatory markers high-sensitive 
C-reactive protein (hsCRP) by Dako ELISA (Glastrup, Denmark), IL-6 and 18 by 
Luminex® Corporation assay (Austin, Texas, USA)).
Statistical analyses
Differences between groups were analyzed by unpaired Student’s t-test and 
Mann-Whitney U test as appropriate. For comparing dichotomous variables the 
Chi-square test was used. All calculations were made using SPSS 16.0 for Windows 
(SPSS Inc., Chicago, Illinois, USA). Data are expressed as means ± SEM, unless 
otherwise indicated. A P-value <0.05 was considered significant in all statistical 
comparisons.
Results
A total of 14 patients were included in each group. Table 1 shows the characteristics 
of the patients. All patients were Caucasian. The two groups (gainers vs. non-gainers) 
were compared after a mean of 4.0 ± 1.6 years insulin therapy (i.e. mean follow-up); 
as per protocol, all patients were still on biphasic insulin. Gainers were longer on 
insulin than non-gainers (4.6 ± 1.7 vs. 3.7 ± 2.1 yr, P = 0.03). 
Table 1  Patient characteristics after a mean of 4 years of insulin therapy
 Gainers Non-gainers
Gender (m/f) 8/6 10/4
Age (yr) 63 ± 7 65 ± 7
Diabetes duration (yr) 9 (2-25) 12 (2-22)
Insulin therapy (yr) 4.6 ± 1.7 3.7 ± 2.1 *
Medication (n)
- Insulin alone
- Insulin + Metformin 
- Insulin + SU † 
- Insulin + Metformin + SU
7
6
0
1
5
7
1
1
Insulin dose (U/day) 68 ± 37              60 ± 37
Insulin dose (U/kg) 0.7 ± 0.4 0.7 ± 0.4
Data are means ± SD or median (range). * P < 0.05. † SU sulfonylurea derivative.
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Change in weight and HbA1c after start of insulin therapy 
As per definition, gainers showed a substantially larger weight gain (+11 kg [range + 5.2 
to + 19.6 kg]) compared to the non-gainers (-1.2 kg [range -7.6 to + 2.5 kg], Fig. 1A 
and B). Of note, body weight at the start of insulin therapy was slightly lower in 
gainers (83 ± 15 vs. 87 ± 13 kg, P = NS). After 4 years of insulin therapy, BMI, waist 
circumference and waist/hip ratio were not significantly different between the two 
groups (BMI 32.3 ± 5.6 vs. 29.0 ± 4.5 kg/m2, waist circumference 110 ± 15 vs. 106 
± 13 cm, WHR 1.05 ± 0.12 vs. 1.03 ± 0.10, for gainers and non-gainers, resp., P = NS). 
Figure 1  A (upper panel) Observed change in weight after start of insulin therapy 
(t=0) comparing gainers (closed squares) and non-gainers (open circles). B (lower 
panel) Absolute change in weight after start of insulin therapy. * P < 0.05.
A
B
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Mean HbA1c decreased from 9.9 ± 2.6 to 7.2 ± 0.7 in gainers versus 8.9 ± 1.3 to 7.4 
± 0.9 % in non-gainers (P = NS for the difference in gainers vs. the difference in 
non-gainers). 
Cardiometabolic risk profile at follow-up
Fat distribution
Gainers had significantly more total body fat (32.4 ± 9.4 vs. 24.6 ± 7.7 kg, P = 0.03) 
and more trunk fat compared to non-gainers (18.3 ± 5.5 vs. 14.1 ± 4.2 kg, P = 0.04). 
Gainers had slightly higher TBWa compared to non-gainers (37.7 ± 7.5 vs. 35.9 ± 7.1 
L, P = NS). FFM was comparable in gainers and non-gainers as measured by DEXA 
(58.4 ± 9.1 vs. 59.6 ± 8.7 kg, P = NS) and by BIA. In both groups the trunk-to-leg ratio 
was similar. 
 As measured by MRI, gainers had significantly higher subcutaneous fat than 
non-gainers (2.5 ± 0.8 vs. 1.8 ± 0.8 L, P = 0.04), while visceral fat was similar (1.7 ± 
0.7 vs. 1.5 ± 0.7 L, P = NS). 
 Sixteen patients (70 %) had LFAT levels above the upper reference value of 5.5 % (18). 
Gainers and non-gainers had similar LFAT (9.6 ± 2.7 vs. 9.3 ± 1.6 %, resp., P = NS).
Physical activity levels
The average total energy expenditure at follow-up was significantly lower in gainers 
than in non-gainers (2275 ± 385 vs. 2632 ± 734 kcal/day, P = 0.005). Physical activity 
duration expressed as metabolic equivalent (MET) ≥ 3, which is consuming ≥ 3 kcal/
kg of body weight per hour, tended to be lower in gainers compared to non-gainers 
(56 ± 51 vs. 83 ± 80 min./day, P = 0.06). Also the amount of vigorous activity 
(MET > 6) was lower in gainers than in non-gainers (2.4 ± 3.4 vs. 6.5 ± 5.5 minutes, 
P = 0.03). The amount of sedentary activity (MET 0-3) and moderate activity (MET 
3-6) was similar between the two groups, as was the number of steps per day (5416 
± 3543 vs. 5282 ± 3681), and the total duration of rest (514 ± 139 vs. 484 ± 148 min.) 
and sleep (409 ± 137 vs. 394 ± 135 min.), all gainers vs. non-gainers, respectively. 
Cardiometabolic markers
Prior to the start of insulin therapy the classical cardiometabolic risk markers (i.e. BMI, 
blood pressure, lipid profiles, smoking, GFR and AER) were similar in the two groups 
(table 2). 
The cardiometabolic risk markers of the two groups measured in the present study 
are shown in table 3. 
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Blood pressure was similar in gainers compared to non-gainers, as was the average 
number (2.1 vs. 2.2) and dose of antihypertensive medication. Total cholesterol and 
low-density lipoprotein cholesterol (LDL-cholesterol) were significantly higher in 
gainers than in non-gainers, as was the level of high-density lipoprotein cholesterol 
(HDL-cholesterol), despite similar use of statins at equipotent doses. 
 There were no differences between the two groups with respect to smoking 
habits. Creatinin was slightly lower in gainers than in non-gainers and urinary albumin 
excretion appeared quantitatively higher in gainers, but the differences were not 
significant. Calculated GFR was significantly higher in the gainers group. FFA and 
adiponectin levels were similar between the two groups. Leptin, and the inflammatory 
cytokines were slightly higher in gainers than in non-gainers. ALT levels were 
significantly higher in gainers. 
Table 2  Baseline cardiometabolic risk markers comparing gainers and 
non-gainers.
Gainers Non-gainers p-value
Classical risk factors
SBP (mmHg) 148 ± 26 153 ± 26 NS
DBP (mmHg) 85 ± 12 88 ± 8 NS
Total cholesterol (mmol/l) 5.1 ± 1.0 4.5 ± 0.9 NS
LDL-cholesterol (mmol/l) 3.0 ± 1.0 2.3 ± 0.9 NS
HDL-cholesterol (mmol/l) 1.2 ± 0.2 0.9 ± 0.2 * 0.01
Triglycerides (mmol/l) 2.0 ± 1.1 3.3 ± 2.4 NS
Smoking (n) 11 12 NS
Creatinin (µmol/l) 92.6 ± 29.7 99.5 ± 28.9 NS
GFR (MDRD; ml/min/1.73m2 79.0 ± 34.6 64.5 ± 0.19 NS
Albumin excretion ratio (µg/min) 29.8 ± 24.6 39.1 ± 53.4 NS
Liverenzymes
ALT (U/l) 36.8 ± 18.4 36.2 ± 20.4 NS
Data are means ± SD. 
SBP: systolic blood pressure, DBP: diastolic blood pressure, LDL: low-density lipoprotein, 
HDL: high-density lipoprotein, GRF: glomerular filtration rate (MDRD: modified diet in renal disease), 
ALT: alanine aminotransferase. 
All data were analysed by Student t-test, except for the data of AER which was analyzed with 
Mann-Whitney U-test. * P < 0.05.
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Discussion 
The main finding of this cross-sectional pilot study is that patients who develop 
pronounced weight gain after long-term insulin therapy have more total, trunk and 
subcutaneous fat, perform less physical activity and show slightly higher cholesterol 
and ALT levels and GFR compared to those who do not gain weight. All together 
these findings suggest that this group of “gainers” may have an unfavorable cardio-
metabolic risk profile compared to “non-gainers”.
 So far, hardly any study has investigated the effects of long-term insulin therapy 
on body weight as a primary endpoint. Follow-up in most studies is limited to 6-12 
Table 3  Cardiometabolic risk markers comparing gainers and non-gainers at 
follow-up. 
 Gainers Non-gainers P-value
Classical risk factors:
SBP (mmHg)
DBP (mmHg)
Total cholesterol (mmol/l)
LDL-cholesterol (mmol/l)
HDL-cholesterol (mmol/l)
Triglycerides (mmol/l)
Smoking (n)
Creatinin (µmol/l)
GFR (MDRD; ml/min/1.73m2)
Albumin excretion ratio (AER; µmol/min)
FFA (µmol/l)
150 ± 23
81 ± 10
4.8 ± 0.9
2.9 ± 0.8
1.2 ± 0.2
2.1 ± 1.4
2
85 ± 29
110 ± 28
113 ± 228
0.6 ± 0.2
146 ± 31
80 ± 11
3.8 ± 0.8 * 
2.1 ± 0.4 *
1.0 ± 0.2 *
1.7 ± 0.6
2
97 ± 38 
85 ± 33
74 ± 143
0.6 ± 0.3
NS
NS
0.001
0.006
0.03
NS
NS
NS
0.04
NS
NS
Fat hormones:
Leptin (ng/ml)
Adiponectin (µg/ml) 
43.3 ± 26.7
3.0 ± 1.4
29.7 ± 21.3
2.1 ± 1.0
NS
NS
Inflammatory markers:
hsCRP (pmol/ml)
IL-6 (pg/ml)
IL-18 (pg/ml)
Liverenzymes:
ALT (U/l)
4.8 ± 3.3
11.5 ± 18.3
139 ± 39
33.1 ± 11.4
3.7 ± 4.2
5.9 ± 2.9
133 ± 46
23.8 ± 9.1 *
NS
NS
NS
0.04
Data are means ± SD. 
SBP: systolic blood pressure, DBP: diastolic blood pressure, LDL: low-density lipoprotein, HDL: 
high-density lipoprotein, GRF: glomerular filtration rate (MDRD: modified diet in renal disease), FFA: free 
fatty acids, hsCRP: high-sensitive CRP, IL-6/18: interleukin-6 and 18, ALT: alanine aminotransferase. 
All data were analysed by Student t-test, except for the data of AER, leptin, hsCRP, IL-6 and 18 which 
were analysed by nonparametric Mann-Whitney U test. * P < 0.05.
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months, with a reported increase in body weight of approximately 2-6 kg (1). Whether 
ongoing weight increase occurs in insulin-treated patients while stable glycemic 
control has been obtained is less clear. Recently, Aas et al. (19) reported a mean 
weight gain approaching 4 kg over three years in insulin-treated participants of the 
DIGAMI study. Approximately 30% of the weight gain took place beyond 1 year of 
therapy. Also Kooy et al. (20) found ongoing weight increase in a group of insu-
lin-treated patients who were followed for over 4 years. The limited findings from 
literature match with general clinical experience and suggest that - at least in a subset 
of patients - weight continues to increase during insulin treatment without further 
improvement in glycemic control. The “gainers” selected in the present study may 
represent this group. 
 The two groups seemed to differ with respect to body weight before the start of 
insulin, with the gainers starting at a lower weight, although this difference was 
statistically not significant. This may suggest that gainers had lost more weight before 
the onset of insulin and thus simply regained more weight after starting insulin, as has 
been suggested before (21). As the initial HbA1c level was also slightly higher in the 
gainers group (not statistically significant), a relative contribution from “initial regain” 
cannot be fully excluded. Indeed, gainers suffered a mean of 4.3 kg ± 6.4 kg weight 
loss within 12 months prior to the start of insulin therapy. However, the observed 
sustained increase in body weight during long-term insulin treatment cannot be 
attributable to exaggerated weight loss before therapy. 
 The adverse effect of a sustained increase in body weight during insulin treatment 
as found in the present study is supported by previous findings. Yki-Jävinen et al. (4) 
reported higher blood pressure and lipid levels in patients with an exaggerated weight 
increase. In a recent report, initiation of insulin treatment after myocardial infarction 
was associated with a significant increase in weight and incidence of re-infarction, 
although the latter was not clearly explained by the increased weight (19). In addition, 
elevated levels of adipokines were found in a group of patients treated with insulin 
who gained weight compared to a group treated by lifestyle intervention that lost 
weight, despite similar glycemic levels. All together these data, though limited, 
suggest that insulin-associated weight gain may indeed negatively affect cardiomet-
abolic risk profile. 
 We found that the group of subjects with pronounced weight increase had higher 
total, trunk and subcutaneous fat. Long term effects of insulin-associated weight gain 
on body composition have not been reported, but in short-term studies, insulin 
treatment showed an increase in fat mass but also FFM, in line with the anabolic 
effect of insulin (22). The present study did not reveal a difference in lean body mass 
between the two groups. Although this does not exclude a beneficial effect of insulin 
treatment in itself on lean body mass, it does show that the exaggerated weight 
increase is explained by an increase in fat only. 
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 Most studies suggest that visceral rather than subcutaneous fat is associated with 
insulin-resistance and may confer increased cardiometabolic risk (23-25). From this point 
of view, the currently reported increase in subcutaneous fat mass may not necessarily 
incur to a strongly elevated cardiometabolic risk, but may still contribute to an adverse 
cardiometabolic risk profile (26). It could be hypothesized that gainers exhibit higher levels 
of adipocytokines (e.g. leptin, IL-6) at the level of subcutaneous adipose tissue compared 
to non-gainers. Furthermore, it could be argued that dietary content (e.g. ceramide 
intake) might influence body weight and metabolic effects on adipose tissue (27). 
Unfortunately, we did not perform subcutaneous fatbiopsies in the two groups and took 
a standardised questionnaire survey for assessing patients dietary habits.  
 It is known that hepatic fat accumulation is associated with (hepatic) insulin- 
resistance in non-alcoholic fatty liver disease and is also a predictor of cardiometabolic 
disease (26). Juurinen et al.  (28) showed that after 7 months of insulin therapy (basal 
insulin) patients had improvement of hepatic insulin sensitivity and reduction of 
hepatic fat content. LFAT content after longer periods of insulin treatment has not 
been studied. The present results found no statistically significant differences 
between the two groups with respect to LFAT content as measured by MRS. Both 
groups had substantial percentages of LFAT (~10%), which is in line with results 
reported in literature (29). The number of subjects in whom LFAT measurements were 
successful in the study were relatively low and thus the lack of a difference may 
represent a power problem, especially as the slightly higher ALT levels suggest that 
the group of gainers may have had slightly higher LFAT. Alternatively, higher ALT 
levels may confer an elevated cardiovascular risk, independent of LFAT (30, 31). 
 MDRD-GFR was higher in the gainers, which was associated with a tendency 
towards lower serum creatinine and an increased albumin excretion rate. Together 
these results suggest the existence of glomerular hyperfiltration, which in itself has 
been listed as a cardiovascular risk marker (32). 
 (Low-grade) inflammation and adipocytokines (i.e. leptin) are associated with 
obesity and cardiovascular disease (33-35). In line with this association, leptin, IL-6, 
IL-18 and hsCRP tended to be higher in gainers. Adiponectin levels are negatively 
associated with obesity and with cardiovascular end points. Adiponectin levels in 
both groups were similar, suggesting that insulin-associated weight gain does not 
necessarily translate in a (further) decrease in adiponectin levels. 
 Physical activity is a strong predictor of future cardiovascular disease and a 
determinant of body weight (36). Gainers had lower levels of total energy expenditure 
compared to non-gainers, and performed less vigorous exercise compared to 
non-gainers. Due to the cross-sectional design of our study, it cannot be determined 
whether the decreased level of physical exercise is the cause of the exaggerated 
 insulin-associated weight gain or the consequence. However, no matter cause or 
consequence, a low physical exercise level remains a cardiovascular risk factor. It can 
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be speculated, for instance, that (pronounced) weight gain in insulin-treated patients 
and change in physical activity is associated with a decrease in mood or tendency 
towards depression. In this study we did not assess (changes in) mood or depression 
score. Further prospective work is warranted in order to investigate the relationship 
between insulin-associated weight gain and level of physical activity. 
 The study has a number of limitations. The cross-sectional comparison cannot 
determine whether the unfavorable cardiometabolic risk profile observed in the 
gainers is the direct consequence of insulin-associated weight gain. The study 
cannot determine whether part of the observed weight gain is due to the “natural” 
course of body weight associated with aging, this would require a control group of 
either matched non-diabetic subjects, or subjects with T2DM on oral medication. The 
study also has a number of strengths. There is a rather homogenous population, 
similarly treated patients from a single centre, all on biphasic insulin. We used a set of 
sophisticated techniques to quantify body fat distribution and physical activity.  
 The results of our study may have clinical implications. As it seems that pronounced 
weight gain during (long-term) insulin therapy is associated with a less favorable 
cardiometabolic risk profile, it may be important to determine what patients are most 
at risk for weight gain. This would require assessment of predictive factors and 
lifestyle characteristics before onset of insulin treatment, which, however, are largely 
unknown. Most authors view the change in glycaemic control (i.e. change in HbA1c) 
as the major determinant of insulin-associated weight gain (2, 3). Although part of the 
short-term insulin-associated weight gain may be explained by change in HbA1c in 
this study, this cannot explain sustained weight gain after long-term insulin therapy 
when stable or even increase in HbA1c is observed. Further prospective studies are 
needed to improve identification of patients who are at risk for extensive body weight 
increase and develop interventions to prevent the weight gain. 
 In conclusion, the present study suggest that pronounced weight gain during 
(long-term) insulin therapy in patients with T2DM is associated with an unfavorable 
cardiometabolic risk profile. Further work is required to determine the individual risk 
factors for exaggerated weight increase, to assess long-term consequences and to 
develop potential interventions.
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Abstract
Insulin therapy in patients with type 2 diabetes mellitus is accompanied by weight 
gain characterized by an increase in abdominal fat mass. Expansion of adipose 
tissue mass is generally paralleled by profound morphological and inflammatory 
changes. We hypothesized that the insulin-associated increase in fat mass also 
results in changes in human subcutaneous adipose tissue morphology and increased 
inflammation, especially when weight gain is excessive. 
 We investigated the effects of weight gain on adipocyte size, macrophage influx 
and mRNA expression and protein levels of key inflammatory markers within the 
adipose tissue in patients with type 2 diabetes mellitus before and 6 months after the 
start of insulin therapy. 
 As expected insulin significantly increased body weight. At the level of subcutaneous 
adipose tissue, insulin treatment led to an influx of macrophages. When comparing 
patients gaining no or little weight with patients gaining > 4% body weight after 6 
months of insulin therapy, both subgroups displayed an increase in macrophage 
influx. However, gainers had higher protein levels of monocyte chemo-attractant 
protein-1, tumor necrosis factor-alfa and interleukin-1 beta after 6 months of insulin 
therapy compared to non-gainers.
 We conclude that insulin therapy in patients with type 2 diabetes mellitus improved 
glycemic control, yet also induces body weight gain and the influx of macrophages 
in subcutaneous adipose tissue. In patients characterized by pronounced insulin- 
associated weight gain, the influx of macrophages into adipose tissue is accompanied 
by a more pronounced inflammatory status. 
Trial registration: clinicaltrials.gov Identifier: NCT00781495
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Introduction
Insulin therapy is frequently needed to achieve adequate glycemic control in patients 
with type 2 diabetes mellitus (T2DM), yet often results in undesirable weight gain. 
Although values differ and studies are generally of limited duration, the estimated 
weight gain during the first year of insulin therapy ranges from approximately 2 to 6 kg 
(1). This weight gain is paralleled by an increase in abdominal fat mass (1). 
 When obesity develops, the adipose tissue undergoes distinct morphological 
changes including adipocyte enlargement and macrophage influx (2). In obese 
adipose tissue, macrophages can be arranged in so called crown like structures 
(CLS) that surround dysfunctional or dying adipocytes (3) and are characterized by a 
more pro-inflammatory trait as compared to individual macrophages dispersed 
throughout the adipose tissue (4). 
 In general, these changes lead to a more pronounced inflammatory status of the 
adipose tissue that reflected by an increased secretion of pro-inflammatory mediators 
by the adipose tissue and reduction in secretion of the insulin-sensitizing protein 
adiponectin (5). The enhanced inflammatory status of the adipose tissue is thought 
to contribute to the development of systemic insulin resistance that may eventually 
evolve into type 2 diabetes. Although inflammatory changes of the adipose tissue are 
well described in individuals that develop obesity, it remains unknown whether similar 
changes in morphological and inflammatory characteristics of subcutaneous adipose 
tissue also occur in type 2 diabetic patients who start insulin therapy, and subsequently 
gain weight.
 An emerging body of evidence suggests that insulin suppresses the inflammatory 
process, not only through preventing hyperglycemia but also by modulating key 
inflammatory molecules. Studies that have examined the effects of (intensive) insulin 
therapy on immune function and inflammatory factors have shown that systemic 
pro-inflammatory cytokines decrease after administration of insulin (6, 7).
 One may hypothesize that the anti-inflammatory effects on insulin at the systemic 
level may be counteracted by the pro-inflammatory changes associated with an 
increased fat mass. This may be particularly true in those who gain most weight. 
To test this hypothesis, we investigated changes in adipose tissue morphological 
characteristics, macrophage influx, mRNA expression and protein levels of key 
inflammatory markers within the adipose tissue, in patients with type 2 diabetes 
mellitus before and 6 months after the start of insulin therapy. We also assessed 
whether potential changes were related to excessive weight gain.
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Patients and Methods
Patients
This study was part of a large prospective, multicenter, observational study aimed at 
identifying determinants of insulin-induced weight gain in type 2 diabetes (abstract 
EASD no. 942; 2012, Berlin; clinicaltrials.gov NCT00781495, n = 65 patients). In short, 
patients with type 2 diabetes who failed on oral on oral glucose-lowering agents and/
or diet and were started on insulin therapy were recruited. All patients were treated 
according to local guidelines. The majority of the patients used an oral glucose 
lowering agent throughout the study (metformin and sulfonylurea derivatives). To 
determine the impact of high weight gain on the inflammatory status of the adipose 
tissue we divided the study population in two subgroups of patients: “gainers” 
(patients displaying > 4% weight gain after 6 months of insulin therapy; n = 10) 
and “non-gainers” (patients with weight gain ≤ 4%; n = 33) (1, 8). Furthermore, 
we included a matched non-diabetic obese subgroup (BMI 27-43 kg/m2 and 
subjects between 40 and 70 years old; n = 42) in order to compare adipose 
tissue morphological characteristics, macrophage influx and protein levels of key 
inflammatory markers. Exclusion criteria were earlier use of insulin, other types of 
diabetes, including steroid-induced diabetes, evidence of psychiatric, renal, cardio-
vascular, liver or other diseases and use of medication (prednisone) that may 
influence study results. 
 Before and after 6 months of insulin treatment, BMI, waist circumference, and 
skinfold thickness are measured. Body composition was assessed by using formulas 
described by Jackson and Pollock (9, 10). At baseline (i.e. prior to insulin treatment) 
and after 6 months of insulin therapy subcutaneous (sc) adipose tissue biopsies were 
obtained under local anesthesia by needle biopsies performed 6–10 cm lateral to the 
umbilicus, after an overnight fast. The same measurements were performed in the 
non-diabetic obese subjects. 
 The study protocol was approved by the local ethical committee. All study 
participants provided written informed consent. 
Biochemical analyses
Plasma glucose concentration and HbA1c were measured by standard laboratory 
methods. Furthermore, we measured plasma adiponectin, leptin, interleukin 8 (IL-8), 
high sensitive C-reactive protein (hsCRP) (R&D systems, Minneapolis, USA). 
Subcutaneous adipose tissue morphology and immunohistochemistry
Morphometry of individual fat cells was assessed using digital image analyses as 
described previously (11). For each subject, the adipocyte cell diameter of all fat cells 
in five to ten microscopic fields of view were counted and measured. On average, 
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~700 fat cells were measured per specimen (range 150–1500). Adipocyte cell size 
distribution was expressed as ratio small (≤ 50 µm) : large adipocytes (≥ 100 µm) (12). 
For detection of macrophages, adipose tissue sections were incubated with a 
CD68-monoclonal antibody (Clone EBM11, Dako, Denmark A/S). The percentage of 
macrophages was expressed as the total number of CD68-positive cells divided by 
the total number of adipocytes counted in 10 random microscopic fields of view x 100. 
A crown-like structure was defined as an adipocyte surrounded by at least three 
macrophages (13).
RNA isolation and qPCR analysis
Total RNA was extracted from sc adipose tissue as described previously (14). cDNA 
synthesis was performed using iScript (Bio-Rad Laboratories, Hercules, USA). 
Expression of genes was determined by real-time PCR analysis using an Applied 
Biosystem, (Warrington, UK). Gene expression results were normalized to β2M levels. 
When comparing gainers and non-gainers, results from a maximum of 10 individuals 
are presented for gainers and from 33 individuals part of the non-gainers group. 
Genes and primer sequences used in this study are listed in supplementary table 1. 
Luminex analysis
Protein levels within the adipose tissue biopsies were measured by Luminex 
fluorescent bead human cytokine immunoassays using manufacturer’s instructions 
(MILLIPLEX MAP, Millipore Corp., Billerica, USA). Briefly, adipose tissue lysates were 
prepared using the milliplex map lysis buffer (Millipore) and protein concentrations of 
Interleukin-1 beta (IL-1β), Interleukin-6 and 8 (IL-6/8), tumor-necrosis factor alfa 
(TNF-α), leptin, adiponectin, monocyte chemoattractant protein (MCP)-1, resistin and 
plasminogen activator inhibitor-1 (PAI-1) were determined. To measure the protein 
levels in adipose tissue using luminex, 30% lysates of each sample were made (300 
mg of adipose tissue in 1000 µl of lysis buffer). Protein concentrations of the various 
samples were measured using a bicinchoninic assay. Equal amounts of protein (28.2 
µg) were analyzed using a Bioplex system (Bio-Rad, Hercules, USA). When comparing 
gainers and non-gainers (1, 8), results from a maximum of 10 individuals are presented 
for gainers and from 33 individuals part of the non-gainers group. A maximum of 37 
non-diabetic obese subjects are presented. Missing values were due to technical 
issues or measurements below the detection level of the luminex assay. 
Statistical analyses
Descriptive patient characteristics and other variables are displayed as means ± SD, 
unless otherwise indicated. Differences after insulin treatment were studied using 
Students’ paired t-test, Wilcoxon signed-rank test and Mann-Whitney U test as 
appropriate. For comparing dichotomous variables the Chi-square test was used. All 
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calculations were performed using SPSS 20.0 for Windows (SPSS Inc., Chicago, 
USA). Two-tailed p-values less than 0.05 were considered significant in all statistical 
comparisons.
Results
Start of insulin therapy
A total of 43 patients with T2DM who started insulin therapy underwent paired adipose 
tissue biopsies. Baseline anthropometric and laboratory characteristics of the study 
group are shown in table 1. 
After 6 months, 25 patients (58%) used basal insulin only, 4 patients (9%) biphasic 
insulin and 14 patients (33%) basal and bolus insulin. At 6 months, patients used 0.37 
± 0.24 U insulin/kg body weight. Fifty-eight percent of the patients injected insulin 
in the thigh area, whereas 42 % of the patients injected insulin into the abdomen. 
Of those patients injecting insulin in the thigh area at initiation of insulin therapy 
(n = 26 (61 %)), 13 patients (30 %) still injected insulin only in the thigh area at 
6 months. Insulin treatment increased body weight from 88.1 ± 18.1 to 89.3 ± 18.0 kg 
[range -4.5 to 7.4 kg] (P < 0.05). In addition, BMI, waist circumference and calculated 
body fat mass increased significantly. HbA1c dropped from 8.7 ± 1.1 to 7.4 ± 1.0 % 
(P < 0.05). 
Subcutaneous adipose tissue samples
Figure 1a-b shows histological overview of adipose tissue sections before and after 
start of insulin therapy. Insulin therapy had no effect on adipocyte cell diameter (69.5 
± 7.7 µm to 70.7 ± 6.9 µm, baseline vs. 6 months respectively, P = 0.43). Similarly, 
insulin did not affect the size distribution of adipocytes (Figure 1c), nor the percentage 
of small adipocytes (baseline 18.3 ± 10.1 vs. 17.7 ± 10.6 % after insulin, P = 0.82) or 
large adipocytes (9.7 ± 8.3 vs. 9.8 ± 8.1 %, P = 0.95). 
The adipocyte cell size was similar compared to the non-diabetic obese subjects 
(Supplemental table 2). 
Macrophage influx
The influx of CD68-positive cells/adipocyte was higher in patients with type 2 diabetes 
mellitus as compared to the non-diabetic subjects (Supplemental Figure 1).
 Strikingly, insulin therapy even further increased macrophage influx, as determined 
by the number of CD68-positive cells/adipocyte (0.07 ± 0.06 versus 0.16 ± 0.09; 
P < 0.001, Figure 2a-f and Supplemental Figure 1). 
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Males and females displayed a similar increase in influx of CD68-positive cells/adipocyte 
(males: 0.1 ± 0.1 versus females: 0.1 ± 0.1; P = 0.38). The increase in CD68-positive 
cells before and after insulin treatment was not correlated with the degree of weight 
gain in our population suggesting that insulin therapy, independently of weight gain, 
increases the number of macrophages within the adipose tissue. Noticeably, the 
number of CLS present in subcutaneous adipose tissue was not significantly changed 
before and after 6 months of insulin therapy (30 vs. 37 %; P = 0.65). The degree of 
macrophage influx was independent of the insulin injection site.
Table 1  Demographic and clinical characteristics of patients with T2DM.
Baseline 6 months 
N 43 43 
Age (yr) 61 ± 9 - 
Gender (m/f) 25/18 -
Duration diabetes (yr) 10 ± 9 - 
Weight loss prior start insulin therapy (kg)† 1.4 ± 2.7 - 
BMI (kg/m2) 29.8 ± 5.2 30.3 ± 5.1* 
Waist circumference (cm) 106 ± 14 107 ± 13# 
Lean weight (kg) 70 ± 14 68 ± 9* 
Fat weight (kg) 19 ± 9 21 ± 9* 
Body fat (%) 20 ± 7 23 ± 7 
SBP (mmHg) 143 ± 20 138 ± 18 
DBP (mmHg) 79 ± 8 79 ± 8 
Fasting glucose (mmol/l) 11.6 ± 3.0 - 
HbA1c (%)/(mmol/mol) 8.7 ± 1.1/(72) 7.4 ± 1.0(57)* 
Alcohol use (n) 13 - 
Smoking (n) 3 - 
Concomitant use of oral glucose lowering  
agents (n) 
- MET only 6 18* 
- SU only 3 3 
- MET + SU 34 22* 
Data presented as mean ± SD. † weight loss 12 months prior to start of insulin. BMI denotes body 
mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HbA1c = glycosylated 
haemoglobin, MET = metformin, SU = sulphonylurea derivatives. - = not applicable.
* P < 0.05, # P = 0.06
Chapter 6
116
Gene expression values in adipose tissue
The degree of influx of macrophages into the adipose tissue as measured by immuno- 
histochemical staining is mirrored by a similar trend in mRNA expression of macrophage- 
specific markers F4/80 and CD38 (Supplemental Figure 2).
 Since an enhancement in macrophage influx into adipose tissue is known to 
increase the inflammatory state of the adipose tissue, we set out to measure the 
changes in mRNA levels of key adipocytokines within adipose tissue biopsies. After 
6 months of insulin treatment, glucose transporter type 4 (SLC2A4) and interleukin-6 
Figure 1  Histological overview of subcutaneous adipose tissue before (A) and after 
6 months of insulin therapy (B) of a patient with type 2 diabetes mellitus. This patient 
gained 3.7 kg after 6 months of insulin treatment, without a change in average 
adipocyte cell size (adipocyte diameter 56.6 µm). Sections were stained with hema-
toxylin-eosin. Magnification: 10x. (C) The graph shows the frequency (percentage) 
distribution of absolute adipocyte cell size (µm) at baseline (solid line) and after 
6 months of insulin treatment (dashed line). Bin width 2 µm. n=43 individuals for 
both time points.
A
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Figure 2  Representative sections of subcutaneous adipose tissue morphology and 
CD68-immunohistochemical staining before and after 6 months of insulin therapy. 
No influx of macrophages before insulin therapy (A) and after 6 months of insulin 
therapy (B) was seen in a patient with 3.7 kg of weight gain. A moderate influx of 
macrophages (arrows) before insulin treatment (C) and a significant increase in 
macrophage influx as well as a CLS (star) after 6 months of insulin therapy (D) were 
seen in a patient with 4.5 kg of weight gain. All sections were counterstained with 
haematoxylin (blue). Magnification ×10. (E) Quantification of macrophage influx 
showing a significant increase in the number of CD68-positive cells after 6 months 
of insulin therapy. 0, baseline, 6, 6 months of insulin therapy. The horizontal lines 
represent the means. n=43 individuals for both time points. *p<0.001. (F) Frequency 
(percentage) distribution of the influx of macrophages (CD68-positive cells per 
adipocyte) at baseline (solid line) and after 6 months of insulin treatment (dashed 
line). Bin width 2 µm. n=43 individuals for both time points.
A
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(IL-6) mRNA expression levels were significantly increased whereas the gene 
expression levels of peroxisome proliferator receptor gamma (PPAR-γ), adiponectin, 
monocyte chemoattractant protein (CCL-2) and interleukin-8 (IL-8) were not changed 
significantly (Figure 3a). The influx of macrophages into the adipose tissue may also 
aid remodelling processes that may occur to accommodate the expansion of adipose 
tissue mass upon insulin-associated weight gain. Hence, we measured several expression 
levels of genes related to adipose tissue remodelling. As shown in Supplemental 
Figure 3, none of the presented gene expressions changed significantly after 6 months 
of insulin therapy. 
Protein levels in adipose tissue
To more extensively characterize the inflammatory status of the adipose tissue before 
and after 6 months of insulin therapy, protein levels of various inflammatory adipokines 
including interleukin 1β, IL-6 and 8, active PAI-1, TNF-α and MCP-1 were determinant 
in adipose tissue. Patients with type 2 diabetes have higher protein levels of IL-8, 
MCP-1, PAI-1 and resistin within the subcutaneous adipose tissue as compared to 
non-diabetic obese individuals (Supplemental Figure 4). Noticebly, adipocyte size 
was similar between both study populations whereas the influx of macrophages was 
enhanced in patients with type 2 diabetes. 
 As shown in Figure 3B, there was no significant change in adipose tissue levels 
of the various pro-inflammatory mediators in adipose tissue after 6 months of insulin. 
Additionally, protein levels of leptin, and resistin were similar before and after 6 
months of insulin treatment.
Figure 1  Continued.
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Figure 3 (A) Changes in the relative gene expression levels of adipose tissue 
function (SLC2A4, PPARG, ADIPOQ) and pro-inflammatory related (CCL2, IL6 and 
IL8) genes. Left axis: IL6, SLC2A4; right axis: PPARG, ADIPOQ, CCL2, IL8. The lowest 
gene expression level in quantitative (q)PCR analysis at baseline was set at 1. The 
mean fold changes of SLC2A4, PPARG, ADIPOQ, CCL2, IL6 and IL8 were 1.37, 1.27, 
1.03, 1.14, 1.55 and 1.00, respectively. 0, at baseline; 6, after 6 months of insulin 
treatment. The horizontal lines represent the means. n=37 individuals per gene per 
time point, except for IL6 (n=35 individuals for both time points). *p<0.05. (B) Protein 
levels measured for the adipose tissue displaying adipose tissue function (leptin, 
resistin) and (C) pro-inflammatory related protein levels (left axis: MCP-1, IL-1β, IL-6, 
IL-8, TNF-α; right axis: PAI-1). 0, at baseline; 6, after 6 months of insulin treatment. 
The horizontal lines represent the means. The mean fold changes of leptin, resistin, 
MCP-1, IL-1β, IL-6, IL-8, TNF-α and PAI-1 were 1.16, 1.05, 0.93, 0.82, 1.18, 0.99, 1.08 
and 1.09, respectively. n=36 individuals per protein per time point.
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Circulating hormones and inflammatory markers
Whether insulin and weight gain may have an impact on circulating plasma markers 
is unknown. Therefore, we collected plasma at baseline and after 12 months of insulin 
treatment (as part of the original study). Circulating leptin levels significantly increased 
after insulin therapy. The other circulating markers did not change significantly 
(Supplemental Figure 5A).
Gainers vs. non-gainers
It is a well-known fact that weight gain favours enlargement of the adipocytes and a 
shift towards a more pro-inflammatory status of the adipose tissue (5). Although 6 
months of insulin therapy significantly enhanced body weight within our study 
population, a pronounced inter-individual variation was observed. Therefore, we 
divided the group in two subgroups of patients: “gainers” (patients displaying > 4% 
weight gain after 6 months of insulin therapy; n = 10) and “non-gainers” (patients with 
weight gain ≤ 4%; n = 33) to determine the effects of high weight gain to no or limited 
weight gain on the inflammatory status of the adipose tissue. Baseline characteristics 
comparing non-gainers and gainers are presented in table 2. At baseline body weight 
in gainers was significantly less compared to non-gainers. 
 Mean weight gain in gainers was 4.7 ± 1.5 kg compared to 0.09 ± 2.3 kg (P < 0.001) 
in non-gainers, and insulin dose at 6 months was 45 IU (0.57 ± 0.37 U insulin/kg 
body weight) in gainers and 29 IU (0.31 ± 0.15 U insulin/kg body weight) (both 
variables P < 0.05) in non-gainers. The change in glycaemic control was -1.79 vs. 
Figure 3  Continued.
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-1.04 % in gainers and non-gainers, respectively (P = 0.11). There was no significant 
increase in adipocyte cell size in both groups (65.8 ± 7.0 to 67.5 ± 6.9 µm vs. 70.6 ± 
7.6 to 71.6 ± 6.7 µm, in gainers vs. non-gainers, respectively (both P = 0.50 for the 
difference in adipocyte cell size within the subgroup). 
 Interestingly, the number of macrophages quantified by the number of CD68- 
positive cells into the adipose tissue was raised significantly in both groups after 
6 months of insulin therapy (Figure 4A), indicating that the influx of macrophages 
was independent of weight gain. No changes in gene expression levels were 
observed when comparing gainers and non-gainers (Figure 4B). However, protein 
Table 2  Baseline demographic and clinical characteristics comparing 
non-gainers and gainers.
Non-gainers Gainers
N 33 10
Age (yr) 61 ±10 64 ± 12
Duration diabetes (yr) 9 ± 6 14 ± 14
Weight loss prior start insulin therapy (kg) † 1.1 ± 2.2 2.2 ± 4.0
BMI (kg/m2) 30.9 ± 5.4 26.3 ± 2.4*
Waist circumference (cm) 109 ± 13 99 ± 12*
Lean weight (kg) 72 ± 14 64 ± 10*
Fat weight (kg) 20 ± 9 13 ± 5*
Body fat (%) 22 ± 7 17 ± 5*
SBP (mmHg) 115 ± 21 138 ± 15
DBP (mmHg) 80 ± 11 78 ± 5
Fasting glucose (mmol/l) 11.3 ± 2.7 12.5 ± 3.9
HbA1c (%)/(mmol/mol) 8.6 ± 0.9/70 9.0 ± 1.4/75
Alcohol use (n) 6 7
Smoking (n) 4 2
Concomitant use of oral glucose lowering  
agents (n) 
- MET 29 8
- SU 26 7
- MET + SU 25 5
Data presented as mean ± SD. † weight loss 12 months prior to start of insulin. BMI denotes body mass 
index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HbA1c = glycosylated haemoglobin, 
MET = metformin, SU = sulphonylurea derivatives. 
* P < 0.05.
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Figure 4 (A) Change in influx of CD68-positive cells into the subcutaneous adipose 
tissue after 6 months of insulin therapy comparing nongainers (white bars; ≤4% 
weight gain) and gainers (black bars; >4% weight gain). Data are presented as mean 
± SEM. n=33 non-gainers vs n=10 gainers for both time points. *p<0.05. (B) 
Changes in the relative gene expression levels of adipose tissue function (SLC2A4, 
PPARG and ADIPOQ) and inflammation (CCL2, IL6 and IL8) showing no significant 
change after 6 months of insulin therapy in patients displaying no or minimal weight 
gain (≤4%; NG) compared with a pronounced weight gain (>4%; G). Left axis: IL6; 
right axis, SLC2A4, PPARG, ADIPOQ, CCL2 and IL8. The lowest gene expression 
level in qPCR analysis at baseline was set at 1. The horizontal lines represent the 
means. n=28 values per gene/fold change for non-gainers and n=9 for gainers, 
except for IL6 (n=27 individuals for gene expression levels in non-gainers and n=8 
individuals for gainers).
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Figure 4 (C) Change in adipose tissue function (leptin and resistin) and (D) pro- 
inflammatory-related protein levels (left axis: MCP-1, IL-1β, IL-6, IL-8, TNF-α and PAI-1) 
after 6 months of insulin therapy comparing patients displaying no or minimal weight 
gain (≤4%; NG) with patients showing a pronounced weight gain (>4%; G). Left axis, 
MCP-1; right axis, IL-1β, IL-6, IL-8, TNF-α, PAI-1. The horizontal lines represent the 
means. n=27 individuals for protein levels measured in non-gainers versus n=9 
individuals for proteins measured in gainers, except for IL-1β (n=8 for gainers). 
*p<0.05, #p=0.09
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levels within adipose tissue displayed significant differences between gainers and 
non-gainers. Protein levels of MCP-1, TNF-α and IL-1β significantly increased in the 
gainers compared to the non-gainers (Figure 4C), suggesting that pronounced insu-
lin-associated weight gain may promote a more pro-inflammatory status of the 
adipose tissue that is independent of the absolute number of macrophages. When 
comparing circulating hormones and inflammatory markers in non-gainers versus 
gainers, we observed in gainers a significantly larger decrease in adiponectin levels 
and a significant larger increase in leptin levels (Supplemental Figure 5B).
Discussion
In the present study we demonstrate that 6 months of insulin therapy per se leads to 
an increase of influx of macrophages into the subcutaneous adipose tissue in patients 
with type 2 diabetes mellitus, an effect independent of the level of weight gain. 
However, the subgroup that gained a more pronounced (> 4%) amount of body 
weight, showed an increased inflammatory status of the adipose tissue as reflected 
by an increase in levels of pro-inflammatory cytokines (MCP-1, TNF-α and IL-1β) in 
the adipose tissue. 
 Mean insulin-associated weight gain in this study equaled 1.2 kg after 6 months, 
with a considerable inter-individual variation. Glycemic control significantly improved, 
HbA1c levels at 6 months of insulin therapy were suboptimal. These changes in body 
weight and glycemic control reflect real-life clinical practice outcomes. 
 Insulin-associated weight gain leads towards an increase in fat mass. Although 
the development of obesity and weight gain induce enlargement of sc adipocyte 
cells size (2), no significant increase in adipocyte cell size after 6 months of insulin 
treatment was observed within our study population. This may be explained by the 
relatively moderate weight gain as observed after 6 months of insulin therapy, 
probably too small to affect adipocyte cell size. It may also be envisioned that insulin 
induces the differentiation of novel adipocytes (15) and thereby increases the storage 
capacity without any changes in adipocyte size.
 Changes of the inflammatory trait of the adipose tissue including the influx of 
macrophages and altered levels of adipocytokines rather than changes in adipocyte 
morphology are more important consequences of insulin-associated weight gain. 
Indeed, 6 months of insulin therapy led to a significant increase of macrophages in 
the sc adipose tissue. The degree of macrophage influx, was however independent 
of the level of weight gain, and the enhanced number of macrophages present in 
adipose tissue was not accompanied by an upsurge in inflammatory status as levels 
of various inflammatory adipokines within adipose tissue were unaltered. These 
results suggest that of the influx of macrophages upon insulin therapy serves a 
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different purpose. A potential explanation for this phenomenon may involve the tissue 
remodeling function of macrophages (16, 17) Macrophages are not only capable of 
mediating inflammatory responses, yet also aid remodelling processes that may 
occur to accommodate the expansion of adipose tissue mass upon insulin-induced 
weight gain. However, expression levels of genes related to adipose tissue remodelling 
including PAI-1, TIMP-1, MMP-2, MMP-3, MMP-11 (18-20) were not changed 
significantly. Although weight gain might led to up-regulation of genes related to 
angiogenesis and extracellular matrix (ECM) remodeling (21), our results suggest 
that insulin-induced weight gain exerts different effects on ECM remodeling. 
Interestingly, lipolysis has been shown to promote the influx of macrophages into 
adipose tissue that function to prevent excessive spillover of free fatty acids into the 
circulation (22). As insulin inhibits lipolysis, the influx of macrophage upon the start of 
insulin therapy appears to be somewhat counterintuitive. However, one might 
speculate that the enhanced influx of macrophages is aimed at limiting the spillover 
of free fatty acids in obese subjects and thereby supports the lipolysis-inhibiting 
effects of insulin. 
 Finally, the influx of macrophages in the adipose tissue may be a direct result of 
injecting insulin in the abdomen. However, we did not observe a difference in influx of 
macrophages in the adipose tissue between patients injecting insulin into the thigh 
area as compared to those who injected insulin in the abdomen (data not shown) 
rendering any direct effects of insulin or its injection site on the influx of macrophages 
unlikely. 
 Although no effects on inflammation were observed in our total study population, 
classification of our patients based on the degree of weight gain did reveal interesting 
differences. Whereas both non-gainers and gainers demonstrated a significant 
increase in adipose tissue macrophage influx, the gainers displayed an increase in 
pro-inflammatory cytokine production (MCP-1, IL-1β, and TNF-α) after 6 months of 
insulin treatment as compared to non-gainers. These results imply that in gainers the 
influx of macrophages is paralleled by an enhancement of inflammatory status of the 
adipose tissue. Since the total number of macrophages present after 6 months of 
treatment were not different between both subgroups, it can be suggested that either 
the phenotype of the macrophage is more pro-inflammatory, adipocytes themselves 
are more inflamed or other immune cells have infiltrated the adipose tissue in subjects 
that gained over 4% of body weight. Although various reports have suggested that 
insulin suppresses inflammatory processes (at least systemically) (6, 7), more 
excessive weight gain after the start of insulin therapy may overrule any anti-inflam-
matory actions of insulin. 
 Even in the absence of weight gain, insulin will have direct effect on adipocytes 
as well as indirect effects through e.g. altered levels of circulating nutrients and 
hormones. Interestingly, only serum leptin increased significantly after insulin 
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treatment. It can be envisioned that effects observed after start of insulin therapy are 
primarily a result of direct effects of insulin and not indirect consequence of changes 
in circulating parameters. Remarkably, the change in adipose tissue macrophage 
numbers upon insulin therapy, is not translated into a systemic enhancement in 
inflammatory status. 
 Our study has several limitations. First, the analyses in our study were done 
using the subcutaneous fat tissue compartment, and do not necessarily implicate 
similar changes in other fat compartments. However, most studies, including our 
own, have found that inflammatory changes in the visceral adipose tissue are mirrored 
by similar changes in sc adipose tissue (23). Additionally, intake and energy 
expenditure of the patients studied was partly unknown and may have affected the 
degree of overweight and adipose tissue inflammation (24, 25). 
 The strength of our study includes the extensive phenotyping of over 40 subjects 
and careful pairwise analysis of subcutaneous adipose tissue morphology and 
inflammatory changes. Additionally, determining protein levels in adipose tissue has, 
to our knowledge, not been applied before and yields more valuable information 
concerning adipose tissue function as compared to measurements of mRNA 
expression levels and circulating protein concentrations. 
 In conclusion, our results demonstrate that 6 months of insulin treatment leads to 
a significant influx of macrophages in patients with type 2 diabetes. This effect is 
independent of weight gain. However, pronounced insulin-associated weight gain 
(> 4 %), is paralleled by pro-inflammatory changes in sc adipose tissue. Furthermore, 
gainers showed higher increase of insulin dose compared to non-gainers suggesting 
that concomitant body weight gain and shift towards a more pro-inflammatory profile 
of the adipose tissue might be associated with insulin resistance. The systemic an-
ti-inflammatory effects of insulin (therapy) might be, at least partially, offset by the 
pro-inflammatory changes associated with an increased fat mass. 
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Supplemental data
Table 1  Primer sequences.
Human
Forward primer
Reverse primer
Gene RT-PCR (real-time PCR)
B2M 5’-ATGAGTATGCCTGCCGTGTG-3’
5’-CCAAATGCGGCATCTTCAAAC-3’
GLUT4 5’-CTCAGCAGCGAGTGACTGG-3’
5’-CCCCAATGTTGTACCCAAACTG-3’
Ppar-γ 5’-ATTGACCCAGAAAGCGATTCC-3’
5’-TCTTCCATTACGGAGAGATCCAC-3’
Adiponectin 5’-ATCGGTGAAACCGGAGTACC-3’
5’-GCATGTTGGGGATAGTAACGTAA -3
MCP-1 5’-CCAGTCACCTGCTGTTATAAC-3’
5’-TGGAATCCTGAACCCACTTCT-3’
IL-6 5’-AACCTGAACCTTCCAAAGATGG-3’
5’-TCTGGCTTGTTCCTCACTACT-3’
IL-8 5’-ACTGAGAGTGATTGAGAGTGGAC-3’
5’-AACCCTCTGCACCCAGTTTTC-3’
B2M = beta-2-microglobulin
GLUT4 = glucose transporter type 4
Ppar-γ = peroxisome proliferator receptor gamma
MCP-1 = monocyte chemoattractant protein-1
IL-6/8 = interleukin-6/8
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Table 2  Demographic and clinical characteristics of non-diabetic obese subjects.
N 42 
Age (yr) 55 ± 9 
Gender (m/f) 24/18
BMI (kg/m2) 31.4 ± 3.5 
Waist circumference (cm) 107 ± 10 
Lean weight (kg) 68 ± 11 
Fat weight (kg) 22 ± 7 
Body fat (%) 24 ± 6 
SBP (mmHg) 143 ± 18
DBP (mmHg) 87 ± 9 
Fasting glucose (mmol/l) 5.2 ± 0.6 
Adipocyte cell size (µm) 67 ± 10 
CD68-positive cells/adipocyte 0.05 ± 0.06
Data presented as mean ± SD. BMI denotes body mass index, SBP = systolic blood pressure, DBP = 
diastolic blood pressure.
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Figure 1 Comparing adipocyte cell size and number of CD68-positive cells/adipocyte 
in an non-diabetic obese group and study group of patients with type 2 diabetes 
mellitus before (0) and after 6 (6) months of insuline therapy. n = 37 obese subjects 
and n = 43 patients with diabetes mellitus (DM). Horizontal lines represent mean. 
* P = 0.06. ** P < 0.05.
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6Figure 2 Change in macrophage specific markers F4/80, and CD38 mRNA expression levels before (0) and after 6 months (6) of insulin therapy. The lowest gene expression 
level in qPCR analysis at baseline was set at 1. Mean fold change of F4/80 is 28.4 and 
for CD38 mean fold change equaled 8.5. Horizontal lines represent mean. # denotes 
outlier. n = 37 individuals per time point for F4/80 gene, n = 37 individuals per time 
point for CD38 gene. * P = 0.05.
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Figure 3  Change in relative expression levels of genes related to adipose tissue 
remodeling.  SERPINE1 = plasminogen activator inhibitor-1 (left y-axis), TIMP1 = tissue 
metallopeptidase inhibitor 1 (right y-axis), MMP2/3/11 = matrix metalloproteinases-2, 3 
and 11 (left y-axis: MMP3/11; right y-axis: MMP2). 0 = baseline, 6 = after 6 months of 
insulin treatment. The lowest gene expression level in qPCR analysis at baseline was 
set at 1. Mean fold changes of SERPINE1, TIMP1, MMP2/3/11 are 1.56, 1.18, 0.87, 3.62, 
1.13, respectively. Horizontal lines represent mean. n = 37 individuals per gene per time 
point, except for MMP11 which includes n = 33 individuals for both time points. 
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Figure 5A  Change in circulating hormones and inflammatory markers before and after 
12 months of insulin treatment. 0 = baseline and 12 = after 12 months of insulin treatment. 
Plasma adiponectin (right y-axis; in µg/ml), leptin levels (left y-axis; in ng/ml), interleukin-8 
(IL8) (right y-axis; in pg/ml) and high sensitive C-reactive protein (hsCRP) (right y-axis; 
in mg/l). Mean fold changes of adiponectin, leptin, IL8 and hsCRP are 0.86, 1.25, 0.83, 
1.04, respectively. Horizontal lines represent mean. n = 38 individuals per circulating 
marker per time point. * P < 0.05.
Figure 4  Protein levels measured within the adipose tissue of non-diabetic obese 
individuals vs. obese individuals with type 2 diabetes including leptin, resistin, MCP-1, 
IL6, IL8 (left y-axis) and PAI-1 (right y-axis). DM = patients with diabetes mellitus. 
Horizontal lines represent mean. n = 36 individuals per protein per time point. * P < 0.05.
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Figure 5B  Changes in circulating hormones and inflammatory markers comparing 
non-gainers and gainers. NG = non-gainers, G = gainers. Change in plasma adiponectin 
(right y-axis; in µg/ml), leptin (left y-axis; in ng/ml), interleukin-8 (IL8) (left y-axis; in pg/ml) 
and high sensitive C-reactive protein (hsCRP) (right y-axis; in mg/l). Horizontal lines 
represent mean. n = 29 non-gainers and n = 9 gainers per circulating marker. * P < 0.01.
Effects of weight gain on adipose tissue morphology and inflammation
135
6
Reference list
1. Jansen, H.J., Vervoort, G., van der Graaf, M., and Tack, C.J. 2010. Pronounced weight gain in insu-
lin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk 
profile. Neth J Med 68:359-366.
2. Farb, M.G., Bigornia, S., Mott, M., Tanriverdi, K., Morin, K.M., Freedman, J.E., Joseph, L., Hess, D.T., 
Apovian, C.M., Vita, J.A., et al. 2011. Reduced adipose tissue inflammation represents an intermediate 
cardiometabolic phenotype in obesity. J Am Coll Cardiol 58:232-237.
3. Sun, K., Kusminski, C.M., and Scherer, P.E. 2011. Adipose tissue remodeling and obesity. J Clin Invest 
121:2094-2101.
4. Wentworth, J.M., Naselli, G., Brown, W.A., Doyle, L., Phipson, B., Smyth, G.K., Wabitsch, M., O’Brien, 
P.E., and Harrison, L.C. 2010. Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are 
associated with insulin resistance in human obesity. Diabetes 59:1648-1656.
5. Lumeng, C.N., and Saltiel, A.R. 2011. Inflammatory links between obesity and metabolic disease. J Clin 
Invest 121:2111-2117.
6. Hasegawa, A., Iwasaka, H., Hagiwara, S., Koga, H., Hasegawa, R., Kudo, K., Kusaka, J., and Noguchi, 
T. 2011. Anti-inflammatory effects of perioperative intensive insulin therapy during cardiac surgery with 
cardiopulmonary bypass. Surg Today 41:1385-1390.
7. Hyun, E., Ramachandran, R., Hollenberg, M.D., and Vergnolle, N. 2011. Mechanisms behind the anti- 
inflammatory actions of insulin. Crit Rev Immunol 31:307-340.
8. St Jeor, S.T., Brunner, R.L., Harrington, M.E., Scott, B.J., Daugherty, S.A., Cutter, G.R., Brownell, K.D., 
Dyer, A.R., and Foreyt, J.P. 1997. A classification system to evaluate weight maintainers, gainers, and 
losers. J Am Diet Assoc 97:481-488.
9. Jackson, A.S., and Pollock, M.L. 1978. Generalized equations for predicting body density of men. Br J 
Nutr 40:497-504.
10. Jackson, A.S., Pollock, M.L., and Ward, A. 1980. Generalized equations for predicting body density of 
women. Med Sci Sports Exerc 12:175-181.
11. Stienstra, R., Duval, C., Keshtkar, S., van der Laak, J., Kersten, S., and Muller, M. 2008. Peroxisome pro-
liferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages 
into adipose tissue. J Biol Chem 283:22620-22627.
12. McLaughlin, T., Sherman, A., Tsao, P., Gonzalez, O., Yee, G., Lamendola, C., Reaven, G.M., and 
Cushman, S.W. 2007. Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive 
obese individuals implicates impaired adipogenesis. Diabetologia 50:1707-1715.
13. Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, 
A.S., and Obin, M.S. 2005. Adipocyte death defines macrophage localization and function in adipose 
tissue of obese mice and humans. J Lipid Res 46:2347-2355.
14. Koenen, T.B., Tack, C.J., Kroese, J.M., Hermus, A.R., Sweep, F.C., van der Laak, J., Stalenhoef, A.F., de 
Graaf, J., van Tits, L.J., and Stienstra, R. 2009. Pioglitazone treatment enlarges subcutaneous adipocytes 
in insulin-resistant patients. J Clin Endocrinol Metab 94:4453-4457.
15. Zhang, H.H., Huang, J., Duvel, K., Boback, B., Wu, S., Squillace, R.M., Wu, C.L., and Manning, B.D. 2009. 
Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One 4:e6189.
16. Mantovani, A., Biswas, S.K., Galdiero, M.R., Sica, A., and Locati, M. 2013. Macrophage plasticity and 
polarization in tissue repair and remodelling. J Pathol 229:176-185.
17. Bourlier, V., and Bouloumie, A. 2009. Role of macrophage tissue infiltration in obesity and insulin 
resistance. Diabetes Metab 35:251-260.
18. Bernot, D., Barruet, E., Poggi, M., Bonardo, B., Alessi, M.C., and Peiretti, F. 2010. Down-regulation of 
tissue inhibitor of metalloproteinase-3 (TIMP-3) expression is necessary for adipocyte differentiation. J 
Biol Chem 285:6508-6514.
19. Chavey, C., Mari, B., Monthouel, M.N., Bonnafous, S., Anglard, P., Van Obberghen, E., and Tartare-Deck-
ert, S. 2003. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and 
modulate adipocyte differentiation. J Biol Chem 278:11888-11896.
Chapter 6
136
20. Ress, C., Tschoner, A., Ciardi, C., Laimer, M.W., Engl, J.W., Sturm, W., Weiss, H., Tilg, H., Ebenbichler, 
C.F., Patsch, J.R., et al. 2010. Influence of significant weight loss on serum matrix metalloproteinase 
(MMP)-7 levels. Eur Cytokine Netw 21:65-70.
21. Alligier, M., Meugnier, E., Debard, C., Lambert-Porcheron, S., Chanseaume, E., Sothier, M., Loizon, E., 
Hssain, A.A., Brozek, J., Scoazec, J.Y., et al. 2012. Subcutaneous adipose tissue remodeling during the 
initial phase of weight gain induced by overfeeding in humans. J Clin Endocrinol Metab 97:E183-192.
22. Kosteli, A., Sugaru, E., Haemmerle, G., Martin, J.F., Lei, J., Zechner, R., and Ferrante, A.W., Jr. 2010. 
Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest 
120:3466-3479.
23. Koenen, T.B., Stienstra, R., van Tits, L.J., Joosten, L.A., van Velzen, J.F., Hijmans, A., Pol, J.A., van der 
Vliet, J.A., Netea, M.G., Tack, C.J., et al. 2011. The inflammasome and caspase-1 activation: a new 
mechanism underlying increased inflammatory activity in human visceral adipose tissue. Endocrinology 
152:3769-3778.
24. Bradley, R.L., Jeon, J.Y., Liu, F.F., and Maratos-Flier, E. 2008. Voluntary exercise improves insulin 
sensitivity and adipose tissue inflammation in diet-induced obese mice. Am J Physiol Endocrinol Metab 
295:E586-594.
25. Enos, R.T., Davis, J.M., Velazquez, K.T., McClellan, J.L., Day, S.D., Carnevale, K.A., and Murphy, E.A. 
2013. Influence of dietary saturated fat content on adiposity, macrophage behavior, inflammation, and 
metabolism: composition matters. J Lipid Res 54:152-163.
Effects of weight gain on adipose tissue morphology and inflammation
137
6

Liver fat content is linked  
to inflammatory changes  
in subcutaneous adipose tissue  
in type 2 diabetes patients  
H. J. Jansen, G.M. Vervoort, M. van der Graaf, R. Stienstra, C.J. Tack
Clinical Endocrinology 2013; 79: 661-666.
Chapter 7
Chapter 7
140
Abstract
Patients with type 2 diabetes mellitus (T2DM) are typically overweight and have an 
increased liver fat content (LFAT). High LFAT may be explained by an increased efflux 
of free fatty acids from the adipose tissue which is partly instigated by inflammatory 
changes. This would imply an association between inflammatory features of the 
adipose tissue and liver fat content. 
 To analyse associations between inflammatory features of the adipose tissue 
and liver fat content we performed a cross-sectional study. 
 Twenty-seven obese patients with insulin-treated T2DM were studied. LFAT 
content was measured by proton magnetic resonance spectroscopy. A subcutaneous 
(sc) fat biopsy was obtained to determine morphology and protein levels within 
adipose tissue. In addition to fat cell size, the percentage of macrophages and 
the presence of crown like structures (CLSs) within sc fat was assessed by CD68- 
immunohistochemical staining. 
 Mean LFAT percentage was 11.1 ± 1.7 % (range 0.75-32.9 %); 63 % of the patients 
were diagnosed with an elevated LFAT (upper range of normal ≤ 5.5 %). Whereas 
adipocyte size did not correlate with LFAT, 3 out of 4 subjects with CLSs in sc fat had 
elevated LFAT and the percentage of macrophages present in sc adipose tissue was 
positively associated with LFAT. Protein concentrations of adiponectin within adipose 
tissue negatively correlated with LFAT. Adipose tissue protein levels of the key 
inflammatory adipokine plasminogen activator inhibitor-1 (PAI-1) were positively 
associated with LFAT.
 Several pro-inflammatory changes in sc adipose tissue associate with increased 
LFAT content in obese insulin-treated patients with T2DM. These findings suggest 
that inflammatory changes at the level of the adipose tissue may drive liver fat 
accumulation.
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Introduction
Most patients with T2DM are obese and have an accumulation of abdominal fat (1, 2) 
Additionally, liver fat content (LFAT) is strongly associated with intra-abdominal fat 
mass (3) and clearly increased in subjects with type 2 diabetes (4). The exact mechanisms 
involved in liver fat accumulation are currently unclear. It has been suggested that 
adipose tissue dysfunction is associated with the development of hepatic steatosis 
(5), yet data that link liver fat content to adipose tissue inflammation are scarce. 
 Adipose tissue expansion and adipocyte hypertrophy lead to inflammation as 
manifested by the infiltration of macrophages. Macrophages can reside in different 
forms in adipose tissue, but especially an arrangement in so called crown like structures 
surrounding adipocytes is viewed as a strong indicator of local inflammation (6). The 
pro-inflammatory status of the adipose tissue is further characterized by the increased 
production of various adipokines including TNFα, IL-6, MCP-1 and PAI-1 and has been 
linked to the development of insulin resistance (7-9). Peripheral insulin resistance 
promotes the release of fatty acids (FFAs) from adipose tissue that are subsequently 
taken up by hepatocytes to drive hepatic triglyceride synthesis and accumulation (10). 
 Therefore, LFAT content may particularly be increased in patients with T2DM in 
whom abdominal adipose tissue shows inflammatory traits. This hypothesis was 
tested in the present study, where we studied inflammatory characteristics of adipose 
tissue (adipocyte morphology, macrophage influx, the presence of crown-like 
structures and adipose tissue protein levels of various markers of adipocyte function) 
in a group of patients with T2DM and investigated whether these markers were 
associated with liver fat content.
 
Patients and Methods
Study population
Obese patients with T2DM who were on stable insulin treatment were included in the 
study. Exclusion criteria were other types of diabetes, significant cardiovascular, 
renal, liver or other co-morbidity, use of corticosteroids, uncontrolled endocrine 
disorders (stable supplementation with thyroid hormone was allowed), bariatric 
treatment, excessive alcohol consumption (>20 g/day), drug abuse, and use of thi-
azolidinedione derivatives.
Demographic and clinical characteristics
Patient demographics, medication, and insulin type and dose were recorded. Body 
weight, height, waist- and hip circumference, and blood pressure were measured 
using standard procedures. 
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Biochemical analyses
Fasting blood samples were drawn to determine: glycated haemoglobin (HbA1c), 
lipids, and free fatty acids (FFAs) (Cobas Mira Plus®, Roche Diagnostics Ltd., Basal, 
Switzerland).
Body composition and liver fat content 
Total-body DEXA scanning (Hologic QDR 4500 densitometer, Bedford, USA) was 
used to determine total fat mass and trunk fat. Magnectic resonance (MR) 
measurements were performed on a Tim-Trio MR system (Siemens, Erlangen, 
Germany). A series of T1-weighted (flash 2D) axial MR images was acquired from a 
region extending from 4 cm above to 4 cm below the fourth to fifth lumbar interspace. 
Visceral and subcutaneous fat areas were determined based on signal intensity. Liver 
fat was assessed by proton MR spectra (MRS) as described previously (2).
Subcutaneous adipose tissue biopsies
Subcutaneous (sc) adipose tissue biopsies were obtained under local anesthesia by 
needle biopsies performed 6–10 cm lateral to the umbilicus, after an overnight fast. 
Morphometry of individual fat cells was assessed using digital image analyses as 
described previously (11). For each subject, the adipocyte cell diameter of all fat cells 
in five to ten microscopic fields of view were counted and measured. On average, 
~700 fat cells were measured per specimen (range 150–1500). Adipocyte cell size 
distribution was expressed as ratio small (≤ 50 µm):large adipocytes (≥ 100 µm) (12). 
For detection of macrophages, adipose tissue sections were incubated with a 
CD68-monoclonal antibody (AbD Serotec, Oxford, UK). The percentage of 
macrophages was expressed as the total number of CD68-positive cells divided by 
the total number of adipocytes counted in 20 random microscopic fields of view x 
100. A crown-like structure was defined as an adipocyte surrounded by at least three 
macrophages (13).
 Protein levels within the adipose tissue were measured by Luminex fluorescent 
bead human cytokine immunoassays (MILLIPLEX MAP, Millipore Corp., Billerica, 
MA). Briefly, adipose tissue lysates were prepared using the milliplex map lysis buffer 
(Millipore) and protein concentrations of Interleukin-1 beta (IL-1b), Interleukin-6 and 8 
(IL-6/8), tumor-necrosis factor alfa (TNF-α), leptin, adiponectin, monocyte chemo-
attractant protein (MCP)-1, resistin and plasminogen activator inhibitor-1 (PAI-1) were 
determined. Equal amounts of protein were analyzed using a Bioplex system (Biorad). 
Informed consent
The ethical committee of the Radboud University Nijmegen Medical Centre approved 
the study protocol. All subjects provided written informed consent. 
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Statistical analyses
Variables are expressed as means ± SEM. Correlations were calculated by Spearman 
rank correlation analyses, unless otherwise specified. All calculations were performed 
using SPSS software (version 16.0; SPSS Inc., Chicago, IL). Two-tailed P <0.05 was 
considered significant.
Results 
A total of 27 Caucasian patients with T2DM participated in the study. Table 1 shows 
the characteristics of the patients. Briefly, the patients were obese (BMI 31.4 ± 1.1 kg/
m2) and the percentage of total and trunk fat mass as measured by DEXA was 43.0 
± 1.5 and 33.2 ± 1.6 %, respectively. Subcutaneous and visceral fat volume (MRI) 
were 2.2 ± 0.2 and 1.7 ± 0.1 liters, respectively. All patients were on long-term insulin 
treatment. 
Liver fat content
Mean, MRS-determined, liver fat content was 11.1 ± 1.7 % (range 0.75-32.9 %) and 63 
% of the patients had LFAT above normal (> 5.5 %; i.e. above the diagnostic cut-off 
of steatosis (14)). LFAT content showed large inter-individual differences (Figure 1A).
Figure 1A  Individual LFAT levels in study participants. The dashed horizontal line 
represents the cut-off limit of liver fat (5.5 %) corresponding to the 95th percentile of 
the distribution of liver fat in healthy subjects (14).
Chapter 7
144
Associations between BMI, body composition, adipose tissue 
morphology, inflammation and LFAT
LFAT was not significantly correlated with BMI (r = 0.25; P = 0.21), or sc fat volume 
(r = 0.05; P = 0.83), yet there was a trend towards a positive correlation between 
LFAT and visceral fat volume (r = 0.36; P = 0.07).
 Mean adipocyte diameter assessed by digital image analyses in subcutaneous 
adipose tissue was 71.9 ± 1.3 µm with large inter-individual variation (range: 58.4-86.6 µm). 
Adipocyte cell size distribution (= ratio fraction small:large adipose tissue cells), that has 
been associated with adipose tissue inflammation (15), equalled 5.1 ± 2.0. Neither 
adipocyte cell diameter nor adipocyte cell size distribution did correlate with LFAT.
Figure 1B  Sc adipose tissue morphology and CD68-immunohistochemical staining 
of 2 representative patients with high LFAT (panel I: LFAT 21.4 % with a crown-like 
structure (asterisk), panel II: LFAT 32.9 %) both showing high influx of CD68-positive 
cells and of 2 representative patients with low LFAT (panel III: adipose tissue of a 
patient with LFAT 1.7 %, panel IV: adipose tissue of a patient with LFAT 3.2 %) both 
with low influx of CD68-positive cells. All sections were counterstained with 
hematoxylin (colored blue). Magnification: 20x. Arrows indicate CD68-positive cells.
I
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 Macrophages arranged in (partial) crown-like structures ((p)CLSs) that are 
characteristic of adipose tissue inflammation, were detected in 15% of the adipose 
tissue slides. Three out of four patients with CLSs in the adipose tissue had clearly 
elevated LFAT content (5.3 %, 27.3 %, 12.0 % and 21.4 % respectively). Representative 
examples of adipose tissue morphology and CD68-positive cells of two patients with 
high LFAT and 2 patients with low LFAT are shown in Figure 1B. There was a trend 
towards a positive correlation between LFAT and the percentage of infiltrated 
macrophages in the adipose tissue (r = 0.31; P = 0.12). 
Adipose tissue protein levels of the inflammatory adipokine plasminogen activator 
inhibitor-1 (PAI-1) correlated positively (r = 0.39; P = 0.045) while the insulin-sensitizing 
marker adiponectin correlated negatively with LFAT (r = -0.48; P = 0.01, Fig. 2A and 
B, respectively). 
Figure 2A  Correlation between adipose tissue PAI-1 protein levels with LFAT.
Figure 2B  Correlation between adipose tissue adiponectin protein levels with LFAT.
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Adipose tissue levels of IL-1b, IL-6, IL-8, TNF-α, leptin, monocyte chemoattractant 
protein (MCP)-1 and resistin levels were not associated with LFAT content (r = -0.14; 
P = 0.56, r = -0.15; P = 0.52, r = -0.17; P = 0.42, r = -0.22; P = 0.32, r = -0.17; 
P = 0.43, r = -0.07; P = 0.75, r = 0.04; P = 0.85, respectively). 
Discussion
In the present study we demonstrate that LFAT in insulin-treated patients with type 2 
diabetes is linked to an inflammatory trait in sc adipose tissue as reflected by the 
presence of CLSs, higher levels of PAI-1 and lower concentrations of adiponectin. 
Together, these findings suggest an association between liver fat content and 
inflammatory features in fat tissue in insulin-treated patients with type 2 diabetes. 
 Studies analyzing sc adipose tissue morphology and inflammatory characteristics 
in relation to LFAT are scarce, especially in patients with T2DM. In line with previous 
studies (4, 16), our results demonstrated that mean LFAT content is high in obese 
diabetic patients. However, LFAT showed a large inter-individual variation within our 
study population, with 37% of study subjects displaying a normal LFAT content 
(i.e. ≤ 5.5 %) (14) implying that obesity, diabetes or the use of insulin by itself not 
readily explain the presence of steatosis.
 The ability of adipocytes to adapt to the increased supply of fat by hypertrophic 
enlargement is limited and may finally promote ectopic fat accumulation resulting in 
liver steatosis in obese subjects. In the present study, the correlation of liver fat 
content with measures of obesity (weight, BMI and MRS determined sc adipose 
tissue mass) was weak and non-significant. It might be envisioned that qualitative 
traits of the adipose tissue such as adipocyte size or macrophage influx are more 
important determinants of liver fat content. Although a positive correlation between 
adipocyte size and LFAT content has been previously reported (17), we were unable 
to replicate this finding. These, apparently conflicting, findings may partially be 
explained by differences in the study population. Whereas Koska et al. (17) 
investigated an obese Pima Indian population without impaired glucose regulation or 
diabetes type 2 diabetes, our study population consists of individuals that are 
diagnosed with type 2 diabetes. 
 We found that the presence of CLSs and macrophages in subcutaneous adipose 
tissue were correlated with the presence of LFAT whereas adipocyte size was not. 
These findings are in line with earlier reports in which adipose tissue inflammation 
characterized by the presence of macrophages and CLSs has been associated with 
insulin-resistance and LFAT content (18-20). Overall, our findings suggest that 
adipose tissue inflammation outweighs adipocyte size in determining hepatic fat 
accumulation in patients with type 2 diabetes. 
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 A potential relationship between liver fat content and adipose tissue inflammation 
is also supported by the positive correlation between adipose tissue levels of PAI-1 
and LFAT content. PAI-1 has been previously identified as a significant risk factor for 
microvascular and marcrovascular complications in diabetes (21-23) and has been 
linked to insulin resistance (24). Moreover, circulating levels of PAI-1 has been 
frequently linked to the development of hepatic steatosis (25, 26), although its tissue 
and cellular origin contributing to hepatic dysfunction remain debatable. In adipose 
tissue, PAI-1 is thought to play a role in TNF-α-induced insulin resistance (27, 28). 
Moreover, it can be viewed that nutritional factors (e.g. free fatty acids) suppress 
 insulin-stimulated glucose uptake and raise circulating PAI-1 concentrations, with a 
concomitant increase in the expression of the PAI-1 gene in adipose tissue (29). 
It is furthermore suggested that adipocyte-derived factors prime adipose 
macrophages so that they respond to nutritional signals (FFAs) by releasing a key 
inflammatory adipokine PAI-1. 
 In line with a lack of association between BMI, subcutaneous fat volume or 
adipocyte size and LFAT, adipose tissue protein levels of leptin, frequently used as a 
marker of fat mass, was not associated with hepatic fat content. Resistin levels in 
subcutaneous adipose tissue did not correlate with LFAT content in our study 
population. It can be envisioned that resistin produced in the visceral adipose depot 
primarily affects LFAT. Alternatively, resistin may not be a key-regulator of adipose 
tissue inflammation in humans. Although the number of macrophages present in 
subcutaneous fat were correlated to LFAT, this was not the case for protein levels of 
the chemoattractant MCP-1. Neither did absolute macrophage numbers correlate 
with MCP-1 levels in adipose tissue (data not shown). These results imply that other 
chemokines may determine the influx of macrophages in adipose tissue of subjects 
with type 2 diabetes. 
 In parallel with an increased inflammatory state of the adipose tissue, protein 
levels of adiponectin were inversely correlated with LFAT content. Inasmuch low 
circulating levels of adiponectin contribute to the development of a fatty liver (30), the 
reduction in adiponectin levels within subcutaneous adipose tissue may subsequently 
contribute to the pathogenesis of liver steatosis in patients with T2DM. 
 Although increased liver fat content is correlated with changes in fat mass, 
adipose tissue stored viscerally is more robustly associated (31) with partitioning of 
fat towards the liver as compared to subcutaneous or peripheral fat mass (32). The 
enhanced inflammatory trait of visceral adipose tissue (VAT) illustrated by its capacity 
to produce enhanced levels of inflammatory cytokines as compared to the 
subcutaneous adipose tissue (SAT) compartment ex vivo (33, 34), may partly explain 
these observations. The analyses in our study were done using the subcutaneous fat 
tissue compartment, which is a limitation, and do not necessarily implicate similar 
changes in the visceral compartment. One may speculate, however, that a relationship 
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between visceral fat inflammation and liver fat will be more robust than the observed 
relationship at the subcutaneous level. The most important finding of the present 
study is the identification of an existing relationship rather than the absolute strength 
of it. Another limitation of the study is the cross-sectional design, which cannot 
determine whether LFAT is a direct consequence of adipose tissue inflammation. 
Despite the limited absolute number of patients, our study also has strengths that 
include the extensive phenotyping of a set of almost 30 subjects and careful analysis 
of subcutaneous adipose tissue morphology. Additionally, determining protein levels 
in adipose tissue sample lysates has, to our knowledge, not been frequently applied 
and yields more valuable information concerning adipose tissue function as compared 
to measurements of circulating protein concentrations. 
 In conclusion, LFAT content shows substantial inter-individual variation, yet is 
positively associated with qualitative, pro-inflammatory changes in sc adipose tissue 
in obese insulin-treated T2DM patients. This suggests that inflammatory changes at 
the level of adipose tissue may be causatively related to liver fat content. Proof of this 
concept will require prospective studies. 
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Abstract
Autophagy, an evolutionary conserved process aimed at recycling damaged 
organelles and protein aggregates in the cell, also modulates pro-inflammatory 
cytokine production in peripheral blood mononuclear cells. Since adipose tissue 
inflammation accompanied by elevated levels of pro-inflammatory cytokines is 
characteristic for the development of obesity, we hypothesized that modulation of 
autophagy alters adipose tissue inflammatory gene expression and secretion. We 
performed ex vivo and in vivo studies of human and mouse adipose tissue.
 Levels of the autophagy marker LC3 were elevated in subcutaneous adipose 
tissue of obese versus lean human subjects and positively correlated to both systemic 
insulin resistance and morphological characteristics of adipose tissue inflammation. 
Similarly, autophagic activity levels were increased in adipose tissue of obese and 
insulin resistant animals as compared to lean mice. Inhibition of autophagy by 
3-methylalanine in human and mouse adipose tissue explants led to a significant 
increase in IL-1β, IL-6 and IL-8 mRNA expression and protein secretion. Noticeably, 
the enhancement in IL-1β, IL-6 and KC by inhibition of autophagy was more robust in 
the presence of obesity. Similar results were obtained by blocking autophagy using 
small interfering RNA targeted to ATG7 in human SGBS adipocytes. 
 Our results demonstrate that autophagy activity is up regulated in adipose tissue 
of obese individuals and inhibition of autophagy enhances pro-inflammatory gene 
expression both in adipocytes and adipose tissue explants. Autophagy may function 
to dampen inflammatory gene expression and thereby limit excessive inflammation in 
adipose tissue during obesity.
Abbreviations: ATG, Autophagy-related proteins; BMI, body mass index; CLS, crown- 
like structure; eWAT, epididymal WAT; KC, keratinocyte-derived chemoattractant; 
3MA, 3-methyladenine; NOB-1, Nin1 binding protein; NOD2, nucleotide-binding 
oligomerization domain containing 2; SAT, sc adipose tissue; SGBS, Simpson- 
Golabi-Behmel syndrome; siRNA, small interference RNA; TBS, Tris-buffered saline; 
VAT, visceral adipose tissue; WAT, white adipose tissue.
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Introduction
Autophagy is a homeostatic mechanism functioning as a disposal system that degrades 
large intracellular organelles or protein aggregates in order to change cellular structure 
during differentiation, or to generate essential nutrients in times of energy deprivation 
(1, 2). When autophagy is activated, a double-membraned vesicle, named the 
autophagosome,  engulfs these components and fuses with lysosomes to complete 
degradation (3). The elongation and shape of the autophagosome is controlled by 
multiple autophagy-related proteins (ATG proteins) that include ATG5, ATG7, ATG8, 
ATG12 and ATG16L1. The mammalian homologue of yeast ATG8, LC3, is a commonly 
used marker of autophagy as this protein is conjugated with the lipid phosphatidyl-
ethanolamine (PE) upon activation of autophagy resulting in LC3-II formation.
 A growing body of evidence suggests that autophagy not only monitors cellular 
energy balance, yet is also important in the regulation of apoptosis and protection 
against infection with pathogens (4-6). Indeed, autophagy has been closely linked to 
control of innate and adaptive immune responses in host defense in part by regulation 
of cytokine production (7). Cytokines including IL-1β, IL-18, TNFα and IL-6 are known 
to be regulated by autophagy (8). For example, macrophages derived from ATG16L1 
deficient mice produced higher levels of IL-1β (9), while mice with a conditional 
deletion of Atg7 in the intestinal epithelium showed an enhanced mRNA expression 
of IL-1β (10). Additional studies using cells from human origin demonstrated that 
inhibition of autophagy led to up regulated production of IL-1β (11, 12). 
 In addition to its role in host defense partly through control of cytokine production, 
autophagy has been shown to regulate fat accumulation within adipocytes. Animals 
lacking the autophagy-related proteins ATG5 and ATG7 are characterized by a limited 
capacity of white adipose tissue (WAT) to store triglycerides and thus display a robust 
reduction in WAT mass as compared to wild-type animals (13-15) suggesting that 
autophagy is essential for normal adipogenesis. Interestingly, autophagy also appears 
to contribute to the development of obesity as adipose tissue of obese human 
individuals is characterized by an enhancement in autophagic activity (16, 17). 
 In parallel with the development of obesity, a chronic inflammation in the adipose 
tissue develops that is partly initiated by adipocytes releasing chemokines, pro- 
inflammatory cytokines and adipokines, resulting in the infiltration of immune cells 
into adipose tissue (18, 19). Various cytokines are known to be released or produced 
by inflamed adipose tissue of obese individuals including IL-1β (20-23), IL-6, TNFα 
and IL-18 (24) and contribute to the development of obesity-induced insulin resistance. 
Despite the importance of pro-inflammatory cytokines in the development of insulin 
resistance, the regulation and potential triggers inducing their production are only 
partly understood. In line with its enhanced activity in adipose tissue during obesity 
and its role in the regulation of inflammatory cytokine secretion, we hypothesized that 
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autophagy modulates adipose tissue inflammation. Our results show that inhibition of 
autophagic activity enhances both gene expression and protein secretion of the 
pro-inflammatory cytokines IL-1β, IL-6 and IL-8 in adipocytes and adipose tissue of 
both humans and mice.
Patients and Methods
Subcutaneous adipose tissue biopsies from lean and  
obese individuals
Adipose tissue samples were obtained from human subjects through advertisements 
in local newspapers. We included overweight (body mass index (BMI) 27-35 kg/m2) 
and normal (body mass index 20-25 kg/m2) subjects between 40 and 70 years old. 
Subcutaneous adipose tissue biopsies were obtained under local anesthesia by needle 
biopsies 6–10 cm lateral to the umbilicus. Samples were taken after an overnight fast. 
Various biochemical measurements including plasma triglycerides, cholesterol, glucose 
and insulin were done using standard laboratory methods. 
In vitro and ex vivo experiments with human and murine  
adipose tissue
Intact adipose tissue fragments from subcutaneous adipose tissue (SAT) or visceral 
adipose tissue (VAT), obtained during surgery from healthy individuals of 30-70 years 
old with a BMI between 20 and 33 kg/m2 were used to study the effects of autophagy. 
Adipose tissue fragments were directly cultured in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal calf serum with or without 3-methyladenine 
(autophagy inhibitor; 3MA, Sigma-Aldrich). Minced adipose tissue was digested 
using collagenase (Sigma-Aldrich) at a concentration of 5 mg/ml dissolved in 
Dulbecco’s modified Eagle’s medium (DMEM). Tissues were incubated for 45 min at 
37 °C and were subsequently filtered through a 250 µM nylon mesh filter. After 
centrifugation at 200 rpm for 10 minutes, the floating cells were collected as 
adipocytes and the pelleted cells as stromal vascular cells. The study protocols are 
approved by the University of Nijmegen Ethical Committee and all participants gave 
written informed consent. Epididymal white adipose tissue (eWAT) obtained from 
lean C57/Bl6 mice and obese leptin deficient (Lep·ob/Lep·ob) mice on a C57/Bl6 
background (25) was similarly treated with 3MA. After 24h of incubation with or 
without 3MA, cytokine secretion and gene expression levels were determined. The 
study protocol was approved by the animal experimentation committee of the 
University Medical Centre of Nijmegen. 
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Small interference RNA (siRNA)
To specifically suppress autophagy-related protein 7 (ATG7) expression in differentiated 
adipocytes, human Simpson-Golabi-Behmel syndrome (SGBS) pre-adipocyte cells 
were differentiated towards mature adipocytes using a standard adipogenic protocol 
(26). After 12 days of differentiation, cells were transfected (X-tremeGENE siRNA 
Transfection Reagent, Roche) with small interference (si)RNA against ATG7 (Thermo 
Scientific). As a non-specific control, scrambled siRNA (Thermo Scientific) was used. 
After 96 hours of incubation, gene and protein expression were analyzed in cells and 
supernatant.
Cytokine measurements
Concentrations of mouse IL-1β were determined by specific radioimmunoassay 
(RIA; detection limit is 20 pg/mL) as previously described (27). Mouse IL-6 and KC 
concentrations were measured by commercial ELISA kits (Invitrogen, CA, USA, 
detection limits 16 pg/ml and R&D Systems, MN, USA, detection limits 16 pg/ml, 
respectively), according to the instructions of the manufacturer. Bio-active IL-1 was 
measured using the NOB-1 assay, which consists of mouse cells derived from the 
EL-4 line which produce IL-2 in response to concentrations of IL-1 as low as 1 pg/ml. 
NOB-1 is not responsive to tumor necrosis factor alpha, tumor necrosis factor beta, 
interferon-gamma and lipopolysaccharide (28). IL-2 was detected using a mouse IL-2 
ELISA kit (R&D Systems, MN, USA, detection limits 16 pg/ml). Human IL-6 and IL-8 
concentrations were measured using commercially available ELISA kits (R&D 
systems, MN, USA).
Western blots
For Western blotting, SGBS cells or approximately 30 mg of SAT or VAT were lysed in 
100 µl of lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 2 mM EDTA, 1% ND40, 50 
mM NaF and 0.25% Sodium Deoxycholate with phosstop phosphatase inhibitor 
cocktail tablet (Roche, Basel, Switzerland) and complete, EDTA-free protease 
inhibitor cocktail tablet (Roche, Basel, Switzerland). The homogenate was frozen, 
then thawed and centrifuged at 4°C for 10 min at 15 000 × g, and the supernatant 
was used for Western blot analysis. Protein concentrations of the 30% lysates were 
determined using a BCA protein assay (Thermo Fisher Scientific, Rockford, IL USA). 
Samples of approximately 20 µg protein were subjected to SDS-PAGE using 12% and 
16% polyacrylamide gels at a voltage of 70-120 V. After SDS-PAGE, proteins were 
transferred to nitrocellulose membrane (0.2 mm) and the membrane was blocked 
with 5% (wt/vol) milk powder in TBS/Tween 20 for 1 hour at room temperature, 
followed by incubation overnight at 4°C with a LC3 antibody (Novus Biochemicals, 
CO, USA) in 5% (wt/vol) milk powder/TBS/Tween 20 or with an actin antibody (Sigma, 
MO, USA) in 5% milk powder in TBS/Tween 20. After overnight incubation, the blots 
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were incubated with HRP-conjugated swine anti-rabbit antibody at a dilution of 
1:5.000 in 5% (wt/vol) milk powder in TBS/Tween 20 for 1 hour at room temperature 
and subsequently developed with ECL (GE Healthcare, PA, USA) or ultra-sensitive 
enhanced ECL (Thermo Scientific, MA, USA), according to the manufacturer’s 
instructions. The intensity of the bands on the Western blots was assessed by Image 
Lab statistical software (Bio-Rad, CA, USA).
Real-time PCR
Total RNA purification of SGBS cells, SAT or VAT was done using TRIzol Reagent 
(Invitrogen, CA, USA) according to manufacturer’s instructions. Isolated RNA was 
subsequently transcribed into complementary DNA using iScript cDNA Synthesis Kit 
(Bio-Rad, CA, USA) followed by quantitative PCR using SYBR Green (Applied 
Biosystems, CA, USA). The following primers were used: for human IL-1β forward 
5’-GCCCTAAACAGATGAAGTGCTC-3’ and reverse 5’- GAACCAGCATCTTCCT-
CAG-3’; for human IL-6 forward 5’-AACCTGAACCTTCCAAAGATGG-3’ and reverse 
5’-TCTGGCTTGTTCCTCACTACT- 3’; for 149 human IL-8 forward 5’-ACTGAGAGT-
GATTGAGAGTGGAC-3’ and reverse 5’-AACCCTCTGCACCCAGTTTTC- 3’; and for 
human ATG7 forward 5’-CAGTTTGCCCCTTTTAGTAGTGC-3’ and reverse 5’-CTTA-
ATGTCCTTGGGAGCTTCA-3’. For mouse primers the following were used: IL-1β 
forward 5’- GCAACTGTTCCTGAACTCAACT-3’ and reverse 5’-ATCTTTTGGGGTC-
CGTCAACT-3’; for mouse IL-6 forward 5’-CAAGTCGGAGGCTTAATTACACATG-3’ 
and reverse 5’-ATTGCCATTGCACAACTCTTTTCT-3’; for mouse IL-8 (KC) forward 5’- 
TGGCTGGGATTCACCTCAA-3’ and reverse 5’- GAGTGTGGCTATGACTTCGGTTT 
-3’; for mouse ATG7 forward 5’- CCTTCGCGGACCTAAAGAAGT-3’and reverse 5’- 
CCCGGATTAGAGGGATGCTC-3’. All primer pairs were tested for efficiency using 
standard curves and were between 95-105 %. Additionally, a melt curve analysis was 
included in every run to ascertain the formation of one single specific PCR product. 
The housekeeping genes β2-microglobulin and 36B4 were selected as human and 
mouse housekeeping genes. Gene expression data obtained from the human 
samples was corrected for expression of the housekeeping genes β2-microglobulin, 
for which the forward primer 5’-ATGAGTATGCCTGCCGTGTG-3’ and reverse primer 
5’-CCAAATGCGGCATCTTCAAAC-3’ were used. For mouse samples, forward primer 
5’-AGCGCGTCCTGGCATTGTGTGG-3’ and reverse primer 5’-GGGCAGCAGTGGTG-
GCAGCAGC-3’ were used to detect 36B4 expression levels and gene expression 
results were corrected using 36B4 values. 
Statistical analyses
Differences in cytokine production capacity and data on mRNA expression levels 
between groups were analyzed using the analysis of variance (ANOVA) with the 
Least Significant Difference post hoc test to detect statistical differences between 
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groups and treatment (SAT vs. VAT, lean vs. obese, control vs. 3MA treatment) after 
variables were log-transformed. Data on immunoblot intensity values were statistically 
analyzed using Student’s t-tests. Differences were considered statistically significant 
at p < 0.05.
Results
Autophagy is up regulated in adipose tissue during obesity
To assess the correlation between autophagy and obesity, subcutaneous adipose 
tissue (SAT) was obtained from healthy individuals (n=33) that varied in body 
mass index from 19 to 40kg/m2 (Supplemental table 1: patient characteristics) and 
were analyzed by Western-blot to detect LC3-II levels (Figure 1A, a representative 
Western-blot is shown). 
 The mammalian homologue of yeast ATG8, LC3, is a commonly used marker of 
autophagy as this protein is conjugated with the lipid phosphatidylethanolamine (PE) 
upon activation of autophagy resulting in LC3-II formation. The autophagy marker 
LC3-II (microtubule-associated protein light chain 3) was more abundantly present in 
obese individuals (average BMI ~ 32 kg/m2) as compared to lean subjects (average 
BMI ~ 22 kg/m2) (Figure 1B). Similarly, LC3 levels were profoundly higher in adipose 
tissue of obese animals lacking leptin (Lep·ob/Lep·ob), compared to lean wild-type 
mice (Figure 1C and D). 
This suggests that autophagy is activated in adipose tissue during obesity and 
confirms previous work by Kovsan et al. (16). In line with these results, a positive 
correlation was observed between LC3-II levels and BMI (r = 0.43; P = 0.01, Figure 
2A). Furthermore, the positive correlation between HOMA-IR and adipose tissue 
levels of LC3-II levels (r = 0.44; P = 0.02, Figure 2B) revealed that insulin sensitivity 
negatively correlated with autophagic activity levels. Since obesity and insulin 
resistance is associated with the development of adipose tissue inflammation that is 
characterized by the influx of macrophages, we set out to correlate macrophage 
influx with LC3-II levels in the subcutaneous biopsies obtained from our study 
subjects. We observed a positive correlation between the influx of macrophages and 
LC3-II levels in subcutaneous adipose tissue (r = 0.38; P = 0.03, Figure 2C). 
Additionally, aggregation of macrophages in pro-inflammatory crown-like structures 
(CLSs) that surround dying adipocytes was accompanied by significantly higher 
LC3-II levels as compared to adipose tissue from individuals that lacked CLSs 
(Figure 2D). 
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Figure 1  Levels of the autophagy marker LC3 determined by western blot in human 
and mouse adipose tissue. (A) Representative western blot of LC3 in human lean 
(BMI ~ 22 kg/m2) and obese subjects (BMI ~ 32 kg/m2). LC3 levels in epididymal 
adipose tissue from C57BL6 wt mice and leptin deficient (Lep·ob/Lep·ob) mice (C). 
LC3-II : actin ratio, that reflects the level of autophagic activity in adipose tissue, is 
calculated by quantification of western blot intensity in n =33 human subjects (B) and 
wildtype (n =5) vs. leptin deficient (Lep•ob/Lep•ob) mice (n =4) (D). Data are 
presented as means ± SEM. *** P < 0.001.
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Figure 2  Correlation between autophagic activity, obesity, insulin sensitivity and 
adipose tissue morphology. Spearman correlations analysis between autophagic 
LC3-II levels and BMI (A), HOMA-IR (B) and influx of macrophages within the adipose 
tissue (C). HOMA-IR denotes the homeostasis model assessment-insulin-resistance. 
HOMA-IR was calculated by HOMA-IR = fasting plasma insulin (µIU/mL) x fasting 
plasma glucose (mmol/L)/22.5. LC3-II activity levels determined in subjects with or 
without the presence of crown-like structures (CLSs) in adipose tissue (D). * P < 0.05.
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Autophagy regulates expression of pro-inflammatory cytokines  
in human adipose tissue ex vivo
To study the role of autophagy in the production and secretion of pro-inflammatory 
cytokines by the adipose tissue, human SAT and VAT explants were cultured in medium 
containing the autophagy inhibitor 3MA or PBS for 24 hours. The concentration of 
3MA (10mM) used throughout the experiments was in accordance with previous 
studies (29). 3MA clearly reduced autophagic activity in adipose tissue according to 
lower LC3-II protein levels (Figure 3A). 3MA treatment resulted in a significant increase 
of IL-1β, IL-6 and IL-8 protein secretion by both SAT and VAT (Figure 3B). In line with 
the cytokine secretion profile, mRNA levels of IL-1β, IL-6 and IL-8 gene expression 
were increased in SAT and VAT tissue explants exposed to 3MA (Figure 3C). Secretion 
levels of leptin and adiponectin were unchanged suggesting that inhibition of 
autophagy by 3MA does not modulate the general endocrine function of adipose tissue 
(Supplemental Figure 1). 
Autophagy regulates expression of pro-inflammatory cytokines  
in mouse adipose tissue explants
To confirm the effects of inhibition of autophagy in mouse fat tissue, epididymal white
adipose tissue (eWAT) derived from obese leptin deficient (Lep·ob/Lep·ob) mice 
and lean wild-type mice was treated with 3MA. Inhibition of autophagy in lean mice 
led to a significant increase of pro-inflammatory protein secretion. Interestingly, 
the induction in IL-1β, IL-6 and KC was more robust in obese animals (Figure 4A). 
Most likely, the enhanced secretion is a result of elevated gene expression levels 
(Figure 4B). Indeed, 3MA treatment led to a 20-fold increase in adipogenic IL-1β gene 
Figure 2  Continued.
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Figure 3  Protein levels and gene expression of cytokines in human SAT and VAT 
treated with 3MA for 24 hours. Western blot analysis of LC3-II levels in human VAT 
explants after treatment with 3MA for 24h (A). Secretion levels of bioactive IL-1 
(indirectly by IL-2 production of NOB-1 assay), IL-6 and IL-8 by human SAT and VAT. 
The secretion levels are expressed as the relative change in pg/ml/mg (cytokine/
volume of supernatant/weight of explant). Mean values of cytokine expression from 
SAT control samples have been set as 100% (B). Gene expressions of IL-1β, IL-6 and 
IL-8 in SAT and VAT (C). Control samples were set as 1. All experiments have been 
repeated three times or more. Data are presented as means ± SEM. * p < 0.05; 
** p < 0.01; *** p < 0.001.
A
B
C
Chapter 8
164
expression in obese animals whereas inhibition of autophagy in lean mice resulted in 
a 3-fold induction in gene expression. Similar results were seen for IL-6 and IL-8 gene 
expression levels (Figure 4B). These data imply that autophagy somehow may act to 
limit excessive inflammatory gene expression in adipose tissue during obesity as 
evidenced by the exacerbated cytokine expression upon autophagic inhibition in 
adipose tissue from obese and insulin resistant animals. Noticeably, 3MA treatment 
Figure 4  Protein levels and gene expression of IL-1β, IL-6 and KC in murine eWAT 
explants treated with 3MA for 24 hours. Cytokine secreted in supernatant by eWAT 
explants from lean C57BL6 mice and obese leptin deficient (Lep•ob/Lep•ob) mice 
(IL-1β, IL-6 and KC). The secretion levels are expressed as the relative change in pg/
ml/mg (cytokine/volume of supernatant/weight of explant). Mean values of cytokine 
expression from lean control samples have been set as 100% (A). Relative gene 
expressions of IL-1β, IL-6 and KC in eWAT from lean mice and obese leptin deficient 
(Lep•ob/Lep•ob) mice (B). Control samples were set as 1. Experiments have been 
repeated three times or more. Data are presented as means ± SEM. * p < 0.05; 
** p < 0.01; *** p < 0.001.
A
B
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Figure 5  Effect of siRNA ATG7 on protein and gene expression of cytokines in 
human differentiated SGBS adipocytes. Relative gene expression of ATG7 in the 
stromal vascular fraction (SVF) and mature adipocytes (MAT) in human white adipose 
tissue (A). Relative gene expression of ATG7 after siRNA treatment (B). Cytokine 
concentrations of IL-1 (indirectly by IL-2 production of NOB-1 assay), IL-6 and IL-8 
secreted in the supernatant by SGBS cells after siRNA treatment (C). Relative gene 
expression levels of IL-1β, IL-6 and IL-8 in SGBS cells after siRNA treatment (D). 
Control samples were set as 1. Data are presented as means ± SEM. * p < 0.05; 
*** p < 0.001 (n=3).
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did not appear to affect the general secretory capacity of the WAT explants since 
leptin and adiponectin secretion levels did not differ upon autophagic inhibition 
(supplemental Figure 2). 
Autophagy inhibition by siRNA ATG7 in human mature adipocytes 
increases cytokine production
Since adipose tissue is composed of both adipocytes and stromal vascular cells, we 
set out to characterize gene expression levels of various autophagy-related genes in 
both cell populations. qPCR analysis revealed that numerous autophagy-related 
genes are expressed in both adipocytes and non-adipocyte cells part of the adipose 
tissue (Figure 5A + supplementary Figure 3). Expression of the autophagy machinery 
in both the SVF and adipocytes suggest that various cell types may contribute to the 
autophagy-mediated inhibition of inflammation. To learn more about the contribution 
of adipocyte-specific autophagy to control of inflammation, ATG7 expression, an 
essential protein in the assembly of autophagosomes by controlling the vesicle 
elongation and predominantly expressed in adipocytes, was blocked by siRNA 
treatment in fully differentiated human SGBS adipocytes. siRNA treatment led to a 
65% reduction in ATG7expression (Figure 5B). The reduction in ATG7 expression 
promoted a significant increase in both gene expression and protein levels of IL-1β, 
IL-6 and IL-8 (Figure 5C and D). These data confirm the involvement of autophagy in 
controlling the inflammatory trait of adipocytes.
Figure 5  Continued.
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Discussion
Autophagy has been shown to affect many cellular processes including inflammation, 
oxidative stress and innate and acquired immune response (30). Our study provides 
evidence that autophagy modulates the inflammatory status of adipose tissue by 
controlling the production of pro-inflammatory cytokines including IL-1β, IL-6 and IL-8. 
Inhibition of autophagy leads to an increase in gene expression and secretion of 
pro-inflammatory cytokines by the adipose tissue. 
 Previous work has shown that insulin inhibits autophagic action and this regulatory 
pathway may partly explain the enhanced levels of LC3 within adipose tissue of 
obese individuals characterized by insulin resistance. Whereas autophagic inhibition 
in adipocytes and total adipose tissue explants both led to an enhancement in 
inflammatory gene expression and secretion of cytokines, it is tempting to speculate 
that changes in autophagy in adipocytes mainly contribute to the observed effects in 
line with a previous study (31). However, inhibition of autophagy is also known to 
promote inflammation in macrophages that are present in adipose tissue and 
profoundly affects its inflammatory status. Although it is challenging to identify the 
responsible cell type in our experimental setup using adipose tissue explants, a close 
interaction between various cell types including adipocytes and macrophages most 
likely determines the inflammatory-modulating properties of autophagy in adipose 
tissue. 
 It is unclear at this point whether the inhibition of autophagy in adipose tissue 
worsens insulin sensitivity via its effects on inflammatory cytokine production. However, 
in line with previous work demonstrating the deleterious effects of inflammation on 
insulin sensitivity (32, 33) one may hypothesis that the enhancement of autophagy in 
adipose tissue during obesity may serve to limit inflammation and prevent further 
worsening of insulin resistance. This hypothesis is supported by our observation that 
inhibition of autophagy in obese adipose tissue severely enhances a pro-inflammatory 
response compared to lean adipose tissue. Thus, obesity-associated inflammation 
in adipose tissue seems to up regulate autophagy in order to mitigate the production 
of pro-inflammatory cytokines. As such, autophagy activity seems a consequence, 
rather than a cause of obesity-induced adipose tissue inflammation. It remains to be 
explored whether (partial) defects in autophagy may contribute to the inflammatory 
process in obesity. 
 Our findings may appear somewhat counterintuitive, since the absence of 
autophagy has been shown to protect against obesity and insulin resistance in mice 
(14, 15). Indeed, adipocyte-specific ATG7 knockout mice exhibit increased insulin 
sensitivity and are protected against high-fat-diet induced obesity (13-15). However, the 
function of autophagy during the development of adipocytes may be quite different as 
compared to its role in expanding adipose tissue in obese subjects. In line with our 
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results, a previous study demonstrated that obese individuals had higher levels of 
autophagy in their adipose tissue compared to lean subjects (16), suggesting that 
autophagy may actually chaperon fat mass expansion during obesity. Since LC3-II 
levels were closely correlated with CD68 influx and the presence of CLSs in adipose 
tissue, autophagy activation may actually be aimed at counterbalancing inflammation. 
As variation in adipose tissue LC3 levels was observed in obese subjects, it might be 
worthwhile to further characterize the inflammatory status in future studies. Indeed, 
one may hypothesize that metabolically healthy obese, that are characterized by 
a lower inflammatory status of the adipose tissue (34), have a lower level of LC3-II 
in adipose tissue since the necessity of the inflammatory dampening action of 
autophagy is diminished. 
 The exact mechanism underlying enhanced inflammatory gene expression 
upon autophagy inhibition in adipose tissue remains to be identified. One possible 
mechanism may involve the intracellular degradation of pro-IL-1β by a process 
involving autophagy that would result in lower secretion levels of IL-1β (35). Hence, 
inhibition of autophagy would prevent intracellular degradation of pro-IL-1β and lead 
to enhanced production of IL-1β by adipose tissue. Inhibition of autophagy may also 
promote activation of the NLRP3 inflammasome in a reactive oxygen species (ROS) 
dependent manner and would thus produce more mature IL- 1β due to more 
caspase-1 cleavage (36, 37). Alternatively, nucleotide-binding oligomerization 
domain containing 2 (NOD2), which recognizes small peptides present in the 
bacterial wall, is important in regulating IL-1β gene expression as it functions by either 
binding to ATG16L1 to induce autophagy or by activating the Erk/NF-kB signaling 
pathway that induces IL-1β gene expression. Autophagy inhibition may down regulate 
ATG16L1 expression which could lead to more NOD2-dependent stimulation of Erk/
NF-kB. This hypothesis is supported by a recent study (12) reporting that production 
of IL-1β by macrophages from individuals with the T300A variant of ATG16L1 is 
enhanced upon stimulation of the NOD2 receptor. Finally, mitochondrial autophagy 
has been linked to insulin resistance (38) and may somehow regulate inflammatory 
gene expression as well. Future studies should be aimed at deciphering the exact 
molecular mechanisms that facilitate pro-inflammatory responses upon inhibition of 
autophagic activity in adipose tissue on the development of inflammation.
 In summary, inhibition of autophagy stimulates pro-inflammatory gene expression 
levels in both human and murine white adipose tissue. In adipose tissue of obese 
mice, the inflammation-promoting properties of autophagy inhibition outclass it effects 
in lean animals even after correction for total fat mass. Therefore, we hypothesize 
that autophagy functions as a mechanism to control pro-inflammatory gene expression 
in adipose tissue in order to prevent chronic inflammation. Altogether, this study 
provides new data showing that autophagy affects the inflammatory status of the 
adipocyte and adipose tissue. 
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Supplemental Data
Table 1  Demographic and clinical characteristics of lean and obese subjects.
Lean  
(n = 17)
Obese  
(n = 16)
p-value 
between 
groups
Demographics
Age (yr) 54 ± 3.9 55 ± 5.7 0.80
Sex, males (%) 35 25 0.80
Anthropometry and hemodynamics
BMI (kg/m2) 22.2 ± 0.3 32.8 ± 1.6 < 0.001
Waist circumference (cm) 82.9 ± 1.5 109.8 ± 3.2 < 0.001
Hip circumference (cm) 96.2 ± 2.1 110.5 ± 2.1 <0.001
Metabolic characteristics
Total cholesterol (mM) 4.3 ± 0.3 4.6 ± 0.4 0.60
LDL-cholesterol (mM) 2.7 ± 0.4 2.8 ± 0.3 0.77
Triacylglycerol (mM) 0.8 ± 0.1 1.6 ± 0.4 0.03
Alcohol use (%) 77 50 0.20
Smoking (%) 0 13 0.60
Data presented as mean ± SEM. BMI denotes body mass index, LDL-cholesterol = low-density lipo - 
protein cholesterol.
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Figure 1  Leptin and adiponectin protein concentrations secreted by SAT and VAT 
after 3MA treatment. The secretion levels are expressed as the relative change in 
pg/ml/mg (cytokine/volume of supernatant/weight of explant). * P < 0.05.
Figure 2  Leptin and adiponectin protein secretion by eWAT after 3MA treatment. The 
secretion levels are expressed as the relative change in pg/ml/mg (cytokine/volume 
of supernatant/weight of explant).
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Figure 3  Relative gene expression levels of ATG1, ATG5, ATG7 and ATG16L1 in 
SVF and MAT fraction of both SAT and VAT of human individuals (n = 4). Control 
samples were set at 1. Data are presented as means ± SEM. *** P < 0.001.
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Abstract
During the development of obesity, the phenotype of the adipose tissue changes 
significantly and shifts towards a more pro-inflammatory status. Although various 
morphological changes are known to accompany the development of obesity- 
induced inflammation, no system to classify the degree of adipose tissue inflammation 
currently exists. 
 In this cross-sectional study, we examined the association of adipose tissue 
morpho logical characteristics related to inflammation with various anthropometric 
measurements, adipose tissue protein levels of inflammatory and metabolic mediators 
and circulating plasma parameters in humans varying in BMI from 19 to 43 kg/m2. 
 Adipocyte cell size was positively associated with body mass index, waist 
circumference, insulin sensitivity (HOMA-IR) and plasma leptin levels. Macrophage 
infiltration and the presence of crown like structures in adipose tissue correlated with 
various anthropometric parameters, insulin sensitivity and adipocyte size. We developed 
an inflammatory score of the adipose tissue, determined by the degree of adipocyte 
hypertrophy, macrophage influx and presence of crown like structures. Individuals 
that were classified with a high inflammatory score of the adipose tissue suffered 
from increased homeostasis model assessment of insulin resistance (HOMA-IR) 
levels. 
 We conclude that there is a close relationship between adipose tissue morpho- 
logical characteristics, obesity and metabolic complications. Furthermore, we 
suggest a histological classification method to quantify adipose tissue inflammation. 
A standardized approach to classify adipose tissue inflammation will lead to more 
accurate measurements of adipose tissue inflammation and will aid comparison of 
different human studies using adipose tissue biopsies. 
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Introduction
During the development of obesity, the phenotype of the adipose tissue significantly 
changes and shifts towards a more pro-inflammatory profile. The enhanced inflammatory 
status in obese individuals, that has been suggested to primarily originate from 
expanding adipose tissue, contributes to the development of systemic insulin resistance 
and type 2 diabetes (1, 2). Indeed, therapeutic approaches that modulate inflammation 
have been shown to improve glycemic control in patients with type 2 diabetes (3, 4). 
 Various morphological changes in adipose tissue accompany the development 
of obesity-induced inflammation. For example, adipocyte enlargement is known to 
promote the inflammatory trait of the cell (5). Larger adipocytes produce higher 
amounts of inflammatory mediators as compared to smaller adipocytes isolated from 
the same adipose tissue depot (6). Enlargement of adipocytes inevitable leads to a 
lack of sufficient oxygen and nutrient supply and result in local hypoxia. Hypoxic 
conditions may result in adipocyte death that subsequently attracts macrophages 
into adipose tissue (7, 8). While also other triggers may initiate macrophage influx, 
macrophage accumulation is a typical characteristic of adipose tissue inflammation 
and aggravates the secretion of pro-inflammatory mediators by the adipose tissue 
and reduces secretion of insulin-sensitizing proteins including adiponectin (9). Upon 
infiltration into adipose tissue, macrophages are frequently displayed in so called 
crown like structures that are thought to surround dysfunctional or dying adipocytes 
(10). Macrophages that cluster into crown-like structures display a more pro- 
inflammatory phenotype (11, 12) and thus inflict a higher inflammatory status of the 
adipose tissue. 
 Changes in morphological characteristics of the adipose tissue are closely correlated 
with a variety of metabolic abnormalities. For example, enhanced macrophage influx 
into adipose tissue is known to positively correlate with hepatic fat deposition (11, 13). 
 Although these inflammatory characteristics of the adipose tissue are frequently 
described in literature, a general classification system of the adipose tissue inflammatory 
status is currently lacking. Whereas the development of fat deposition and inflammation 
in the liver is classified using a uniformed system (14, 15), adipose tissue inflammation 
currently describes a whole range of inflammatory changes that vary from influx of 
macrophages or other immune cells to changes in adipocyte gene expression and 
protein levels. 
 In the present study we first correlated human adipose tissue morphological 
characteristics including adipocyte size, macrophage influx and the presence or absence 
of crown-like structures with several anthropometric measurements, circulating plasma 
parameters and adipose tissue protein levels of various inflammatory and metabolic 
proteins to determine the contribution of adipose tissue dysfunction to metabolic 
abnormalities. 
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 Based on the morphological characterization of the adipose tissue, we subsequently 
developed an inflammatory score. This approach may lead to a more accurate 
assessment of the inflammatory status of the adipose tissue and will aid comparison 
of different studies that use human adipose tissue biopsies. 
Material and Methods
Subjects 
In this study healthy subjects and patients with type 2 diabetes (T2DM) were included. 
Healthy subjects consisted of lean, overweight and obese subjects and were 
recruited through multiple advertisements in local newspapers. We included normal 
(body mass index 19-25 kg/m2), overweight (body mass index 25-30 kg/m2), and 
obese (body mass index 30-45 kg/m2) subjects between 40 and 70 years old. The 
obese subgroup presented in the results consisted of both the overweight and obese 
subgroup. Furthermore, we included patients with T2DM who were on long-term 
stable oral glucose lowering treatment yet were not using any insulin. Exclusion 
criteria were other types of diabetes, significant cardiovascular, renal, liver or other 
co-morbidity, use of corticosteroids, uncontrolled endocrine disorders (stable sup-
plementation with thyroid hormone was allowed), bariatric treatment, excessive 
alcohol consumption (>20 g/day), drug abuse, and use of thiazolidinedione 
derivatives. All patients with diabetes were treated according to local guidelines. 
Subject characteristics (age, gender, race, smoking habits) were noted and clinical 
data, including body weight, height, blood pressure, HbA1c, diabetes duration, and 
type of oral glucose-lowering medication were measured, and blood samples were 
obtained. 
 Healthy, obese and non-obese individuals underwent a history and a complete 
physical examination. The inclusion and exclusion criteria were reviewed at the 
screening visit. Subsequently, extended anthropometric and metabolic tests were 
performed and subcutaneous adipose tissue biopsies were obtained. The local 
institutional review board of the Radboud University Nijmegen Medical Centre 
approved the study protocol. All subjects provided written informed consent. 
Body fat distribution
Patients were measured in fasted overnight conditions with an empty bladder. Waist 
circumference was measured midway between the lower rib margin and the iliac crest 
at expiration, and hip circumference over the greater trochanter. Body composition 
was assessed by using the formula described by Jackson and Pollock (16).
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Biochemical analyses
Plasma glucose concentration, HbA1c, lipids, free fatty acids were measured by 
standard laboratory methods. Homeostasis model assessment of insulin resistance 
(HOMA-IR) was calculated by using the following formula: fasting plasma insulin 
(µIU/mL) x fasting plasma glucose (mmol/L)/22.5. Plasma concentrations of leptin 
and total adiponectin were determined using enzyme-linked immunosorbent assays 
(R&D Systems, Minneapolis). Furthermore, high sensitive C-reactive protein (hsCRP) 
was measured by enzyme-immunoassay according to the instructions from the 
manufacturer (Dako, Glastrup, Denmark).
Subcutaneous adipose tissue biopsies
Subcutaneous (sc) adipose tissue biopsies were obtained under local anesthesia by 
needle biopsies performed 6–10 cm lateral to the umbilicus, after an overnight fast. 
Morphometry of individual fat cells was assessed using digital image analyses as 
described previously (17). For each subject, the adipocyte cell diameter of all fat cells 
in five to ten microscopic fields of view were counted and measured. On average, 
~700 fat cells were measured per specimen (range 150–1500). For detection of macro - 
phages, adipose tissue sections were incubated with a CD68-monoclonal antibody 
(Clone EBM11, Dako, Denmark A/S). The percentage of macrophages was expressed 
as the total number of CD68-positive cells divided by the total number of adipocytes 
counted in 20 random microscopic fields of view x 100. A crown-like structure was 
defined as an adipocyte surrounded by at least three macrophages (10).
 Total RNA was extracted from sc adipose tissue as described previously (17). 
cDNA synthesis was performed using iScript (Bio-Rad Laboratories, Hercules, CA). 
Expression of genes was determined by real-time PCR analysis using an Applied 
Biosystem (Warrington, UK). Gene expression results were normalized to β2M levels. 
Any missing values were due to technical issues during qPCR analysis. Genes and 
primer sequences used in this study are listed in supplementary Table 1. 
 Protein levels within the adipose tissue were measured by Luminex fluorescent 
bead human cytokine immunoassays (MILLIPLEX MAP, Millipore Corp., Billerica, 
USA). Briefly, adipose tissue lysates were prepared using the milliplex map lysis 
buffer (Millipore) and protein concentrations of Interleukin-6, leptin, and monocyte 
chemoattractant protein (MCP)-1 were determined. Equal amounts of protein were 
analysed using a Bioplex system (Bio-rad Laboratories Ltd., United Kingdom). 
Missing values were due to measurements beneath the detection level or to low 
adipose tissue biopsy sample collection. 
Statistical analyses
Variables are expressed as means ± SEM. Correlations were calculated by Pearson 
correlation and Spearman rank correlation analyses, as appropriate. The Wilcoxon 
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signed rank test was used to compare non-parametric data. A one-way ANOVA was 
used to compare variables between different classes of inflammation, after variables 
were log-transformed. 
 All calculations were performed using SPSS software (version 20.0; SPSS Inc., 
Chicago, IL). Two-tailed P <0.05 was considered significant.
Results
A total of 118 subjects (29 lean, 46 obese subjects and 43 patients with T2DM) were 
included in this study and underwent a subcutaneous adipose tissue biopsy. 
The baseline anthropometric and laboratory characteristics of the study group are 
shown in Table 1. Glycaemic control (HbA1c) in the diabetes group was 8.7 ± 0.2 %. 
Table 1  Characteristics of study population.
Mean ± SE / %
(n = 118)
Demographics
 Age (yr) 57 ± 0.8
 Sex, no. of males (%) 63 (51)
Anthropometry and hemodynamics
 BMI (kg/m2) 28.5 ± 0.5
 Waist circumference (cm) 100 ± 1.3
 Hip circumference (cm) 102 ± 0.8
 SBP (mmHg) 140 ± 2
 DBP (mmHg) 83 ± 1
Metabolic characteristics
 TC (mmol/l) 4.5 ± 0.1
 TG (mmol/l) 1.7 ± 0.1
 HDL (mmol/l) 1.1 ± 0.04
 LDL (mmol/l) 2.8 ± 0.1
 FFAs (µmol/l) 0.52 ± 0.02  
 Alcohol use (%) 47
 Smoking (%) 12 
BMI denotes body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, TC = total 
cholesterol, TG = triglycerides, HDL = high-density lipoprotein cholesterol, LDL = low-density lipoprotein, 
FFAs = free fatty acids.
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Subcutaneous adipose tissue biopsy phenotyping 
Calculated lean body mass was 64.3 ± 1.1 kg and fat mass equalled 17.0 ± 0.9 kg. 
A significant variation in adipocyte size was observed amongst the non-diabetic 
subjects (Figure 1A and B). Similarly, the influx of macrophages, quantified as the 
amount of CD68-positive cells/adipocyte, varied among the study population (Figure 
1C and D). Noticeably, we were also able to detect clustering of macrophages in so 
called crown-like structures (10) in multiple adipose tissue biopsies (Figure 1C). 
Because adipocyte size is closely connected to bodyweight and total body fat, we 
initially set out to correlate adipocyte size with various anthropometric measurements. 
In line with previous studies (5, 7), BMI and waist circumference were positively 
correlated with adipocyte size (Table 2). Additionally, various circulating parameters 
including leptin, primarily used as a marker for adipose tissue mass, correlated with 
adipocyte size (Table 2). Whereas leptin was positively correlated with adipocyte size, 
Figure 1A  Sc adipose tissue morphology and variation in adipocyte size among the 
study population (n = 4 subjects). Panel I: mean adipocyte size 45 µm, panel II: 58 
µm, panel III: 70 µm, panel IV: 86 µm. All sections were stained with hematoxylin 
(colored blue). Magnification: 10x.
I
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II
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Figure 1B  Adipocyte cell size distribution within our study population. Bin width 2 µm. 
n = 118 individuals.
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Figure 1C  CD68-immunohistochemical staining of 3 representative patients with no 
influx of CD68-positive cells in the sc adipose tissue (panel I), high influx of CD68- 
positive cells (panel II) and sc adipose tissue with a crown-like structure (panel III). 
All sections were counterstained with hematoxylin (colored blue). Magnification: 20x. 
Arrows indicate CD68-positive cells.
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enlargement of adipocytes was not associated with circulating concentrations of 
adiponectin. We measured high sensitive C-reactive protein (hsCRP) as a systemic 
inflammation marker to correlate with the adipocyte cell size. There was a borderline 
association between adipocyte cell size and hsCRP (Table 2). HOMA-IR index, 
generally used as a circulating readout of insulin sensitivity, correlated positively with 
adipocyte size implying that a deterioration in insulin sensitivity is accompanied by an 
enlargement of adipocytes (Table 2). 
 Adipocyte cell size did not correlated with gene expression levels of adiponectin 
or GLUT4. In contrast, gene transcription levels of MCP-1 positively correlated with 
adipocyte size (Table 2). 
Adipokine levels within adipose tissue correlated with adipocyte 
cell size 
In various studies, anthropomorphic measurements and circulating concentrations of 
various proteins only indirectly reflect adipose tissue function. Therefore, we measured 
the concentration of various proteins within the subcutaneous adipose tissue using 
luminex techniques and correlated these values to adipocyte size. There were 
significant correlations between adipocyte cell size and protein levels of leptin, 
monocyte chemotactic protein-1 (MCP-1), and interleukin-6 (IL-6) measured within 
the adipose tissue (Table 2).
 Noticeably, protein levels of leptin measured in the adipose tissue significantly 
correlated with systemic leptin and hsCRP levels (r = 0.30; P = 0.005 and r = 0.25; 
P = 0.02, respectively). 
Figure 1D  Distribution of CD68+-cells influx within our study population. Bin width 
2 µm. n = 118 individuals.
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Macrophage infiltration in subcutaneous adipose tissue correlates 
with BMI, waist circumference, insulin sensitivity and adipocyte size
To learn more about the role of macrophage influx in the development of obesity, 
insulin resistance and inflammation, we correlated the number of macrophages, as 
quantified by CD68-staining, with various morphometric and circulating parameters. 
As shown in Table 2, the number of CD68-positive cells within the adipose tissue 
positively correlated with body mass index, waist circumference, adipocyte cell size, 
hsCRP levels and HOMA-IR (borderline significance). 
Clustering of macrophages in crown like structures is correlated with 
a worsening in adipose tissue characteristics and insulin resistance
Adipose tissue macrophages are known to cluster in so called crown-like structures 
that possess a high inflammatory trait (11). Classification of our study population 
based on the presence or absence of crown-like structures (CLSs) within sub- 
cutaneous adipose tissue, revealed that subjects with crown like structures present 
in subcutaneous adipose tissue had a significantly higher adipocyte cell size, influx 
of macrophages, MCP-1 protein levels and HOMA-IR (borderline significance) as 
compared to subjects that lack any CLS in adipose tissue (Figure 2). Subjects with 
and without CLSs did not differ regarding mRNA levels of adiponectin, GLUT4, and 
MCP-1, BMI or waist circumference. 
Classification of adipose tissue inflammation
Although the term adipose tissue inflammation is frequently used throughout 
literature, no standard classification system is currently available to rank severity of 
adipose tissue inflammation. The available data on adipose tissue histology in this 
study was used to categorize the degree of adipose tissue inflammation. By applying 
three parameters of adipose tissue morphology that can be assessed in a similar 
manner in various laboratories using standard histological techniques, we defined a 
classification method. A combined score using means as cut-off points of adipocyte 
size (mean adipocyte cell size diameter was 65.4 µm, so adipocyte cell size ≤ 65.4 
µm was scored as 0 and adipocyte cell size > 65.4 µm was scored as 1), macrophage 
influx (mean number of macrophages present in the adipose tissue was 0.04/
adipocyte, so macrophage influx of ≤ 0.04 was scored as 0 and macrophage influx 
> 0.04 was scored as 1) and the presence of crown like structures (no = 0 or 
yes = 1), will add up to a minimal value of 0 or maximal value of 3. A score below 1 
was regarded as no inflammation of the adipose tissue; a score between 1 and 2 as 
moderately inflamed adipose tissue and a score above 2 as severely inflamed 
adipose tissue. Table 3 shows the proposed scoring system for quantifying adipose 
tissue inflammation. 
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Figure 2  Significant differences in adipocyte cell size (panel I: CLS- n = 84; CLS+ 
n = 34), CD68-positive cells/adipocyte (panel II: CLS- n = 85; CLS+ n = 34; 5 
subjects in CLS- group displayed no CD68-positive cells/adipocyte), monocyte 
chemotactic protein-1 (MCP-1) protein levels (panel III: CLS- n = 80; CLS+ n = 31) 
measured within the subcutaneous adipose tissue and homeostasis model 
assessment–insulin resistance (panel IV: HOMA-IR; CLS- n = 70; CLS+ n = 29)) 
comparing the group without crown-like structures (CLS-) and with crown-like 
structures (CLS+). HOMA-IR was calculated by: fasting plasma insulin (µIU/mL) x 
fasting plasma glucose (mmol/L)/22.5. Horizontal lines within figures represent mean 
levels. * P < 0.05, ** < 0.001, # P = 0.10.
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Figure 2  Continued.
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Based on this score, n = 42 subjects (36%) were defined as no inflammatory status, 
n = 31 (26%) subjects as moderate and n = 45 subjects (38 %) as severe adipose 
tissue inflammation. Table 4 shows the distribution of subjects within the different 
inflammatory classes. 
Interestingly, subjects characterized by severe adipose tissue inflammation score 
had higher HOMA-IR indices indicating the presence of insulin resistance (Figure 3). 
Table 3  Adipose tissue inflammatory classification.
Parameter Cut-off Score
Adipocyte cell size ≤ 65.4 µm 0
Adipocyte cell size > 65.4 µm 1
CD-68 positive cell influx/adipocyte ≤ 0.04 0
CD-68 positive cell influx/adipocyte > 0.04 1
CLS* No 0
CLS Yes 1
* CLS = crown-like structures. A score below 1 represents no adipose tissue inflammation. A score of 
1-2 represents moderate adipose tissue inflammation. A score of > 2 represents severe adipose tissue 
inflammation. In this analysis 42 subjects were assigned as no adipose tissue inflammation, 31 subjects 
were assigned as having moderate adipose tissue inflammation and 45 subjects assigned as having 
severe adipose tissue inflammation.
Table 4  Distribution of subjects within different inflammation classes.
Lean Obese T2DM
No inflammation (IF-class < 1) 22 (76%) 13 (28%) 7 (16%)
Moderately inflamed AT (IF-class 1-2) 6 (21%) 14 (30%) 11 (26%)
Severely inflamed AT (IF-class > 2) 1 (3%) 19 (42%) 25 (58%)
Distribution of subjects (n/%) within the different inflammatory classes. AT denotes adipose tissue, 
IF-class denotes inflammatory class, and T2DM denotes type 2 diabetes mellitus. 
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Discussion
While animal studies have extensively documented that the development of obesity 
is accompanied by adipose tissue inflammation that includes adipocyte enlargement 
and macrophage influx, inflammatory changes in adipose tissue in humans, have 
been less frequently described. The present study, in which almost 120 patients and 
adipose tissue samples are included, reveals that changes in adipose tissue 
morphology closely relate to obesity and metabolic complications in a large group of 
subjects varying in BMI with or without diabetes. Moreover, we propose using a 
classification system in which three morphological parameters are scored to 
categorize the inflammatory status of the adipose tissue. This may lead to a more 
accurate measurement of adipose tissue inflammation and may help to compare 
different human studies. 
 In line with previous work (5, 18), our data reveal that not only the absolute numbers of 
macrophages dictate a worsening in adipose tissue inflammation, systemic inflammation 
Figure 3  Classification of study population based on adipose tissue inflammatory 
classification. Higher inflammation class (0à2) is associated with increased insulin 
resistance as measured by HOMA-IR. Data were analyzed with one-way analysis of 
variance (ANOVA) after variable was log transformed. L = number of lean subjects, 
O = number of obese subjects (overweight and obese subjects were included in this 
group) and D = number of patients with diabetes. * P < 0.05.
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and insulin sensitivity, but that localization in so called crown like structures is of 
importance. Indeed, classification of individuals using the absence or presence of 
crown like structures in subcutaneous adipose tissue as a selection criterion revealed 
that CLSs are associated with a larger adipocyte size and insulin resistance. 
 Despite the fact that various studies have reported on human adipose tissue 
morphology, a uniform method to quantify adipose tissue inflammation is currently 
lacking. As a consequence, different readouts to define adipose tissue inflammation 
are used throughout literature, hence making it difficult to directly compare results of 
various human studies. By using three morphological determinants that include 
adipocyte size, the severity of macrophage influx and the presence of crown like 
structures, we propose a classification tool to determine the severity of adipose tissue 
inflammation. Our model does not take into account the influx of various other 
immune cells and future refinements may lead to improvements of our scoring model. 
For example, additional immunohistochemical stainings to detect and quantify other 
immune cells like T-cells or B-cells may be included. More irreversible features of 
adipose tissue morphology including fibrosis that occur during obesity (19) may also 
need to be included to further fine-tune the classification system. However, these 
morphological characteristics are not as well established as compared to macrophage 
influx and adipocyte size and will first need to be more carefully evaluated before 
inclusion into a model to predict inflammatory changes of human adipose tissue. 
 A more standardized approach to classify adipose tissue inflammation will lead 
to a more accurate measurement of adipose tissue inflammation and may help to 
compare different human studies. Combining results of different studies and thereby 
increasing power, may eventually aid the identification of circulating biomarkers that 
help to predict the inflammatory status of the adipose tissue. Increasing power by 
including other studies may aid the discovery of a set of (novel) circulating biomarkers 
that may eventually be used to predict the inflammatory status of the adipose tissue. 
As such, it may allow for a more personalized therapeutic approach to target 
inflammatory pathways specifically in obese patients that suffer from a high degree 
of adipose tissue inflammation. 
 Although the use of only one fat depot is a drawback of our study, morphological 
parameters of the subcutaneous adipose tissue correlated well with various 
anthropometric measurements and HOMA-index. Whereas future studies ideally 
include measurements in visceral adipose tissue, our results imply that inflammatory 
changes in subcutaneously stored adipose tissue are correlated to systemic effects 
including levels of insulin sensitivity. Important other points of consideration include 
differences in the inflammatory profile by biopsy sampling (needle versus surgical 
techniques) (20). It is known that biopsy techniques influence the gene expression 
underlying the biological themes currently discussed in obesity (e.g. inflammation, 
extracellular matrix, and metabolism). 
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 In conclusion, our data clearly demonstrate that morphological changes in 
subcutaneous adipose tissue are strongly associated with various metabolic 
abnormalities. Using a classification system in order to categorize the inflammatory 
status of the adipose tissue provides a tool to compare different clinical studies. 
Increasing power by combining different studies may assist in establishing a 
combination of circulating plasma parameters that can be used to predict the 
inflammatory status of the sc adipose tissue. Knowledge of the adipose tissue 
inflammatory status may help in determining the optimal (personalized) therapeutic 
strategy to treat patients suffering from obesity and type 2 diabetes. 
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Supplemental data 
Table 1  Primer sequences.
Human
Forward primer
Reverse primer
Gene symbol RT-PCR (real-time PCR)
B2M 5’-ATGAGTATGCCTGCCGTGTG-3’
5’-CCAAATGCGGCATCTTCAAAC-3’
SLC2A4 5’-CTCAGCAGCGAGTGACTGG-3’
5’-CCCCAATGTTGTACCCAAACTG-3’
ADIPOQ 5’-ATCGGTGAAACCGGAGTACC-3’
5’-GCATGTTGGGGATAGTAACGTAA -3’
CCL2 5’-CCAGTCACCTGCTGTTATAAC-3’
5’-TGGAATCCTGAACCCACTTCT-3’
B2M = beta-2-microglobulin
SLC2A4 = glucose transporter type 4
ADIPOQ = adiponectin
CCL2 = monocyte chemoattractant protein-1
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Summary and conclusions 
The treatment of patients diagnosed with type 2 diabetes mellitus (T2DM) requires 
lifestyle changes and often oral glucose lowering medication to maintain blood 
glucose levels in the near normal range. When glucose control fails with oral 
medication, insulin is needed to achieve adequate glycemic control, but often at the 
expense of weight gain. While insulin therapy has several beneficial effects, insulin- 
associated weight is clearly undesirable in an already obese population. Furthermore, 
weight gain may cause several complaints (e.g. joint problems) and increase the risk 
of cancer. 
 From a clinical perspective it is known that not all patients starting insulin 
treatment will gain weight and it would be valuable to identify factors that determine 
inter-individual differences with respect to insulin-associated weight gain. In addition, 
potential consequences of insulin-associated weight gain on body composition, 
subcutaneous abdominal adipose tissue and cardiovascular risk are currently 
unknown. Identifying determinants and cardiometabolic consequences of insulin-as-
sociated weight gain may open avenues towards therapeutic strategies to limit or 
even prevent this weight gain. In this thesis, we describe the results of a series of 
investigations aimed at identifying the determinants and consequences of insulin-in-
duced weight gain in patients with T2DM. 
 Chapter 1 provides an overview of proposed determinants and consequences 
of  insulin-associated weight gain as described in literature. This chapter also provides 
background information regarding some of the measurements used in our studies. 
 In chapter 2 the results of a retrospective study about the relationship between 
insulin-associated weight gain and change in HbA1c in 122 patients with type 2 
diabetes are described. Data over a period of three years was collected. Body weight 
increased substantially by 0.54 kg per month in the first 9 months after start of insulin 
therapy. As expected, there was a large inter-individual variation with approximately 
15 % of patients not gaining any weight, but also approximately 30 % of patients in 
whom body weight increased by more than 10 kg after 36 months of insulin therapy. 
The increase in body weight was most pronounced in the first 9 months, but continued 
over the whole 3 years after the start of insulin therapy. By using a linear mixed model, 
individual body weight profiles could be estimated and related to a change in HbA1c 
over this 36 month period. Unlike earlier findings, only 12 % of the bodyweight gain 
found in our study could be attributed to the change in HbA1c. It was also observed 
that obese patients show less insulin-associated weight gain compared to patients 
with lower body weight. These findings suggest that the presence of obesity should 
not be a reason to withhold insulin therapy because of fear for weight gain. 
 While improved glycemic control explains a part of insulin-induced weight gain, 
several other factors are probably involved. A decrease in physical activity upon the 
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start of insulin therapy may induce weight gain. We first questioned ourselves whether 
physical activity was decreased in patients with insulin-treated T2DM compared to 
lean and weight-matched obese non-diabetic subjects. Sleep duration has also been 
associated with physical exercise level and weight. In a cross-sectional study, we 
quantitatively measured physical activity by accelerometry (Sensewear Pro Armband 
TM, see Chapter 1) in patients with T2DM and compared the results to groups of 
obese and lean subjects. In addition, sleep duration and quality were assessed. 
Indeed, patients with insulin-treated T2DM performed significantly less physical 
activity. However, this was not explained by a difference in sleep duration or quality. 
These results are described in chapter 3.
 From the findings in chapter 3 it may be hypothesized that patients with T2DM 
decrease their physical activity after starting insulin treatment. In order to evaluate 
physical activity and other determinants of insulin-associated weight gain in patients 
with T2DM a prospective study was conducted (chapter 4). In this study, 65 patients 
with T2DM who started insulin therapy were followed for 12 consecutive months. The 
study was primarily powered to detect a relationship between insulin-associated 
weight gain and a change in physical activity. Other potential determinants of weight 
gain, including insulin dose and diabetes-related distress were measured as 
secondary outcomes. Not only baseline predictors, but also the contribution of 
changes of clinical variables over time were investigated. Again, we used a linear 
mixed model to assess the relationship between weight gain and changes in clinical 
variables. After 12 months of insulin therapy, mean body weight had increased 
significantly and physical activity (measured as metabolic equivalent (METS)) 
decreased, but this was not significantly related to weight changes. Similarly, reported 
caloric intake decreased significantly. However, diabetes-related distress (assessed 
by PAID-score) at baseline turned out to be a significant predictor of insulin-associated 
weight gain. The Problem Areas in Diabetes (PAID) survey was developed as a measure 
of diabetes-related stress and associates between psychological adjustment to 
diabetes and adherence to self-care behaviors. Other independent baseline predictors 
were: initial insulin dose and calculated body fat content. Also the change in insulin 
dose significantly influenced body weight over time. 
 The findings of this study may have clinical implications. First, health education 
should encourage insulin-treated patients to maintain, or even increase physical 
activity levels, to counteract, amongst others, weight gain. The clinical importance of 
identifying emotions that impact on body weight gain such as sadness in patients 
with type 2 diabetes may translate towards specific interventions (see below). 
Furthermore, as higher initial insulin dose was associated with more pronounced 
 insulin-induced weight gain, it might be envisioned that (low) initial insulin dose and a 
more gradual titration of insulin over time may limit or even prevent body weight gain.
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 Next we investigated whether insulin-induced weight gain, especially when 
outspoken, would have adverse consequences. 
 Chapter 5 describes the results of a cross-sectional study in which two extreme 
groups (patients with large insulin-associated weight gain: “gainers” and patients 
with minimal weight gain after start of insulin: “non-gainers”) were compared with 
respect to cardiometabolic risk. Each subgroup consisted of 14 patients. Gainers 
had significantly more total body and trunk fat (especially subcutaneous fat) 
compared with non-gainers. Gainers had similar liver fat content, and slightly higher 
levels of hormones derived from adipose tissue. Furthermore, gainers performed 
significantly less physical activity. Lastly, gainers had higher total cholesterol, 
low-density lipoprotein cholesterol, and alanine aminotransferase levels with similar 
cholesterol-lowering treatment. Thus, patients with T2DM who show pronounced 
weight gain during insulin therapy have a less favourable cardiometabolic risk profile 
compared with patients who show no or minimal weight gain. 
As shown, patients with T2DM who start insulin therapy, gain weight. Especially the 
subcutaneous abdominal compartment will increase. An increase in fat mass in 
obesity is associated with enlargement of adipocytes and pro-inflammatory changes 
in fat tissue. We questioned ourselves whether the expansion of adipose tissue mass 
would also be paralleled by morphological and inflammatory changes. We 
investigated the effects of weight gain on adipocyte size, macrophage influx and 
mRNA expression and protein levels of key inflammatory markers within the adipose 
tissue in patients with T2DM before and 6 months after the start of insulin therapy. 
This was the group of patients described in Chapter 4, and the results of this study 
were described in Chapter 6.
 As expected, insulin significantly increased body weight. At the level of sub - 
cutaneous adipose tissue, insulin treatment led to an influx of macrophages. When 
comparing patients gaining no or little weight with patients gaining > 4% body weight 
after 6 months of insulin therapy, both subgroups displayed an increase in macro - 
phage influx. However, gainers had higher protein levels of monocyte chemo-attractant 
protein-1, tumor necrosis factor-α and interleukin-1β after 6 months of insulin therapy 
compared to non-gainers. There was no significant change in adipocyte cell size. 
 We conclude that insulin therapy in patients with T2DM improved glycemic 
control, yet also induced body weight gain and the influx of macrophages in 
subcutaneous adipose tissue. In patients characterized by pronounced insulin-asso-
ciated weight gain, the influx of macrophages into adipose tissue is accompanied by 
a more pronounced inflammatory status. 
Patients with T2DM are typically overweight and have an increased liver fat content 
(LFAT). High LFAT may be explained by an increased efflux of free fatty acids from the 
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adipose tissue which is partly driven by inflammatory changes. We hypothesized that 
there would be an association between inflammatory features of the adipose tissue 
and liver fat content. In chapter 7 we measured LFAT content by proton magnetic 
resonance spectroscopy. A subcutaneous fat biopsy was obtained to determine 
morphology and protein levels within adipose tissue. In addition to fat cell size, the 
percentage of macrophages and the presence of crown like structures (CLSs) within 
sc fat was assessed by CD68-immunohistochemical staining. Mean LFAT was high 
(~11 %) and showed large inter-individual differences. Adipose tissue protein levels 
of the key inflammatory adipokine plasminogen activator inhibitor-1 (PAI-1) were 
positively associated with LFAT. Several pro-inflammatory changes in sc adipose 
tissue associate with increased LFAT content in obese insulin-treated patients with 
T2DM. These findings suggest that inflammatory changes at the level of the adipose 
tissue may accompany or even drive liver fat accumulation. 
Autophagy, an evolutionary conserved process aimed at recycling damaged 
organelles and protein aggregates in the cell, also modulates pro-inflammatory 
cytokine production in peripheral blood mononuclear cells. Since adipose tissue 
inflammation accompanied by elevated levels of pro-inflammatory cytokines is 
characteristic for the development of obesity, we hypothesized that modulation of 
autophagy alters adipose tissue inflammatory gene expression and secretion. 
Chapter 8 presents results of a study in which we performed ex vivo and in vitro 
studies of human and mouse adipose tissue. Our results demonstrate that autophagy 
activity is up regulated in adipose tissue of obese individuals and inhibition of 
autophagy enhances pro-inflammatory gene expression both in adipocytes and 
adipose tissue explants. Thus, autophagy may function to dampen inflammatory 
gene expression and thereby limit excessive inflammation in adipose tissue during 
obesity.
 
In literature, many studies investigate the inflammatory process within the adipose 
tissue. However, no exact definition exists with respect to the term “inflammation”. We 
propose a novel classification method to quantify inflammation in the adipose tissue. 
This classification method uses 3 morphological characteristics (i.e. adipose cell 
size, influx of macrophages and presence of crown-like structures) to quantify 
inflammation. In chapter 9, the inflammatory characteristics of adipose tissue of lean, 
non-diabetic obese subjects and patients with T2DM were compared. We conclude 
that there is a close affinity between adipose tissue morphological characteristics, 
obesity and metabolic complications. A standardized approach to classify adipose 
tissue inflammation will lead to more accurate measurements of adipose tissue 
inflammation and will aid comparison of different human studies using adipose tissue 
biopsies.
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Conclusions and future perspectives 
Insulin-associated weight gain in patients with type 2 diabetes patients is a serious 
clinical problem and leads to relevant changes in body composition, cardiometabolic 
profile and alters the inflammatory status at the adipose tissue level. In this thesis we 
investigated determinants and consequences of weight gain after start of insulin 
therapy. 
A change in glycemic control, hence correction of glucosuria, is widely listed as a 
main determinant of insulin-associated weight gain. This factor may be most relevant 
in the initial phase of insulin treatment. However, the relationship between change in 
glycemic control and change in weight is complex and varies over time. We confirmed 
that a change in glycemic control (HbA1c) is significantly associated with insulin-as-
sociated weight gain. Nevertheless, the intention of insulin therapy is to improve 
glycemic control and to decrease HbA1c. As such, change in HbA1c is the 
consequence of insulin therapy. Therefore, although in our multiple linear regression 
model, change in HbA1c was related to weight gain, we did not include this variable 
in the final analyses because it does not represent a true independent variable. 
 We postulated that a change in physical exercise might contribute to insulin-as-
sociated weight gain. Indeed, we found that, after 12 months of insulin treatment, 
patients perform less physical activity as compared to before initiation of insulin 
therapy. However, while a decrease in physical activity in itself is unfavorable from a 
health care perspective, it did not appear to determine weight gain. Nevertheless, 
active counseling of physical activity, to prevent an unnecessary drop in level of 
exercise seems advisable. 
 Caloric intake to assess energy intake did not seem to be a determinant of insu-
lin-associated weight gain either. In contrast, patients reported less intake at 6 and 12 
months of insulin treatment. 
 We identified a number of new predictors of insulin-associated weight gain: initial 
insulin dose, diabetes-related distress as measured by PAID questionnaire and age. 
Our findings suggest a relevant influence of emotions and depressive complaints 
that may translate to eating an unhealthier diet or becoming less physically active and 
predominates to more insulin-associated weight gain. Based on these results, a 
therapeutic strategy may be to employ questionnaires (such as PAID) to assess dia-
betes-related distress before starting insulin therapy to provide insight into the mood 
of a patient. In patients with a high diabetes-related distress score, an intervention 
aimed at reducing distress may prevent or limit weight gain. Whether such an 
intervention is effective remains to be established. 
 The finding that a higher initial insulin dose was prospectively associated with 
more weight gain was new and intriguing. The starting dose was determined by the 
Chapter 10
206
physician and may be partly based on the level of hyperglycemia and /or on the 
estimated level of insulin resistance. The choice to start with a certain amount of 
insulin may also be physician dependent, or centre-dependent. A related determinant 
which influenced body weight significantly over time is change in insulin dose – more 
rapid increase in insulin dose was associated with more weight gain. The potentially 
involved mechanisms deserve further exploration, but the finding may have clinical 
consequences. One might consider to start with an (low) initial insulin dose and a 
more gradual titration of insulin over time to limit or even prevent body weight gain. 
Again, whether this translates to reduced insulin-induced weight gain remains to be 
proven. 
With respect to the consequences of insulin-associated weight gain, we focused on 
the (change in) body composition and subcutaneous adipose tissue. Although not 
surprisingly, we showed that patients gaining pronounced body weight after the start 
of insulin therapy exhibit more subcutaneous adipose tissue, higher lipid levels and 
slightly higher levels of hormones derived from adipose tissue. It can be stated that 
this group of patients (“gainers”) suffer from a less favorable cardiometabolic risk 
profile. This finding was also confirmed by exploring the subcutaneous adipose 
tissue with respect to morphology and inflammatory profile. We found that the 
influx of macrophages into adipose tissue is accompanied by a more pronounced 
inflammatory status in those patients suffering from pronounced weight gain. The 
systemic anti-inflammatory effects of insulin (therapy) might thus, at least partially, 
be offset by the pro-inflammatory changes associated with an increased fat mass. 
Theoretically, this subgroup of patients might benefit from anti-inflammatory therapy 
(like IL-β blockade) to reduce or even reverse the enhanced inflammatory status.  
It is clear from our studies that insulin-associated weight gain may offset part of the 
beneficial effects of improved glycemic control and hence it is important to investigate 
new therapeutic modalities for patients suffering from insulin-associated weight 
gain. Besides lifestyle interventions and changes in insulin regimens, also additional 
pharmacological therapy could be considered. Glucagon-like peptide-1 (GLP-1) 
analogues may counteract insulin-induced body weight without deteriorating 
glycemic control. Recently, we initiated a clinical trial (ELEGANT) (clinicaltrials.gov 
Identifier: NCT00781495) to investigate whether addition of the GLP-1 analogue 
liraglutide can reverse weight gain while maintaining glycemic control in patients 
recently started on insulin who showed a pronounced weight gain. Results are 
expected in 2014. 
 Whether addition of the new class of glucose lowering drugs, the SGLT-2 inhibitors, 
has therapeutic value in counteracting insulin-induced weight gain requires additional 
studies. 
Summary and conclusions
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The research described in this thesis contributes to a better understanding of insulin- 
associated weight gain in patients with T2DM by identifying important determinants 
including diabetes-related distress score, initial insulin dose and age. This may 
lead to the development of therapeutic strategies to limit or possibly prevent insulin- 
associated weight gain in order to optimize the care for patients with T2DM. Such a 
more personalized approach towards insulin treatment may result in more optimal 
use of one of main cornerstones of diabetes management.
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Dit onderzoek gaat over oorzaken en consequenties van gewichtstoename bij 
personen met type 2 diabetes mellitus, ook wel “ouderdoms suikerziekte” genoemd 
en die behandeld worden met insuline. 
 De behandeling van mensen met type 2 diabetes mellitus heeft als doel het 
verkrijgen en behouden van een zo normaal mogelijke bloedglucosewaarde. De 
therapie bestaat allereerst uit dieet- en leefstijladviezen. Daarbij wordt, zo nodig, 
medicatie in de vorm van tabletten voorgeschreven die het glucosegehalte in het 
bloed verlagen. Indien tabletten niet (meer) voldoende helpen om de bloedsuiker te 
verlagen wordt gestart met behandeling met insuline. Insuline wordt onderhuids 
toegediend middels een injectie. Er zijn meerdere soorten insuline; langwerkende, 
kortwerkende en combinaties ervan. 
 Het gebruik van insuline heeft belangrijke positieve effecten. Allereerst geeft het 
een goede glucoseregulatie, waardoor mensen minder klachten hebben van hoge 
bloedsuikers. Verder wordt met insulinetherapie het risico op complicaties van de 
kleine en grote bloedvaten op langere termijn verminderd. Waarschijnlijk heeft dit 
te maken met het feit dat insuline een dempende werking lijkt te hebben op ont-
stekingsreacties in de bloedvaten. 
Een ander, negatief, effect van insulinebehandeling dat kan optreden is gewichts-
toename. Gewichtstoename bij personen met, maar ook zonder diabetes, kan leiden 
tot allerlei problemen zoals gewrichtsklachten, een verhoogd risico op kanker en op 
hart- en vaatziekten. Veel personen met type 2 diabetes mellitus hebben overgewicht. 
Extra gewichtstoename ten gevolge van insulinetherapie is ongewenst.
 In de praktijk blijkt dat niet alle mensen met type 2 diabetes aankomen in gewicht 
na het starten van insulinebehandeling. Het is onduidelijk welke factoren een rol 
spelen bij de gewichtstoename die samenhangt (is geassocieerd) met insuline; de 
zogenoemde determinanten van de insuline-geassocieerde gewichtstoename. 
Verder is het onbekend welke gevolgen insuline-geassocieerde gewichtstoename 
heeft op de vetverdeling in het lichaam, op de kenmerken van het onderhuids 
vetweefsel en op het risico op hart- en vaatziekten.
 Het identificeren van de determinanten van insuline-geassocieerde gewichts-
toename en het vergroten van het inzicht op de gevolgen hiervan kunnen leiden tot 
strategieën om gewichtstoename bij insulinegebruik te voorkomen dan wel te verminderen. 
In dit proefschrift zijn de resultaten van verschillende onderzoeken naar de oorzaken 
en gevolgen van de insuline-geassocieerde gewichtstoename en de consequenties 
hiervan bij personen met type 2 diabetes mellitus beschreven. Bij de meeste van 
deze studies betreft het klinisch, patiënt-gebonden, onderzoek. Meerdere onder-
zoeksmethodes zijn toegepast om van deze studiedeelnemers klinische gegevens te 
verzamelen. Door middel van laboratoriumonderzoek werd onder meer de bloed-
glucoseregulatie bepaald. Ook werd beeldvormend onderzoek toegepast, namelijk 
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Magnetische Resonantie Imaging/Spectroscopie (MRI/MRS), om onderhuids vet - 
weefsel en vetweefsel rondom de inwendige organen en levervet te meten. Door het 
dragen van een bewegingsarmband, de SenseWear Pro ArmbandTM, werd 
 bewegingsactiviteit gemeten. Dit apparaat werd een aantal dagen aan de rechter 
bovenarm gedragen en registreerde kwantitatief bewegingsactiviteit. Ook werd bij de 
meeste mensen een stukje onderhuids vet afgenomen. Bij dit vetbiopt werd onder 
lokale verdoving met een holle naald naast de navel ongeveer 1 g vetweefsel 
afgenomen. Dit stukje vetweefsel werd bewerkt om individuele vetcellen en de 
architectuur ervan te bekijken (histologie), immuuncellen (met name macrofagen) te 
kwantificeren en om ontstekingsactiviteit te meten. 
Hoofdstuk 1 is een algemene inleiding. Hierin wordt beschreven welke oorzaken en 
gevolgen van insuline-geassocieerde gewichtstoename bij personen met type 2 
diabetes mellitus bekend zijn in de literatuur. Dit hoofdstuk geeft eveneens achter-
grondinformatie over de diverse meetmethoden die zijn gebruikt in de verschillende 
onderzoeken. Het bevat ook een beschrijving van mogelijke mogelijkheden om 
 gewichtstoename bij insulinegebruik te voorkomen. 
 In elk van de volgende hoofdstukken wordt een studie beschreven. De hoofd- 
stukken 2 tot en met 4 beschrijven de resultaten van de studies over de oorzaken van 
insuline-geassocieerde gewichtstoename. Vervolgens gaan de hoofdstukken 5 tot en 
met 9 over de resultaten van de studies naar de gevolgen van insuline-geassocieerde 
gewichtstoename bij personen met type 2 diabetes mellitus. 
 Veel diabetesexperts relateren gewichtstoename bij insuline aan de verandering 
van diabetesinstelling; verbetering van de glucoseregulatie en daardoor verandering 
van HbA1c. Ze verklaren de gewichtstoename doordat minder glucose wordt uitgeplast 
(per saldo minder calorieverlies) en bij gelijke calorie inname en onveranderd gebruik 
de energiebalans dus positiever wordt. 
 In hoofdstuk 2 worden de resultaten beschreven van de retrospectieve studie 
waarbij is gekeken naar de relatie tussen gewichtstoename en verandering van 
HbA1c bij 122 personen met type 2 diabetes mellitus. Met een statistisch model (het 
zogenaamde “lineair mixed model”) is de verandering van de waardes van het 
gewicht en HbA1c van de mensen in het verloop van 36 maanden geanalyseerd. 
Personen kwamen significant aan in gewicht, maar de verandering van HbA1c 
verklaarde slechts 12 % van deze gewichtstoename. Verder kon geconcludeerd 
worden dat personen die al dik waren minder gewichtstoename leken te ontwikkelen. 
Overgewicht bij de start van insulinetherapie lijkt min of meer “beschermend” te zijn 
tegen nog extra gewichtstoename bij gebruik van insuline. Hieruit kan worden 
geconcludeerd dat personen met type 2 diabetes en overgewicht insulinetherapie 
juist niet onthouden zou moeten worden.  
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Hoofdstuk 3 gaat over de resultaten van de studie naar bewegingsactiviteit in relatie 
tot insuline-geassocieerde gewichtstoename. Voor het meten van lichamelijke 
activiteit in dit proefschrift werd de Sensewear Pro Armband TM gebruikt, waarmee 
kwantitatief bewegingsactiviteit is gemeten. De bewegingsactiviteit van personen 
met type 2 diabetes en overgewicht werd vergeleken met die van personen zonder 
diabetes mellitus met en zonder overgewicht. Uit de metingen bleek dat personen 
met diabetes minder bewegen dan de controle-personen. De bewegingsarmband 
heeft ook de slaapduur en -kwaliteit gemeten. Deze slaapkarakteristieken blijken 
echter geen verklaring te zijn voor de gemeten verschillen.
Om gevolgen van gewichtstoename bij insulinetherapie vast te stellen is onderzoek 
noodzakelijk dat herhaaldelijk meet over de tijd, zogenaamd prospectief onderzoek. 
Hoofdstuk 4 beschrijft de resultaten van een prospectief onderzoek waarbij mensen 
vanaf de start met insuline 12 maanden lang gevolgd zijn. Hierbij werd primair 
gekeken naar de relatie tussen de verandering van lichamelijke activiteit in relatie tot 
de gewichtstoename. Deelnemers aan de studie bleken gemiddeld ruim 3 kg te zijn 
aangekomen na 12 maanden insulinebehandeling. Met behulp van de bewegings-
armband is gekeken naar de verandering van lichamelijke activiteit. Tussen 6 en 12 
maanden na het starten van insuline blijkt er een significante daling van de lichamelijke 
activiteit. Nadere analyse toonde aan dat deze verandering van lichamelijke activiteit 
echter niet als verklaring kon gelden voor de toename van het lichaamsgewicht. 
 In deze studie is verder gekeken naar andere mogelijke voorspellende dan wel 
verklarende factoren voor de gewichtstoename. Daarbij werd onder meer gekeken 
naar de mate van diabetes gerelateerde klachten (zoals moeheid, stemmings-
problematiek, cognitieve problemen) met behulp van de PAID-vragenlijst. Het bleek 
dat deelnemers die meer last hadden van diabetes-gerelateerde klachten een grotere 
gewichtstoename lieten zien. Een andere voorspellende factor voor meer gewichts-
toename die naar voren kwam was een hogere start insulinedosering. 
In de studie beschreven in hoofdstuk 5 is onderzocht of autofagie, het opruim-
mechanisme van een vetcel, een rol speelt in vetweefsel bij muizen en mensen. 
Autofagie is een proces dat samenhangt met gewichtsverandering. Dit heeft mogelijk 
te maken met ontstekingsprocessen in vetweefsel. 
 Uit de studie bleek dat bij personen met overgewicht sprake was van een hoger 
niveau van autofagie. Indien deze autofagie geremd werd dan nam de ontstekings-
activiteit in het vetweefsel toe. Deze gegevens suggereren dat een verhoogde 
autofagie activiteit bij personen met overgewicht mogelijk dempend kan werken om 
de ontstekingsactiviteit te beperken.  
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In hoofdstuk 6 zijn twee uiterste groepen personen met type 2 diabetes met elkaar 
vergeleken wat betreft het risico op hart- en vaatziekten. De ene groep liet na gebruik 
van insuline geen tot weinig gewichtstoename zien (“non-gainers”) en de andere 
groep bestond uit personen die juist veel in gewicht waren aangekomen (“gainers”). 
Er werd gekeken naar de hoeveelheid lichaamsvet, de mate van lichamelijke activiteit 
en naar de laboratoriumwaardes. De studie toonde aan dat de groep die het meeste 
in gewicht was aangekomen een ongunstiger cardiovasculair profiel had. Deze groep 
had meer totaal lichaamsvet, bewoog minder en leek meer leverontsteking te hebben 
(ALAT leverenzym).
 
In de hoofdstukken 7-9 is onderhuids vetweefsel bij gezonde personen met en 
zonder overgewicht onderzocht en vergeleken met het vetweefsel van personen met 
type 2 diabetes mellitus. Na de start van insuline werden deelnemers aan de studie 
significant dikker (hoofdstuk 2 en 4). Tevens was al aangetoond dat bij gewichts-
stijging vooral een toename te zien is van het abdominale vet (hoofdstuk 6). Dit 
abdominale vet werd gemeten middels MRI. 
 De vraag van de studie in hoofdstuk 7 was welke (nadelige) effecten insuline-
therapie zou kunnen hebben op het onderhuidse vetweefsel. Na 6 maanden insuline-
behandeling werd gekeken welke effecten insuline had op onderhuids vetcelmorfologie, 
influx van macrofagen en verandering in ontsteking (inflammatie). Er bleek geen 
significante verandering van de vetcelmorfologie (vetcelgrootte), ondanks het feit dat 
bij personen met type 2 diabetes sprake was van gewichtstoename dus meer vet- 
massa. De macrofageninstroom bleek echter wel toe te nemen na insulinebehandeling 
en dit effect was onafhankelijk van de gewichtstoename. Als laatste werd aangetoond 
dat een forse gewichtstoename nadelige effecten had op de ontsteking van het 
vetweefsel. 
 Deze groep (“gainers”) zou theoretisch baat kunnen hebben bij gelijktijdig gebruik 
van ontstekingsonderdrukkende medicatie naast de insuline. 
 Toename van de hoeveelheid onderhuidse vetweefsel, door toename van de 
vetcelgrootte (hypertrofie) of door toename van het aantal vetcellen (hyperplasie), 
kan aanleiding geven tot een vetzurenflux naar organen zoals de lever. Hierdoor kan 
levervet ontstaan. 
 Tot nu toe was de relatie tussen de hoeveelheid levervet van personen met type 
2 diabetes en karakteristieken van het onderhuidse vetweefsel niet bekend. In een 
doorsnede onderzoek werden bij 27 personen die langdurig insuline gebruikten 
onderhuidse vetbiopten afgenomen en middels MRS de mate van levervetting 
gemeten. Het bleek dat de mate van leververvetting gerelateerd was aan de ontste-
kingsparameters in het onderhuidse vetweefsel, zoals een toename van macrofagen 
en PAI-I waarden gemeten in het vetweefsel. Voor de resultaten van dit onderzoek 
wordt verwezen naar hoofdstuk 8.
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In de literatuur wordt vaak gesproken over de mate van inflammatie in het onderhuidse 
vetweefsel, maar een eenduidige definitie van inflammatie in het onderhuidse vet- 
weefsel ontbreekt. In hoofdstuk 9 is gekeken naar vetweefsel van gezonde personen 
met en zonder overgewicht en personen met type 2 diabetes die glucose-verlagende 
tabletten gebruikten. Hierbij is getracht aan de hand van karakteristieken van het 
vetweefsel, namelijk vetcelgrootte, instroom van macrofagen en aanwezigheid van 
zogenaamde “crown-like structures”, een classificatie te maken om de mate van 
ontsteking in het vetweefsel te kwantificeren. Deze classificatie kan gebruikt worden 
om verschillende studies onderling te kunnen vergelijken. 
 Hoofdstuk 10-11 geven een samenvatting van dit onderzoek (Engels en Nederlandse 
vertaling). 
 Tenslotte worden in hoofdstuk 12 woorden van dank uitgesproken aan degenen 
die hebben bijgedragen aan de totstandkoming van dit proefschrift.   
Conclusies en toekomstige onderzoeksonderwerpen
Personen met type 2 diabetes mellitus die gaan starten met insulinetherapie komen 
significant aan in gewicht. Na 12 maanden insulinebehandeling gaan personen minder 
bewegen, en dat lijkt ongewenst, hoewel dit geen oorzaak is van de gewichtstoename. 
Voorspellers van insuline-geassocieerde gewichtstoename zijn: start insulinedosis, 
diabetes-gerelateerde klachten (PAID) en lichaamsvet (negatieve correlatie). 
Determinanten die gewichtstoename over de tijd beïnvloeden zijn verandering van 
insulinedosering. De verklaring die altijd wordt gegeven, de verandering in het HbA1c 
lijkt slechts een geringe rol te spelen in insuline-geassocieerde gewichtstoename. Na 
het starten van insulinetherapie wordt op het HbA1c “gestuurd”, zodat de parameter 
HbA1c niet volledig als onafhankelijke variabele beschouwd mag worden. De 
interpretatie van het effect van verandering van HbA1c op lichaamsgewicht wordt 
hierdoor bemoeilijkt. 
 De gevolgen van insuline-geassocieerde gewichtstoename bij personen met 
type 2 diabetes mellitus zijn: een minder gunstig cardiovasculair profiel, met name bij 
personen die fors aankomen in gewicht bij insulinetherapie. Dit wordt verklaard 
doordat personen met type 2 diabetes minder gaan bewegen na de start van insuline-
therapie, veel levervet hebben, en het onderhuidse vetweefsel meer “ontstoken” 
lijkt te zijn. Er werd verder een correlatie gevonden tussen het levervet en onder- 
huids vetweefsel voor wat betreft ontsteking. Als laatste wordt in dit onderzoek een 
 classificatiesysteem voor het uitdrukken van de mate van ontsteking in het vetweefsel 
voorgesteld. Op deze manier kan onderzoek naar ontstoken vetweefsel beter worden 
vergeleken.
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 Het is nog onduidelijk welke andere voorspellers en determinanten bijdragen 
aan de gewichtstoename bij insulinetherapie. Verder moet nog onderzocht worden of 
de potentieel nadelige effecten van insulinetherapie bij “gainers” op vetweefselniveau 
opwegen tegen de gunstige effecten van insuline op glucose-instelling. Onderzocht 
moet worden of mensen met een lagere startdosis en/of een langzame dosisverhoging 
van insuline minder aankomen in gewicht. Misschien dat mensen die veel problemen 
hebben rondom het hebben van diabetes eerst een therapie zouden kunnen volgen 
die problemen wat kan doen verminderen. 
 Als laatste is het belangrijk om te onderzoeken of er aanvullende behandelingen 
zijn om de gewichtstoename bij insuline te verminderen. De zogenaamde glucagon- 
like peptide-1 (GLP-1) agonisten met gunstige effecten op diabetesinstelling en 
gewicht lijken in aanmerking te kunnen komen voor personen met forse insuline- 
geassocieerde gewichtstoename. In de “The effect of Liraglutide on insulin-associated 
weight gain in patients with type 2 diabetes” (ELEGANT) trial, wordt gekeken naar de 
effecten van liraglutide (Victoza®) op lichaamsgewicht en diabetesinstelling. Er zal 
hierbij ook onderzocht worden of personen minder insuline kunnen gaan gebruiken 
en minder hypoglycaemieën ondervinden. 
De uitkomsten van dit proefschrift dragen bij aan een beter begrip van insuline- 
geassocieerde gewichtstoename bij personen met type 2 diabetes mellitus. Dit kan 
leiden tot therapeutische strategieën om deze ongewenste gewichtstoename te 
verminderen om zo de zorg rondom personen met type 2 diabetes mellitus die gaan 
starten met insulinetherapie te verbeteren. 
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Dankwoord
Graag zou ik een groot aantal mensen willen roemen en danken die hebben bijgedragen 
aan de totstandkoming van dit proefschrift. 
Allereerst wil ik natuurlijk alle diabetespatiënten en vrijwilligers heel hartelijk bedanken 
voor hun inzet, geduld en de goede sfeer tijdens alle uren van hun deelname aan de 
onderzoeken. 
Hooggeleerde heer dr. C.J. Tack, beste Cees, 
Toen ik bij jou kwam met de vraag of ik klinisch wetenschappelijk diabetes onderzoek 
kon komen doen met jou als begeleider, was de “deal” snel gesloten. Jij had het 
onderwerp “insulinetherapie en gewichtstoename” in gedachte en dit sprak mij ook 
erg aan. Zo werd het onderwerp “insuline- geassocieerde gewichtstoename bij 
patiënten met type 2 diabetes mellitus” de rode draad van dit proefschrift. 
Ik wil je heel hartelijk bedanken voor je gestelde vertrouwen in mij. Ik bewonder je 
creativiteit, jouw liefde voor wetenschap en je vasthoudendheid. Dit kwam zeker 
goed van pas als het even wat minder liep of in het geval van weerbarstige editors die 
moeite hadden te begrijpen wat wij bedoelden. Je bleef mij voorhouden dat het wel 
goed zou komen; je hebt gelijk gekregen. Heel erg bedankt voor alles!
Beste dr. G. Vervoort, beste Gerald, 
Al tijdens de opleiding tot internist was je voor mij het voorbeeld van een patiënt 
vriendelijke en klinisch zeer kundige internist. Toen ik hoorde dat jij mijn begeleider 
zou worden bij mijn onderzoek, verheugde ik me op onze samenwerking. Gedurende 
mijn onderzoeksperiode was jij echt mijn steun en toeverlaat. Tijdens onze donderdag-
ochtendbesprekingen hadden we het niet alleen op constructieve wijze over inhoud 
en strategie, maar kwamen ook vele andere onderwerpen aan bod. Soms werd ook 
nog een extra thuisvergadering ingelast (dank Willemieke!). 
Ik wil je heel graag bedanken voor alles!
Beste dr. ir. R. Stienstra, beste Rinke, 
Hartstikke bedankt voor het meedenken, uitvoeren en opschrijven van de verschillende 
studies. We zaten soms na een restofanthapje tot ‘s avonds laat samen kleuringen te 
doen. Ik kon altijd met je overleggen en zo nodig werd een thuisvergadering belegd 
(dank Marloes!). Ook onze andere gezamenlijke interesses hebben we in de praktijk 
gebracht (zoals wielrennen, ieder op zijn eigen niveau, en intelligente actiefilms in de 
bioscoop bekijken). 
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Beste dr. J. Hendriks en dr. A. de Haan, beste Jan en Ton, 
Dank voor jullie statistische ondersteuning bij onze artikelen. Hoewel het wederzijds 
niet altijd even makkelijk was om elkaars “taal” te spreken, is er toch een vruchtbare 
samenwerking ontstaan; bedankt hiervoor. 
Beste dr. ir. M. van der Graaf, beste Marinette, 
De magnetische resonantie spectroscopie is jouw stokpaardje. Met deze techniek 
konden we bij een groep diabetespatiënten heel nauwkeurig het levervetpercentage 
meten. Dank voor je inzet en al ons overleg.
Beste dr. P. Netten en dr. P. Bouter, beste Paetrick en Paul, 
Tijdens de opleiding tot internist bij jullie werd mijn liefde voor de richting Algemeen 
Interne Geneeskunde met speciale aandacht voor diabeteszorg gewekt. Dankzij 
jullie kon ik het profiel diabetes en endoscopie verder ontwikkelen. Via Paetrick kwam 
ik bij Cees terecht. Dank dat jullie deel hebben genomen aan onze klinische studies. 
Ook jullie persoonlijke raad en betrokkenheid heb ik erg gewaardeerd. Ik ben heel blij 
dat ik nu deel uit maak van jullie team. Heel hartelijk bedankt voor alles.
Beste collega’s van de maatschap Interne Geneeskunde/MDL van het Jeroen Bosch 
Ziekenhuis, beste maten,
Heel hartelijk voor het gestelde vertrouwen in mij en de prettige samenwerking! Laten 
we verder bouwen aan een prachtige toekomst.
Beste collega’s Mulder (Slingeland Ziekenhuis, Doetinchem), Rossen (Huisartsen-
praktijk De Teselaar, Bemmel), dr. de Grauw (Huisartsenpraktijk Berghem, Berghem), 
Janssen (Huisartsenpraktijk Vier Kwartieren, Boxtel) en Leclercq (Bernhoven Ziekenhuis, 
Oss), beste Alexandra, Jan en Wim, Marjo en Monique, 
Hartelijk dank voor jullie medewerking aan onze prospectieve studie, waarin jullie 
studiepatiënten hebben geïncludeerd. Het was een hele prettige samenwerking!
Beste Annet, Ria, José, Sandra, Sandra, Petra, Liza, Jonie, Christien, Els, Pieta en Paul, 
allen diabetesverpleegkundigen, 
Ik wil jullie speciaal bedanken, aangezien de meeste studiepatiënten door jullie 
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onder leiding van Prof. dr. J.B.M.J. Jansen, dr. D. de Jong, maag-darm-leverartsen 
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en dr. P. Bouter, drs. P.J. Lestrade, de opleiding tot endoscopist gevolgd. De registratie 
tot internist werd in 2008 verkregen. In dat jaar werd een aanvang gemaakt met de 
klinische studies die uiteindelijk hebben geleid tot dit proefschrift. Vanaf 2009 tot 
2011 was hij staflid Algemeen Interne Geneeskunde, sectie Diabetes waarbij klinische 
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Lucas en Femke.
